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ABSTRACT 




Exocytosis of intracellular granules is critical for conversion of inactive, 
circulating neutrophils to fully activated cells. The p38 MAPK pathway plays a central 
role in neutrophil exocytosis, although its mechanism of action is unknown. We used 
several proteomic approaches to identify granule proteins and find targets of the p38 
MAPK and its downstream kinase, MK2, on granules. Our analysis identified 286 
proteins on neutrophil granules, four of which were known MK2 substrates. Known p38 
substrates were not detected. However, MRP-14 was identified as a novel p38 MAPK 
substrate. MRP-14 was phosphorylated by p38 MAPK in neutrophils upon cell 
stimulation and translocated to plasma membranes and gelatinase granules, as well as to 
Triton X-IOO-insoluble structures at the base of lamellipodia. Phosphorylation of the 
MRP-14 by p38 MAPK increased binding to actin in vitro. These results suggest that 
MRP-14 is a potential mediator of p38 MAPK-dependent exocytosis in human 
neutrophils. 
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Role of Neutrophils in Host Defense and Tissue Damage 
Neutrophils (also called polymorphonuclear leukocytes or PMNs) are phagocytic 
granulocytes that are crucial to host defense. These cells provide the initial cellular 
response at sites of infection and inflammation. Upon exposure to pro-inflammatory 
chemo attractants , chemokines, and cytokines, neutrophils are transformed from benign 
circulating cells to cells capable of adhesion to vascular endothelium, migration along 
chemoattractant gradients to sites of infection or trauma, phagocytosis of opsonized 
pathogens, and the release of antimicrobial agents [1]. In all of the above-mentioned 
processes, exocytosis of mobilizable membrane-bound compartments plays a central role. 
Although the infiltration of neutrophils into injured tissue protects it from 
invading pathogens, substantial evidence exists showing that neutrophil-induced host 
tissue injury contributes to inflammatory diseases, ischemia-reperfusion injury, and 
impaired wound healing [2-5]. Upon neutrophil activation the secretion of granule 
proteinases, peroxidases and cationic peptides acts in concert with the release of reactive 
oxygen intermediates to promote chemotaxis by digestion of extracellular matrix or to 
directly damage host cells [6,7]. As the intracellular events that lead to neutrophil 
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exocytosis are poorly characterized, understandirig the mechanism of neutrophil 
degranulation could be of significant clinical importance. 
Neutrophil Granules and Their Role in Neutrophil Function 
Neutrophils possess four types of mobilizable membrane-bound compartments: 
secretory vesicles, tertiary (gelatinase) granules, secondary (specific) granules, and 
primary (azurophil) granules [8,9]. These compartments differ in their protein content, 
physiological role, and physical characteristics. Differences in density of the granule 
subsets can be used to separate and enrich these subsets by isopycnic centrifugation on 
Percoll gradients [10]. Secretory vesicles are derived from the plasma membrane by 
endocytosis. Their lumen contains plasma proteins, while their membranes are rich in 
receptors and adhesion molecules, indicating that a major role of exocytosis of this 
compartment is to enhance plasma membrane expression of these molecules. The 
azurophil, specific, and gelatinase granules contain a variety of proteins in their luminal 
spaces and membranes, with distinct proteins being associated with each granule type. 
Neutrophil granule subsets are differentially mobilized, a process termed graded 
exocytosis, and the luminal and membrane protein content of each compartment 
determines the physiological role of exocytosis of secretory vesicles and the three subsets 
of granules [11,12]. Secretory vesicles are the most easily mobilized, followed in order of 
the ease of mobilization by gelatinase granules, specific granules, and azurophil granules. 
Stimulation of cells with optimal concentrations of the chemotactic peptide N-formyl-
methionyl-Ieucyl-phenylalanine (fMLP) results in complete mobilization of secretory 
vesicles, exocytosis of about 25% of gelatinase granules, and release of 5-7% of specific 
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granules, while azurophilic granule exocytosis is negligible [12]. Graded exocytosis 
allows neutrophils to reach a fully activated phenotype in stages that correspond to the 
events occurring during neutrophil response to inflammatory stimuli, as described next. 
Neutrophil stimulation by inflammatory mediators or cross-linking of selectins 
causes rapid exocytosis of secretory vesicles and gelatinase granules [13-15]. This results 
in increased plasma membrane expression of integrins, allowing the cell to adhere to 
vascular endothelium [16,17]. Class IV and class V collagens are substrates of gelatinase 
(matrix metalloproteinase 9), and local release of gelatinase is believed to playa major 
role in neutrophil migration through vascular basement membranes [14,18]. Exocytosis 
of specific and gelatinase granules, whose membranes are the main stores of complement 
receptor CR3 and flavocytochrome bss8 [19], enhances bacterial phagocytosis and 
NADPH oxidase assembly, which generates reactive oxygen species (ROS) [20]. 
Exocytosis of specific granules releases large amounts of collagenase and lactoferrin. 
Collagenase is important for cell migration through tissues [21,22], and lactoferrin limits 
bacterial growth by blocking access to iron [22,23]. Azurophil granules are lysosome-
related granules that exhibit limited exocytosis [24]. Azurophil granules fuse with 
phagosomes, thereby exposing ingested bacteria to hydro lases, proteases, and bactericidal 
peptides [25,26]. 
The luminal contents are tightly packaged in neutrophil granules. Most of the 
luminal proteins, including lactoferrin, myeloperoxidase, and lysozyme are positively 
charged, which normally would result in strong electrostatic repulsion among proteins 
within granules. To counter these repUlsive forces, neutrophil granules contain negatively 
charged acidic proteoglycans, such as chondroitin sulfate, that condenses the basic 
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proteins into a crystalline state, thus both packaging and inactivating them [27,28]. This 
matrix can act as an ion-exchange gel and release bound proteins upon contact with 
counter-ions. In neutrophil granules, the vast majority of sulfated proteoglycans (80%) 
have been localized to azurophil granules, which contain the most basic proteins, while 
the rest were found distributed in specific and gelatinase granules [29]. 
The packaging of luminal proteins occurs during granule biogenesis, which takes 
place throughout myeloid cell maturation. Different granule subsets form at different 
stages of maturation (Figure 1) [30]. Electron microscopy of neutrophil granules during 
developmental progression from a myeloblast to a neutrophil revealed that azurophil 
granules arose by aggregation and fusion of dense core vesicles derived from the trans-
Golgi complex. These granules were abundant in the cytoplasm of immature cells, but 
declined in number at later stages of development due to cell division and lack of 
formation of new azurophil granules. During the middle and late stages of myeloid cell 
maturation, myeloperoxidase-negative granules (specific and gelatinase granules) formed 
by a mechanism similar to azurophil granule biogenesis [30]. 
The differences in the protein content among neutrophil granules are determined 
by differences in the timing of synthesis of different granule proteins, not by selective 
targeting of proteins to different granules [31,32]. This conclusion is based on the 
observation that granule subsets are formed at specific stages of cell development [30]. 
Granule luminal and membrane proteins that are synthesized at the same time are 
targeted into the same type of granule [31-34]. The well-known targeting ofmannose 6-
phosphate-containing glycoproteins to lysosomes via the mannose 6-phosphate receptors 
[35] does not participate in targeting proteins to neutrophil granules [36,37]. Overlap 
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Figure 1. A diagram of granule biogenesis during stages of neutrophil maturation. 
Granules are drawn 1.5 X scale, and only half the average number determined by actual 
counts are included for a given stage. Myeloperoxidase-positive (azurophil) granules are 
shown in black and myeloperoxidase-negative (specific and gelatinase) granules in gray. 
The myeloblast is a small, undifferentiated cell. At progranulocytic and myelocytic stages 
of maturation cells grow and the amount of endoplasmic reticulum and Golgi apparatus 
increases in size to allow for protein synthesis and granule biogenesis. Azurophil and 
specific granule formation occurs at pro granulocytic and myelocytic stages, respectively. 
The metamyelocyte (not shown) and band cell are stages during which there is a 
progressive decrease in cell size, changes in the shape of the nucleus, a gradual 
diminution of most cytoplasmic organelles, and a shift to the synthesis of gelatinase 
granules. The mature neutrophil has a multilobed nucleus and a cytoplasm containing 
primarily granules. Number of azurophil granules per cell declines after pro granulocytic 
stage due to lack of synthesis of new azurophil granules coupled with cell division. 




among the windows of synthesis of different granule proteins gives rise to a spectrum of 
granules that are dominated by the three distinct granule types, some of whose contents 
overlap [31,32]. 
Little is known regarding mechanisms that bring luminal and membrane proteins 
together during granule biogenesis. In many cells targeting of membrane proteins to 
granules is accomplished by specific sequences in the cytosolic carboxy-terminal tails of 
these proteins [38,39]. Such signals have been reported only for LAMP-l and LAMP-2, 
which are neutrophil specific granule membrane proteins [40], and LAMP-3 (CD63), 
which is an azurophil granule protein [41]. Thus, the appearance of other membrane 
proteins in neutrophil granule membranes may be a passive process. Luminal proteins 
may be directed to granule precursors by matrix proteoglycans by facilitating co-
aggregation of granule luminal and membrane proteins in the trans-Golgi network 
[42,43]. Indeed, this role in neutrophil granule formation was recently confirmed for the 
proteoglycan serglycin [44]. 
Granule heterogeneity provides the neutrophil with the ability to segregate 
proteins that cannot be stored in the same compartment, as well as to differentially 
exocytose proteins that are stored in different granules. For instance, azurophil granules 
carry terminally processed and active serine proteases, antibiotic peptides, and 
myeloperoxidase. Specific granules, on the other hand, store metalloproteases and 
antibiotic peptides as inactive pro forms. Mixing of contents from azurophil and specific 
granules results in the cleavage and activation of the pro- forms of specific granule 
proteins by azurophil granule proteases [18]. Granule content mixing will also bring the 
peroxidase-negative granule component flavocytochrome b558 and azurophil granule 
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myeloperoxidase into close proximity. Myeloperoxidase transforms oxygen radicals 
made by the NADPH oxidase into even more toxic hypochlorous acid [45]. This mixing 
was confirmed by studies showing that the interaction of superoxide anion with 
myeloperoxidase converts luminol to aminophthalate to generate light in intracellular 
compartments in neutrophils [20]. Since the cytoplasm is loaded with oxygen radical 
scavengers, diffusion of superoxide anion to the azurophil granule is unlikely to occur, 
and the fusion of specific granules with azurophil granules is a more plausible 
explanation. Intracellular granule-to-granule fusion in neutrophils has also been 
documented by membrane capacitance techniques and electron microscopy [46]. Up to 
20 percent of exocytotic events in neutrophils may occur by fusion of granules with each 
other prior to their fusion with the plasma membrane (compound exocytosis), which 
includes the fusion of one granule with another that has already fused with the plasma 
membrane (cumulative fusion) [46]. 
Neutrophil Granules Exocytosis 
General Aspects of Neutrophil Exocytosis 
Granule exocytosis can be divided into several steps that lead to the granule 
membrane fusion with the plasma membrane. [47,48]. The events that occur during 
exocytosis can vary from cell to cell, and some steps may not occur in a particular cell 
type. Usually, granule exocytosis involves Ca2+-, ATP-, GTP-, and lipid-mediator-
dependent events. These include physical movement of granule to the subplasmalemmal 
region of the cell, reorganization of the subplasmalemmal and/or granule-associated 
cytoskeleton to allow granules access to the plasma membrane, tethering and then 
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docking on the plasma membrane, triggered membrane fusion, and finally, the release of 
granule contents through a fusion pore (illustrated in Figure 2). 
Many cells can regulate the extent of degranulation by maintaining a readily 
releasable or primed pool of granules that are docked to the plasma membrane, or are 
immobilized in close proximity to it [49-52]. Granules are not found docked or otherwise 
segregated in neutrophils [53-55]. Following stimulation, granules are localized to a 
region near lamellipodia, but they are still randomly distributed [56]. Thus, neutrophils 
do not utilize physical segregation of different granule subsets as the means of achieving 
graded exocytosis. Although the mechanism of graded exocytosis is not clear, 
quantitative or qualitative differences in the expression of membrane proteins that control 
membrane fusion is one possible explanation. 
Membrane Fusion Machinery 
Membrane fusion during exocytosis of intracellular vesicles and granules is 
carried out by similar protein complexes in all eukaryotic cells. This protein complex 
consists of a hexameric ATPase NSF (N-ethylmaleimide-§ensitive fusion protein), a, ~, 
or y SNAPs (§oluble NSF ~ttachment groteins) and SNAREs (SNAP receptors) [57]. 
Mammalian SNAREs are divided into three families: VAMPs (yesicle ~ssociated 
membrane grotein), syntaxins, and SNAP-23/25 (§Y!1aptosome-~ssociated grotein). 
Some evidence suggests that SNAREs can reside on vesicles (v-SNAREs) or on target 
membranes (t-SNAREs), possibly adding specificity to the vesicle-target membrane 
interaction [58]. 
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Figure 2. Schematic representation of the steps leading to secretory granule 
exocytosis. This represents the events observed in neuroendocrine cells. In this case, 
subcortical actin cytoskeleton is disassembled. Concurrently, Ca2+_ and ATP-dependent 
granule-associated cytoskeletal reorganization participates in the granule recruitment to 
the plasma membrane. Tethering and docking of the granule can then occur. 
Subsequently, membrane fusion and the release of granule contents takes place. Adapted 
from Burgoyne and Morgan [47]. 
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SNARE proteins are characterized by SNARE helical motifs [59]. An alternative 
SNARE classification is based on the presence of a conserved glutamine (Q-SNARE) or 
arginine (R-SNARE) in the SNARE motif [60]. Q-SNAREs are almost always t-SNAREs 
and R-SNAREs are almost always v-SNAREs. Upon contact between SNAREs, SNARE 
motifs assemble into parallel four-helix bundles containing 3 Q-helices from two t-
SNAREs and one R-helix from a v-SNARE [60,61]. These coiled-coil bundles are 
stabilized by the burial of hydrophobic helix surfaces in the interior of the structure 
[62,63]. The coiling of SNARE motifs within complexes brings the membrane of the 
granule/vesicle and the plasma membrane into close proximity [64]. Assembled SNARE 
complexes are resistant to SDS and have extremely high thermal stability [65,66]. Thus, 
the complex formation likely releases sufficient energy to overcome the hydration barrier 
and initiate bilayer fusion. After the SNARE complex is formed, aSNAP binds to the 
complex and recruits NSF from the cytoplasm. NSF then uses ATP hydrolysis to 
dissociate the SNAREs and prepare them for another round of fusion [67]. 
Access of v-SNAREs to t-SNAREs is regulated by proteins termed SNARE-
masters, including Munc-18, Munc-13, and Ca2+ -binding synaptotagmin [68-70]. These 
proteins are regulated by post-translational modifications and/or by binding to second 
messengers. For example, phosphorylation of Munc-18 releases it from syntaxin-4, 
allowing syntaxin-4 to interact with V AMP-2 [70]. Munc-13 is recruited to the plasma 
membrane by binding to diacylglycerol (DAG), where it enhances exocytosis [71]. 
Only a limited number of membrane proteins have been identified from 
neutrophil granules [8,9]. They are listed in Table 1. Among the identified proteins are a 
few SNARE proteins. The v-SNARE, V AMP-2, has been found in the membranes of 
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Table 1 
Known proteins of neutrophil granules 
Gelatinase Granules Specific Granules Azurophil Granules 
Membrane CDIIb CDIIb CD63 
CDI8 CDI8 CD68 
Cytochrome bSS8 CD66b Presenilin 1 
Formyl peptide receptor CD67 Stomatin 
LAMP-I, LAMP-2 Cytochrome bSS8 V-type H+-ATPase 
Leukolysin fibronectin receptor 
SCAMP formyl peptide receptor 
SNAP-23 G-protein u subunit 
VAMP-2 Laminin receptor 






~umen Acetyltransferase 132-Microglobulin iAcid l3-glycerophosphatase 
132-Microglobulin Collagenase !Acid mucopolysaccharide 
Gelatinase SGP-28 (CRISP-3) u-Mannosidase 













Proteins that have been identified as components of the three neutrophil granule subsets 
are listed (modified from references 8 and 9). 
l3 
secretory vesicles and specific and gelatinase granules, but not azurophil granules [72]. 
The plasma membrane of neutrophils contains t-SNAREs, syntaxin-4 and syntaxin-6 
[72,73]. Specific and gelatinase granules contain SNAP-23 [73], which participates in the 
SNARE complex formation with syntaxin-4 and V AMP-2 in non-neuronal tissues 
[74,75]. SNAP-23 and V AMP-2 act as v-SNAREs on specific and gelatinase granules, 
while syntax in 4 and 6 act as t-SNAREs in the plasma membrane [76). A v-SNARE for 
azurophil granules has not been defined. Additionally, syntaxin 7 has been found to be 
expressed upon neutrophil-like differentiation of HL-60 cells [77). VAMP-I, V AMP-3, 
SNAP-25, synaptotagmin, and NSF were not detected in neutrophils, while no data are 
available regarding the presence of a, p, or y SNAPs [72,78). No reports of vesicle 
tethering proteins or SNARE masters being discovered on neutrophil granules exist. 
Role of Cytoskeleton in Neutrophil Degranulation 
Most cells, including neutrophils, possess actin filaments organized into a cortical 
F-actin network beneath the plasma membrane [47]. It has been suggested that this 
cortical actin network forms a barrier to exocytosis and, thereby, acts as a site of 
regulation of exocytosis [79,80). The most compelling indication that cytoskeleton plays 
an important role in neutrophil exocytosis comes from the fact that pretreatment of 
neutrophils with an actin-depolymerizing drug, cytochalasin, prior to the cell stimulation, 
depolymerizes subcortical F -actin and greatly enhances exocytosis of all granule subsets 
[8). F-actin depolymerization alone, however, does not lead to granule exocytosis. 
Cortical actin disassembly is likely to be carried out by actin-depolymerizing 
proteins, many of which are activated by elevated calcium [81). These proteins have been 
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shown to act in reorganization of subcortical actin during secretion in chromaffin cells, 
allowing granules to reach the plasma membrane in a calcium-dependent manner [82-84]. 
Such studies have not yet been carried out in neutrophils, and mechanisms that mediate 
subcortical actin reorganization during exocytosis in PMNs are unclear. 
F-actin is found on granules, and structural changes that occur in this pool of F-
actin are required for exocytosis [83,85-87]. Lipid bilayers do not undergo fusion 
spontaneously, since there is a large electrostatic force between two lipid bilayers that 
opposes their fusion [88]. Actin was shown to spatially restrict fusogenic proteins to 
fusion sites and/or apply force to aid membrane fusion during zymogen granule 
exocytosis in pancreas [80]. Generation of force may be occurring through interaction of 
F-actin with tropomyosin [81]. F-actin also interacts with myosin motor proteins found 
on granules, and this interaction is important for granule locomotion through actin 
network and immobilization of granules near the plasma membrane [89]. Actin 
cytoskeleton has been shown to interact with SNARE proteins, for example, a-fodrin, a 
major component of subplasmalemmal cytoskeleton interacts with syntaxins [90], while 
the actin motor protein myosin V binds VAMPs in a calcium-dependent manner [91]. 
Apart from actin, cytoskeleton also consists of tubulin (microtubules) and 
vimentin (intermediate filaments). There is evidence that microtubules and intermediate 
filaments participate in neutrophil exocytosis. A direct interaction of specific and 
azurophil granules with microtubules was reported by Rothwell et ai., who observed that 
binding of granules to microtubules increased upon fMLP stimulation [92]. Further 
studies identified a microtubular motor protein kinesin on both types of granules [93]. 
Microtubules likely act as tracks for long-range movement of granules. Using colchicine, 
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a microtubule-depolymerizing drug, it was shown that microtubules directed azurophil 
granules, and to a lesser extent of specific granules, to phagosomes [94]. 
Microtubule dynamics in neutrophils are controlled in part by second messengers. 
It was shown that an increase in intracellular cGMP levels increased the formation of 
microtubules in neutrophils and enhanced degranulation [95,96], while agents that 
increase cAMP levels have opposite effects [96,97]. cGMP may also signal to vimentin, 
which has been implicated in neutrophil degranulation. In fMLP-treated neutrophils 
vimentin filaments reorganized with a concomitant increase in cGMP levels and 
degranulation, while inhibition of guanylate cyclase inhibited granule content secretion 
and vimentin filament reorganization [98]. , 
Like actin, vimentin and tubulin interact with membrane fusion machinery. 
Vimentin filaments bound SNAP-23 and maintained a reservoir of this SNARE protein in 
fibroblasts [99]. SNAP-23 dissociated from vimentin filaments upon cell stimulation and 
translocated to the plasma membrane. Microtubules were shown to interact with Munc-I8 
in mast cells and participate in its redistribution [100]. In both studies the redistribution 
of these proteins was important for degranulation. Such studies have not been carried out 
in neutrophils. It is clear, however, that microfilaments, microtubules, and intermediate 
filaments are involved in neutrophil granule exocytosis, although their exact functions 
remain to be elucidated. 
Signal Transduction in Neutrophil Exocytosis 
Calcium, G proteins, lipid mediators, and protein kinases all mediate signaling 
events that lead to exocytosis in neutrophils, although the mechanisms of their action are 
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sti11largely unclear. The following section provides a brief overview of major pathways 
and signaling molecules that are involved in neutrophil degranulation. 
Role of Calcium in Neutrophil Exocytosis 
The best-characterized signal-transduction event leading to a rise in intracellular 
free Ca2+ concentrations ([Ca2+]i) in neutrophils is that induced by agonists that bind to G-
protein-coupled receptors. Phospholipase C (PLC) is activated, which cleaves 
phosphatidylinositol 3,4 bisphosphate (PIP2) into diacylglycerol (DAG), a PKC agonist, 
and inositol 1,4,5-trisphosphate (IP3) [101]. IP3 induces [Ca2+]i elevation by releasing 
Ca2+ from intracellular stores into the cytoplasm. This Ca2+ release is followed by an 
influx of extracellular Ca2+ via plasma membrane calcium channels (reviewed in ref. 
[102-104]. 
It has been documented that neutrophil exposure to various secretagogues, such as 
fMLP [105], IL-8 [106], and C5a [107] leads to a concomitant increase in [Ca2+Ji, TNFa 
and GM-CSF, both weak secretagogues, did not increase [Ca2+]i in adherent neutrophils 
[108]. Chelation of intracellular calcium to levels below the resting level, however, 
inhibited TNFa- and GM-CSF-induced degranulation in adherent cells. Thus, Ca2+_ 
dependent processes may participate in neutrophil degranulation even when the 
secretagogue does not induce a measurable increase in [Ca2+Ji, 
Lew et al. showed that buffering of intracellular calcium prevented fMLP-induced 
degranulation [109]. There were other factors, however, that were important for full 
exocytotic response upon fMLP-stimulation. Thus, a given rise in [Ca2+]i elicited by the 
fMLP was associated with a much greater degree of exocytosis than was the same or 
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larger rise in [Ca2+]i produced by calcium ionophore ionomycin. Therefore, fMLP 
generates an important excitatory signal in addition to a rise in [Ca2+]i. 
The sensitivity of granule release to Ca2+ follows a hierarchical pattern that 
reflects the overall hierarchy of granule exocytosis in neutrophils [11,11 0]. 
Measurements of dependence of exocytosis of each granule type on [Ca2+]j, showed that 
the cytosolic Ca2+ levels that induce half-maximal exocytosis (EC50) were: for secretory 
vesicles - 140 nM, for gelatinase granules - 250 nM, for specific granules - 550 nM, and 
for azurophilic granules - 680 nM [11]. FMLP-induced gelatinase and specific granule 
exocytosis from MAPTAM-Ioaded (a calcium chelator) cells placed in a calcium-free 
buffer were only 42% and 32%, respectively, of the exocytosis in normal neutrophils. 
Thus, total depletion of intracellular and extracellular Ca2+ did not abolish exocytosis in 
neutrophils. 
The differences in granule sensitivity to calcium may be due to the differences in 
composition of Ca2+ binding proteins on granule subsets. The effect of calcium on 
exocytosis and membrane fusion is likely to be mediated by calcium-binding proteins 
found in neutrophil cytosol and on granules. The calcium-dependent SNARE modulator, 
synaptotagmin, is not found in neutrophils. Three calcium binding proteins, annex in I, 
annexin III, and grancalcin, have been reported to associate with neutrophil granules. 
Grancalcin is a 28 kDa protein abundant in neutrophils, and its quantity on the granule 
surface increases upon neutrophil activation [111,112]. Using grancalcin-deficient mice, 
Roes et ai. showed that this protein is not essential for leukocyte effector functions 
required to control microbial infections [113]. 
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Annexins are calcium and phospholipid-binding proteins that are known to 
aggregate liposomes in a calcium-dependent manner [114,115]. Annexin III was found in 
the cytosol and also associated with the specific granules in neutrophils [116], and 
promoted Ca2+-dependent aggregation of isolated specific granules [117]. Additionally, 
upon introduction of recombinant annexin III into permeabilized cells, degranulation was 
significantly enhanced upon exposure to calcium, while the addition of annexin I resulted 
only in a modest increase in secretion [118]. In this study, the authors found that 
induction of degranulation by calcium was completely inhibited when intracellular ATP 
was depleted prior to permeabilization. Moreover, exocytosis was rescued upon addition 
of Mg-ATP to ATP-depleted, permeabilized cells. Thus, in addition to calcium, cells 
required ATP for exocytosis, and sufficient amounts of ATP remained in cells after 
permeabilization, but not after ATP-depletion. 
Theander et al. investigated ATP dependence of calcium-induced neutrophil 
granule exocytosis in greater detail in cytochalasin B-treated cells [119]. In this study, 
intracellular ATP concentrations were depleted to different values, and the cells were 
stimulated by intracellular delivery of Ca2+ using cell permeabilization or fMLP 
stimulation. Depletion of ATP reduced calcium-stimulated exocytosis. Additionally, 
fMLP-induced granule exocytosis required higher concentrations of ATP than exocytosis 
induced by ionomycin. This suggests that fMLP-induced exocytosis has ATP-dependent 
steps even in the presence of cytochalasin B, which are bypassed by ionomycin 
treatment. Overall, the importance of calcium in neutrophil exocytosis is well 
documented, however, the requirement of other factors in PMN degranulation is clear. 
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Role of GTP-binding Proteins in Neutrophil Granule Exocvtosis 
Chemokines and chemotactic peptides that induce neutrophil degranulation bind 
to G protein-coupled receptors whose activation induces the dissociation of Ga and G~y 
subunits of heterotrimeric G proteins [120]. As mentioned above, heterotrimeric G 
proteins are involved in exocytosis through modulation of calcium fluxes. In many cells, 
including neutrophils, G proteins activate additional pathways that are important for 
exocytosis. Stimulation of permeabilized neutrophils with the nori-hydrolysable analog of 
GTP, GTP-y-S, induced calcium flux and exocytosis in permeabilized neutrophils, 
however, significant exocytosis occurred even when an increase in [Ca2+]i was prevented 
by chelation [121-124]. 
GTPyS activates both heterotrimeric and monomenc G proteins, preventing 
delineation of which G proteins participate in exocytosis. Both monomenc and 
heterotrimeric G proteins have been implicated m neutrophil exocytosis. The 
involvement of heterotrimeric G-proteins was confirmed by using pertussis toxin, which 
ADP-ribosylates Gai and Gao subunits and inhibits their activation. This toxin inhibited 
neutrophil granule exocytosis induced by fMLP, C5a, or leukotriene B4 [125]. It did not 
affect granule enzyme release initiated by Ca2+ ionophore or PMA. This is reflective of 
the locus of action of heterotrimeric G proteins, which transmit activation signal from 
surface receptors to downstream signals leading to a rise in intracellular Ca2+. This 
conclusion is demonstrated by the finding that the rise in intracellular Ca2+ induced by 
fMLP or LTB4, is greatly reduced in pertussis toxin-treated neutrophils [126]. 
Gai inhibits adenylyl cyclase and Gao activates PLCP [127]. Inhibition ofGai by 
pertussis toxin could lead to a rise in the levels of cAMP, which would inhibit exocytosis 
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by negatively affecting microtubule assembly [96,97]. Likewise, inhibition of Gao would 
prevent activation of PLC~ and generation of IP3, which releases Ca2+ from intracellular 
stores, and DAG, which activates PKC. Inhibition of these processes may negatively 
influence exocytosis. G~y subunits of heterotrimeric G-proteins are involved in neutrophil 
exocytosis by their ability to activate PLC~ as well as phosphatidylinositol-3-kinase 
(PI3K), which has also been implicated in degranulation [127,128]. Thus, G proteins 
regulate multiple pathways involved in exocytosis. 
Monomeric or small G-proteins are also involved in exocytosis. Ras-like GTPases 
Rapl and Rap2 are present on specific and gelatinase granules [129,130], while a G 
protein of the Rho family, Rac2, associates with the azurophil granules [130]. Rac2 
regulates cytoskeletal actin dynamics in neutrophils and together with another small G 
protein, Cdc42, stimulates actin filament assembly [131]. Viral transfection of 
neutrophils with dominant-negative Rac2 or Cdc42 revealed that Rac2 plays a major role 
in the control of directed granule mobilization toward Candida albicans phagosomes 
[132]. In addition, using neutrophils from rac2-1- mice, Rac2 was found to be 
indispensable for azurophil granule exocytosis in cytochalasin-treated cells, while 
specific and gelatinase granule release was normal [133]. 
Role of Lipid Mediators in Neutrophil Degranulation 
Lipid mediators released by phospholipases participate In neutrophil 
degranulation. Phospholipase A2 (PLA2) inhibition significantly reduces exocytosis, and 
arachidonic acid, a PLA2 product, augments fusion between liposomes and aggregated 
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specific granules [134,135]. Similar data exist regarding phospholipase D, which is 
activated by various secretagogues, and its product, phosphatidic acid [136-140]. 
Additionally, phosphatidic acid is a precursor of another lipid mediator, DAG. DAG is 
also generated by PLC [141], however, DAG has only a marginal effect on neutrophil 
exocytosis [139]. The artificial analogue of DAG, PMA, is a strong stimulant of 
neutrophil degranulation [73]. PMA and DAG may influence exocytosis by activating 
certain isoforms ofPKC, which has been implicated in degranulation of mast cells [142]. 
PKC does not playa major role in neutrophil degranulation [143,144]. Both DAG and 
PMA, however, also directly bind and activate Munc13, which is important in membrane 
fusion [71,145]. 
Phosphatidic acid itself may augment neutrophil degranulation by inducing non-
receptor tyrosine kinase activity in neutrophils, especially that of Fgr tyrosine kinase 
[146]. Activation of Fgr by direct binding of phosphatidic acid leads to neutrophil 
calcium mobilization and F-actin polymerization [146,147]. Tyrosine kinases may also 
act through phosphorylation of neutrophil PLD [148], as genistein-sensitive PLD tyrosine 
phosphorylation controls its activity and augments PMN degranulation [149]. 
Role ofKinases in Neutrophil Degranulation 
As alluded to above, tyrosine kinases have been implicated in neutrophil 
exocytosis. Tyrosine kinases are activated by various secretagogues [150,151], and 
tyrosine kinase inhibitors reduce degranulation [151,152]. In addition, tyrosine kinases 
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have been localized to neutrophil granules. For example, Fgr associates with specific 
granules [153], while Hck is on azurophil granules [154]. Using gene knockout mice, 
Mocsai et al. showed that hck/-fgf/- mouse neutrophils were deficient in adhesion-
dependent and fMLP-induced degranulation [155]. Syk, Yes, and Lyn formed a complex 
with, and activated another kinase that plays an important role in neutrophil 
degranulation, phosphatidylinositol-3-kinase (PI3K) [156, 157]. 
PI3K is also activated by ~y subunit of heterotrimeric G proteins [128,158]. 
Inhibition of PI3K reduced neutrophil degranulation [159-162]. PI3K activates various 
signaling proteins that are relevant to exocytosis, for example PLC and PLD [163], as 
well as guanylate cyclase [164]. In addition, PI3K activates a protein kinase that seems to 
play a central role in neutrophil exocytosis, the p38 mitogen-activated protein kinase 
(MAPK), which is described next. 
The p38 MAPK Pathway and Its Role in Neutrophil Exocytosis 
P38 MAPK, of which there are four isoforms (a,~,y,8), is one of four members of 
a family of proline-directed serine/threonine kinases that also includes extracellular 
signal-regulated kinases (ERKl/2), c-jun N-terminal kinases (JNKs) , and atypical 
MAPKs such as ERK5 [165-167]. MAPKs exist as three-kinase modules composed of a 
MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK. MAPKs are 
activated by dual phosphorylation on the Thr-X-Tyr motif by a MAP2K. MAP2Ks are 
controlled by phosphorylation on a serine or threonine by a MAP3K. MAP3Ks are 
activated by other kinases and/or by small GTP-binding proteins of the Ras and Rho 
family. The components of three-kinase modules are specific to each MAPK. MKK3 and 
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MKK6 phosphorylate and activate p38 MAPK, while the upstream MAP3Ks for the p38 
MAPK module include transforming growth factor beta-activated kinase 1 (TAK1), 
apoptosis signal-regulating kinase 1(ASK1), mixed lineage kinase (MLK) , tumor 
progression locus 2 (Tpl-2), p21-associated kinase (PAK), and thousand and one amino 
acid protein kinase (TAO) kinases. The actual composition of this module is cell type-
specific. 
Similarly to other MAPKs, p38 MAPK is activated by a wide array of mitogenic 
and stress-related stimuli. Upon activation it phosphorylates numerous substrates, 
including various transcription factors and protein kinases, one of which is MAPK-
activated protein kinase 2 (MK2) [165,166,168]. The expression ofp38 isoforms is also 
cell type-dependent. Neutrophils express only p38a and p388 isoforms [169], of which 
only p38a is inhibited by pyridinyl-imidazoles (e.g. SB203580) [170]. These compounds 
inhibit p38 kinase activity by competing for the ATP-binding site. Their selectivity is 
determined by differences in nonconserved regions within or near the ATP binding pocket 
[171]. As neutrophils are short lived, terminally differentiated cells, genetic manipUlation 
of the p38 MAPK pathway cannot be accomplished. Therefore, SB203580 and related 
inhibitors have been invaluable in elucidating p38 functions in these cells. 
A large number of secretagogues activate p38 MAPK in neutrophils. 
Chemoattractants stimulate p38 activity in a G-protein, PI-3K-and calcium-dependent 
manner [172-176], while stimulation by TNFa is PI-3K independent [173] and Src 
family tyrosine kinase-dependent [177]. Cross-linking of Fc receptors also leads to 
degranulation [178], and homotypic or heterotypic crosslinking of FcyRIIa or FcyRIITh 
activates p38 in a Src family kinase- and PI3K-dependent manner [179]. P38a is also 
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activated by LPS [169,180] and this activation is cGMP-dependent kinase- (PKG-) 
dependent [181,182]. PLCy is involved in the activation of p38 MAPK in PMNs 
challenged with Mycobacterium tuberculosis [183]. 
The requirement of p38 MAPK activity in neutrophil degranulation has been well 
documented. Inhibition of p38 MAPK by pyridinyl-imidazole compounds in neutrophils 
substantially reduced surface upregulation of granule membrane markers induced by 
Staphylococcus aureus [184], TNFa [185,186], IL-8 or L-selectin cross-linking [15], IL-
18 [187], fMLP [188], and LTB4 [189]. Although activation of p38 is essential for 
neutrophil granule exocytosis, selective activation of p38 alone by anisomysin does not 
result in PMN degranulation [190]. Thus, other signals are required. Mocsai, et al. 
showed that fMLP-induced p38 activation and degranulation required Hck, Fgr, and Lyn 
activities [188], while Yes tyrosine kinase was required for LTB4-induced exocytosis 
[189]. Unlike p38 MAPK, ERK inhibition does not affects degranulation [152,186,191], 
while JNK is not activated by proinflammatory stimuli in neutrophils in suspension 
[172,183,192]. 
The mechanism by which p38 MAPK controls neutrophil degranulation is not 
known, as the substrates of p38 MAPK that mediate this process are unknown. P38 
MAPK substrates include kinases - MAPK-activating protein kinase-2 and 3 (MK2 and 
MK3), p38-regulated kinase (PRAK), MAPK-interacting protein kinase 1 (MNKl), 
mitogen- and stress-activated protein kinases-l and -2 (MSKI and MSK2), and casein 
kinase 2 (CK2); transcription factors - MEF 2C and 2A, Elk-I, CHOP/GADDI53, 
CEBPP, p53, STAT 1, ATF-l and -2, CREB, Usf-l, NFATp, CDX3, PGC-l, and SAP-
1; and other substrates - cytosolic PLA2, stathmin, NalH exchanger, Cdc25b, and p47phox 
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[175,193] Of the known p38 substrates, only MK2 and p47phox phosphorylation by p38 
have been demonstrated in neutrophils [175,194,195]. P47phox participates in NADPH 
oxidase activation and MK2 phosphorylates the small heat shock protein Hsp27 that 
functions in actin remodeling [175,196]. Recently, inhibition of MK2 was shown to 
reduce TNFa-induced neutrophil degranulation, but had no effect on tMLP-stimulated 
exocytosis [195]. MK2 phosphorylates LSPl, 14-3-3s and p16-Arc in neutrophils, which 
are involved in cytoskeletal reorganization [197-199], and 5-lipoxygenase, which 
functions in the pathway of conversion of arachidonic acid to leukotrienes [200]. The role 
of phosphorylation of these proteins in neutrophil exocytosis has not been examined. 
MK2 phosphorylates vimentin [201] and myosin regulatory light chain [202], but these 
phosphorylation events have not been examined in neutrophils and their role in 
exocytosis is unclear. A recent proteomic study identified 25 proteins as downstream 
targets of the ERK pathway, of which only 5 were previously characterized ERK 
effectors [203]. This suggests that a number of substrates of the p38 MAPK pathway 
remain to be identified in order to better understand the role of p38 MAPK in neutrophil 
exocytosis. 
Application of Proteomics to Protein and Phosphoprotein Identification 
Proteomic Technology for Protein Identification 
The term "proteomics" refers to the large-scale analysis of complex protein 
mixtures. The technology used in proteomic analysis consists of sample deconvolution 
and identification of its protein content. Gel electrophoresis and liquid chromatography 
26 
are the most common methods for the protein deconvolution, while mass spectrometry 
(MS) is used for the identification of proteins. 
Two-dimensional gel electrophoresis (2DE) is a powerful method for protein 
separation [204]. It separates proteins first by isoelectric focusing (IEF) in a pH gradient 
and then by mass using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
P AGE). Introduction of immobilized pH gradient (JPG) acrylamide strips of various pH 
range and the precast gradient acrylamide gels for SDS-PAGE have made 2DE a 
relatively simple and widely available method [205]. 2DE has inherent limitations, such 
as inability to effectively resolve proteins with isoelectric points below 3 and above 9, 
and with masses above 100 kDa and below 10 kDa [205,206]. Hydrophobic and 
membrane proteins are also significantly underrepresented among proteins identified by -
2DE [207-209]. Introduction of high sensitivity fluorescent protein dyes such as SYPRO 
Ruby [210], novel zwitterionic detergents such as ASB-14 [211,212], and non-ionizable 
thiol-reducing agents as tributyl phosphine [213] have generally resulted in improved 
visualization and identification only of the type of proteins that were amenable to 2DE 
analysis, but has not enlarged the spectrum of proteins detected. Identification of proteins 
following their separation by 2DE requires excision of the protein spot from a gel, in-gel 
digestion using a protease or a chemical agent, and preparation of the resultant peptides 
for MS analysis. 
Liquid chromatographic separation of proteolytic peptides and their subsequent 
analysis by MS avoids problems associated with 2DE. Although proteins in simple 
mixtures can be successfully identified by combining single-dimensional liquid 
chromatography and mass spectrometry, the presence of a large number of peptides from 
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complex protein mixtures overwhelms the resolution capability of one-dimensional 
chromatography [214]. To address this problem, a recently developed method called the 
direct analysis of large protein complexes (DALPe) couples multidimensional liquid 
chromatography with tandem mass spectrometry (MS/MS) [215,216]. This method 
employs direct proteolytic digestion of complex protein mixtures and fractionation of 
resultant peptides by two-dimensional chromatography prior to their analysis by MS/MS. 
The first chromatographic step separates peptides by charge using an acidified sample 
and a strong cation-exchange (SeX) microcapillary column. Peptides in individual sex 
fractions are then further fractionated by hydrophobicity over a reversed-phase high-
pressure liquid chromatography (RP-HPLC) column and eluted with an acetonitrile 
gradient. Peptides in the eluate are directly analyzed by electro spray ionization (ESI)-
MS/MS and the protein content of the original sample is then deduced from the thousands 
of collected MS/MS spectra by genome-assisted computer analysis [214]. Using this 
approach, large protein complexes such as ribosomes and transcriptional machinery have 
been successfully analyzed [215,216]. 
Mass spectrometry allows identification of proteins at femtomol quantities [217]. 
Mass spectrometers deliver peptides to a mass detector by ionizing them and accelerating 
the ionized peptides using magnetic fields [218]. Two common methods of ionization are 
matrix-assisted laser desorption/ionization (MALDI), and electro spray ionization (ES!). 
MALDI ionizes peptides by laser light-induced energy transfer from the light-absorbing 
matrix to the matrix-embedded peptides. ESI causes ionization by electrically generating 
a fine mist of peptide-containing liquid droplets that reach a size limit at which charge 
repulsion exceeds the surface tension of the droplet, resulting in desorption of peptides 
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from droplets as bare ions. The mass to charge ratios (mlz) of the resultant ions are then 
analyzed by time of flight (TOF) analysis, quadrupole (Q) MS, or Fourier transform ion 
cyclotron resonance (FT -ICR) MS. When used in tandem (MSIMS), TOF and Q MS 
instruments can generate peptide sequence data (FT-ICR is a tandem spectrometer in 
itself). The first MS analysis obtains mlz values for peptides generated by protein 
digestion, which is followed by gas-generated collision-induced dissociation (CID) or 
fragmenting of selected peptides into smaller ions, which can also be analyzed for mlz 
values. Comparison of the acquired spectra with the predicted spectra from genome 
databases using mathematical algorithms, allows for matching of the obtained spectrum 
with the spectra of proteins in the database, thus identifying the proteins present in the 
sample. 
Proteomic Methods for Identification of Phosphoproteins 
Detection and identification of phosphoproteins is a challenging task due to the 
low abundance of these proteins, low stoichiometry of phosphorylation, and the 
complexity of protein mixtures. Advances in proteomics technology resulted in 
availability of several approaches for phosphoprotein identification. These include gel 
electrophoresis-based, chromatography-based, and mass spectrometry-based approaches 
[219]. 
The oldest method of phosphoprotein detection is the radioactive labeling of 
proteins using e2p]ATP in vitro or e2p]orthophosphate in vivo prior to separation of 
proteins by 2DE. This is followed by total protein staining, comparison of 
autoradiographs with stained gels and identification of phospho proteins using MS. In vivo 
29 
labeling of proteins with e2p]orthophosphate does not allow detection of 
phosphoproteins with low phosphate turnover, and identification of substrates of a 
specific kinase for the large number of phosphoproteins is difficult. In vitro labeling of 
proteins with e2p]ATP has been used to successfully identify substrates of a specific 
kinase [198,199]. This approach uses solubilization of cellular proteins in 9M urea buffer 
to effectively extract proteins and inactivate endogenous kinases by denaturation. This is 
followed by reduction of the urea concentration to 1M to allow activity of the 
endogenously added recombinant kinase, which phosphorylates proteins in the presence 
of e2p]ATP. Proteins are then subjected to 2DE, phosphoproteins visualized by 
autoradiography, and identified by MS. 
Western blotting can also be used for phosphoprotein identification. Western 
blotting of gels using antibodies against phospho serine, phosphothreonine, or 
phosphotyrosine can be carried out and the obtained pattern of spots can be compared to 
a pattern of protein spots on a gel that was run in parallel to the transferred gel and 
stained for total protein [220]. The spots visualized by western blotting are matched 
against the corresponding spots on the gel, and the protein in this spot is then identified 
using MS. This method is limited by the quality and specificity of anti-phosphoamino 
acid antibodies. 
Another method that utilizes 2DE for phosphoprotein identification takes 
advantage of detection of a pI shift upon protein phosphorylation [203]. In this approach, 
the protein pI shifts are compared between gels loaded with protein extracts from 
untreated cells, cells treated with kinase activators in the presence or absence of specific 
kinase inhibitors, and cells with constitutively active kinase. Proteins in question are then 
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identified using MS. Although quite successful at identifying novel kinase substrates, the 
limitation of this approach is that some shifts in the pI are too small to observe, or may be 
produced by post-translational modifications other than phosphorylation. 
A novel and promising approach to phosphoprotein detection and identification is 
the use a recently described phosphoprotein-specific fluorescent dye ProQ Diamond 
(Molecular Probes) [221,222]. It discriminates between phosphorylated and 
unphosphorylated proteins with a high specificity, and it is compatible with protein dyes 
such as SYPRO Ruby. It can be used to stain phosphoproteins in acrylamide gels and its 
compatibility with SYPRO Ruby allows the simultaneous identification of proteins and 
phosphoproteins for more effective localization of phosphoprotein spots for excision and 
identification by MALDI-MS. Although the ProQ Diamond dye is novel and its 
usefulness is not yet completely characterized, it appeared to permit identification of 
phosphoproteins in nanogram quantities per spot [222]. 
Phosphoproteome analysis in a complex sample is difficult. Immunoprecipitation 
of phosphorylated proteins is possible only with anti-phosphotyrosine antibodies, as they 
possess sufficient affinity to immunoprecipitate proteins that contain phosphorylated 
tyrosine residues [223]. The antibodies that recognize pho spho serine and 
phospho threonine are typically sensitive to surrounding amino acids and have lower 
affinity, thus not permitting enrichment of phosphorylated proteins by 
immunoprecipitation [220]. To address this problem of sample deconvolution, 
immobilized metal-affinity chromatography (IMAC) has been adopted for the enrichment 
of phosphopeptides and phosphoproteins. In this technique, trivalent metals (most 
commonly Ga3+ or Fe3+) are immobilized on a solid-phase support conjugated to metal-
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chelating moieties (iminodiacetc acid - IDA, or nitrilotriacetic acid - NT A), and the 
peptide or protein mixture is applied [224,225]. Acidic phosphate residues bind 
noncovalently to trivalent metals and can be eluted by phosphoric acid. Modification of 
acidic amino acids by methylesterification is advantageous in elimination of non-specific 
binding of peptides [226], but results in loss of some phosphorylated peptides [227]. 
When IMAC was coupled with HPLC-ESI-MS/MS, hundreds of phosphopeptides were 
detected (sensitivity was 5 fmol per phosphorylated peptide) [225,226]. Peptide IMAC is 
characterized by bias toward enrichment of mUltipely phosphorylated peptides, which 
bind trivalent cations better than singly phosphorylated ones. This bias is reduced and 
more phosphopeptides are detected when protein IMAC is combined with the peptide 
IMAC [228]. 
Advances III mass spectrometry have also improved phosphoproteome 
identification and allowed identification of phosphorylation sites in proteins [219,229]. 
Two methods that have contributed significantly to the MS analysis of phosphoproteins 
are precursor-ion scanning and neutral-loss scanning of peptides, which rely on tandem 
mass spectrometry. In precursor ion scanning for peptides with phosphoserines and/or 
phosphothreonines, the mass spectrometer is usually operated in a negative mode 
(analyzes negatively charged peptides, which will include the phosphopeptides). When 
sufficiently stringent CID conditions are chosen, the loss of a molecule of phosphoric 
acid will generate a negative P03 ion (79 Da). Following a survey analysis of the 
spectrum, the instrument can be operated in the positive-ion mode to select those peptides 
and obtain MS/MS spectra from them. That approach, however, does not allow 
identification and sequencing in the same run. Operation of the instrument in the positive 
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ion mode can be used for the analysis of peptides with phosphotyrosine, which is much 
more stable than phosphoserine and phosphothreonine, but will usually generate a 
positive immonium ion at mlz 216. Precursor ion detection and MS/MS are performed in 
the positive-ion mode that allows the identification and sequencing in the same analysis. 
The disadvantage is that the identification of phosphotyrosine in that approach might not 
be specific, because some amino acid doublets or triplets generate ions with mlz values 
very close to 216 [230]. 
Another approach to the identification and analysis of phosphopeptides is the use 
of neutral-loss scanning. In the CID of phospho serine- and phosphothreonine-containing 
peptides, phosphoric acid can be lost through ,B-elimination. That neutral loss of 
phosphoric acid (98 Da) is used to identify phosphorylated peptides from a complex 
peptide mixture. After peptides with a loss of 98 Da in mass are identified, the MS/MS 
spectra can be acquired from to obtain amino acid sequence information. This approach 
can also be used to identify phosphotyrosine by a search for the immonium ion at mlz 
216 after fragmentation. Thus, acquisition of peptide spectra with and without 
fragmentation can be accomplished simultaneously. 
Project Goals and Specific Aims 
The signaling pathways that govern the mobilization of neutrophil granules are 
largely unknown. It has been shown in our laboratory that p38 mitogen-activated protein 
kinase (MAPK) and its downstream target, MAPK-activated protein kinase-2 (MK2), 
playa role in neutrophil exocytosis. The mechanism by which the p38 MAPK cascade 
mediates this process is not clear. Understanding the role of p38 MAPK and MK2 in 
neutrophil exocytosis will require identification of downstream targets that mediate 
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exocytosis. We examined the hypothesis that p38 MAPK and/or MK2 regulate 
neutrophil degranulation by phosphorylating granule membrane proteins that 
modulate exocytosis. Proteomics were used to identify the substrates of the p38 MAPK 
pathway that are associated with neutrophil granules. These data may identify targets for 
phannacological regulation of neutrophil function during autoimmune and inflammatory 
diseases. The specific aims of the project were: 
1 - Identify potential p38 MAPK and MK2 substrates on granules using proteomics. 
Experimental Approaches. We used 2DE and liquid chromatography and mass 
spectrometry-based approaches to investigate the proteome of each granule subset 
and identify known MK2 and/or p38 MAPK substrates on granules. To discover 
novel substrates on granules we utilized the in vitro labeling of urea-solubilized 
granule proteins with e2p]ATP using recombinant MK2 and p38 MAPK followed 
by separation and identification of labeled proteins using 2DE and mass 
spectrometry. 
2 - Confirm the ability of p38 MAPK and/or MK2 to interact with and phosphorylate 
these substrates in vitro and in situ. 
Experimental Approaches. In vitro kinase reactions were carried out under non-
denaturing conditions using e2p]ATP, the recombinant kinase, and the purified 
substrate, to confinn that the identified protein was indeed a substrate for the 
kinase in vitro. Immobilized metal affinity chromatography (IMAC) and mass 
spectrometry were used to identify the putative phosphorylation site on the 
protein. Identity of the phosphorylated residue was confinned by expressing a 
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mutant recombinant protein with the putative phosphorylated residue changed to 
an alanine, and sUbjecting wild-type and mutant recombinant proteins to an in 
vitro kinase reaction using recombinant kinase and e2p]ATP. In situ 
phosphorylation of the candidate substrate was screened by labeling neutrophils 
with e2P]orthophosphate and observing the phosphorylation of the candidate 
substrate in stimulated cells using 2DE and autoradiography in the presence or 
absence of the specific inhibitor of the kinase. 
3 - Determine the role of phosphorylation of selected p38 and MK2 substrates in 
granule exocytosis. 
Experimental Approaches. The biological significance of substrate 
phosphorylation was assessed by investigating the phosphorylation-dependence of 
substrate translocation to granules and cytoskeleton in stimulated neutrophils in 
the presence or absence of the kinase inhibitor. Confocal microscopy of 
neutrophils and western blot analysis of isolated granule subsets was utilized for 
this purpose. Furthermore, the dependence of substrate binding to actin 
cytoskeleton on the phosphorylation of the substrate by the kinase was 
investigated by an in vitro binding assay using F -actin and purified 
phosphorylated or unphosphorylated substrate. 
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CHAPTER II 
PROTEOMIC ANALYSIS OF HUMAN NEUTROPHIL GRANULES 
Foreword 
The goal of the project was to define targets of the p38 MAPK pathways that 
regulate neutrophil exocytosis. Previous studies showed that inhibition of p38 MAPK 
significantly attenuates exocytosis stimulated by IL-8, TNFo" fMLP, and LTB4 
[15,185,188,189]. The downstream kinase of p38 MAPK, MAPKAPK2, was shown to 
mediate p38 MAPK-dependent exocytosis of specific granules [195]. The molecular 
mechanism by which p38 MAPK and/or MAPKAPK2 regulate exocytosis is unknown. 
To accomplish the goal of the project, two separate proteomic approaches were applied. 
First, to identify potential mediators of p38 MAPK-dependent exocytosis, the proteome 
of neutrophil granule subsets was defined. This proteome was used to identify known 
targets of p38 MAPK and MAPKAPK2 on granules. Second, the p38 MAPK and MK2 
phosphoproteome on neutrophil granules was determined by proteomic technology 
(described in Chapter III). The following chapter presents the proteome, defined by two-
dimensional gel electrophoresis (2DE) followed by matrix-assisted laser desorption and 
ionization mass spectrometry (MALDI-MS) and by two-dimensional HPLC and 
electro spray ionization tandem mass spectrometry (2D-HPLC ESI-MSIMS), of 
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neutrophil granule subsets enriched by subcellular fractionation using Percoll density-
gradient centrifugation. 
Introduction 
Stimulated exocytosis of membrane-bound compartments plays a critical role in 
converting inactive, circulating neutrophils to fully activated cells capable of directed 
migration, phagocytosis, and killing of microbes [9]. Four subsets of membrane-bound 
compartments exist in neutrophils: secretory vesicles, gelatinase (tertiary) granules, 
specific (secondary) granules, and azurophil (primary) granules [8,9]. Secretory vesicles 
are generated by endocytosis, resulting in membranes rich in receptors, signaling 
proteins, and adhesion molecules, while their lumen contains plasma [8]. Azurophil, 
specific, and gelatinase granules contain various enzymes and host defense proteins in 
their luminal spaces, while their membranes contain receptors, signaling proteins, 
adhesion molecules, and enzymes [8,24]. The targeting of proteins to individual granule 
compartments is determined by the timing of protein synthesis during myeloid progenitor 
cell differentiation, not by granule-specific sorting [31]. Thus, granule proteins that are 
synthesized at a given stage of cellular differentiation will be localized to the same type 
of granule [231,232]. The overlap between the timing of synthesis of different granular 
proteins gives rise to some overlap of contents among different granule subsets [32,232]. 
The extent of mobilization of the three types of granule depends on the stimulus 
intensity, while the order of mobilization is fixed, a process termed graded exocytosis 
[11,12]. Gelatinase granules are most easily mobilized, followed by specific granules, 
and then azurophil granules. Graded exocytosis results in stepwise addition of granule 
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membrane proteins to the plasma membrane and stepwise release of granule luminal 
contents into the extracellular space. The controlled exocytosis of neutrophil granules 
allows sequential acquisition of functional responses and targeted delivery of toxic 
granule proteins, thereby reducing damage to normal host tissue. 
In addition to graded granule release, neutrophil exocytosis is distinguished by 
two other attributes. The first is a lack of spatial organization of granules [30,233,234]. 
The random distribution of granules in the cytosol of circulating neutrophils suggests that 
graded exocytosis requires a mechanism to discriminate among granule subsets. The 
second attribute is compound exocytosis, the fusion of two or more granules prior to their 
fusion with the plasma membrane [46]. Compound exocytosis requires recognition of 
granule subsets as target membranes to allow for homotypic or heterotypic fusion. 
Homotypic fusion enhances the localized delivery of granule contents. Heterotypic fusion 
allows processing of certain granule constituents into active forms by proteolytic 
cleavage [235]. 
The molecular mechanisms that control exocytosis of neutrophil granules are 
poorly defined. Additionally, the full complement of functional changes resulting from 
exocytosis of different granule subsets remains to be identified. A major reason for this 
limited understanding of neutrophil exocytosis is an incomplete identification of 
membrane and luminal proteins of each granule subset. To address this problem, we 
performed proteomic profiling of the components of azurophil, specific, and gelatinase 
granules from human neutrophils. Two different methods for granule protein 
identification were applied. One used two-dimensional gel electrophoresis (2DE) 
followed by matrix-assisted laser desorption ionization time of flight mass spectrometry 
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(MALDI-TOF MS) analysis of pep tides obtained by in-gel trypsin digestion of proteins. 
In the other, peptides from tryptic digests of granule membrane proteins were separated 
by two-dimensional microcapillary chromatography using strong cation exchange and 
reverse phase microcapillary high pressure liquid chromatography and analyzed with 
electro spray ionization tandem mass spectrometry (2D-HLPC ESI-MSIMS). Our analysis 
identified 286 proteins on the three granule subsets. Additionally, optimal methods for 
protein identification differed among granule subsets based on their physical .properties 
and luminal components. 
Methods 
Neutrophil Isolation 
Neutrophils (8 x 108 cells) were isolated from healthy donors using plasma-
Percoll gradients as described by Haslett et al. [236]. Trypan blue staining revealed that 
at least 97% of cells were neutrophils with >95% viability. After isolation neutrophils 
were suspended in Krebs-Ringer phosphate buffer (pH 7.2) at 4 x 107 cells/ml and treated 
with 1 0 ~M diisopropyl fluorophosphate for 10 minutes on ice to inhibit proteases [237]. 
The Human Studies Committee of the University of Louisville approved the use of 
human donors. 
Subcellular Fractionation for Granule Enrichment 
Neutrophil granules were enriched by centrifugation on a three-layer Percoll 
density gradient as described by Kjeldsen et al. [19]. Briefly, isolated neutrophils (4 x 
107/ml) were resuspended in disruption buffer containing 100 mM KCI, 1 mM NaCI, 1 
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mM ATPNa2, 3.S mM MgClz, 10 mM PIPES, and O.S mM PMSF, and disrupted by 
nitrogen cavitation at 380 psi and 4°C. The cavitate was collected, supplemented with 1.S 
mM EGTA, and nuclei and intact cells were removed by centrifugation at SOO x g for S 
minutes. The postnuclear supernatant was layered onto a discontinuous Percoll gradient 
formed from three 9 ml layers of Percoll prepared in a buffer containing 100 mM KCI, 3 
mM NaCI, 1 mM ATPNa2, 3.S mM MgClz, 1.2S mM EGTA, 10 mM PIPES, and O.S mM 
PMSF, to achieve final densities of 1.0S0 glml, 1.090 glml and 1.120 glmi. The gradient 
was centrifuged at 37,000 x g for 30 minutes in an SS-34 fixed angle rotor in a Sorvall 
RC-SB centrifuge. The separated granule fractions were recovered from the gradient 
interfaces by aspiration, and Percoll was removed by ultracentrifugation of each granule 
subset at 100,000 x g for 90 minutes. 
Sample Preparation for 2DE 
Preparation of Whole Granules. Whole granule fractions were resuspended in 4 
ml of disruption buffer, and centrifuged at 100,000 x g for 20 minutes to obtain a solid 
pellet. Buffer was removed by aspiration and the pellets were washed briefly with 
deionized water to remove residual salt. 
Fractionation of Granule Proteins. To separate granule proteins into membrane 
and luminal fractions, granules were resuspended in 10 volumes of 0.1 M sodium 
carbonate, sonicated at high setting for S seconds, and subjected to three freeze-thaw 
cycles each followed by sonication [238]. Disrupted granules were incubated on ice for 
30 minutes and carbonate-washed membranes were pelleted at 100,000 x g. The 
supernatant from the carbonate wash was concentrated by ultrafiltration through 1 kDa 
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cutoff centrifugal devices (Microsep Omega, Pall, East Hills, NY), and the retentate 
proteins were precipitated using chloroform-methanol desalting-precipitation [239]. The 
precipitate was dried on room air and subjected to 2DE. 
To separate granule proteins based on differential solubility in ammonium sulfate 
solution, whole granules were solubilized in 3 volumes of lysis buffer containing 50 mM 
Tris pH 7.2 and 2% Triton X-lOO, and centrifuged at 20,000 x g to remove insoluble 
proteins. The Triton X-100-insoluble pellet was subjected to 4-12% acrylamide gradient 
SDS-PAGE and MALDI-MS analysis, while the cleared lysate was used for fractionation 
by ammonium sulfate precipitation of proteins. One volume of 100% saturated 
ammonium sulfate solution was added to the cleared lysate. The resulting precipitate was 
pelleted (sub fraction one) and supernatant was removed. Solid ammonium sulfate was 
added to the supernatant until saturation, and the protein precipitate was pelleted 
(sub fraction two). Precipitated protein pellets were re-dissolved in the lysis buffer and 
subjected to chloroform-methanol desalting-precipitation [239]. 
Protein Separation by 2DE and Identification by MALDI-TOF MS 
Whole granules and granule sub fractions were dissolved in 160 /-lL of 7 M urea, 2 
M thiourea rehydration buffer (Genomic Solutions, Ann Arbor, MI). Proteins in all 
samples were separated by 2DE using non-linear pH 3-10 IPG strips for the first 
dimension and 4-12% gradient acrylamide gels for the second dimension (Invitrogen, 
Carlsbad, CA). The gels were visualized by colloidal Coomassie staining. Proteins were 
excised, in-gel trypsin digested, and the resulting peptides analyzed by MALDI-TOF MS 
using the thin film sample preparation method, as previously described [198,199]. Protein 
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identification was carried out by searching peptide spectra against the NCBI database 
using the Mascot web-based search engine. The search parameters used were: taxonomy -
H. Sapiens, allowed error - 150 ppm, fixed modification - carbamidomethylation, 
variable modification - methionine oxidation, mass values - MH+, maximum allowed 
missed cleavage - 1. 
Protein Identification by 2D-HPLC ESI-MS/MS 
Granule membranes obtained following treatment with 0.1 M sodium carbonate, 
as described above, were washed in 50 mM ammonium bicarbonate and then 
resuspended by sonication in 300 lJ-I of 50 mM ammonium bicarbonate. Trypsin digestion 
was performed by addition of 20 ng/ml trypsin to the suspension, and samples were 
incubated on a rotator overnight at 37°C. Residual particulate material was removed by 
centrifugation at 100,000 x g, and the trypsin generated mixture was analyzed using an 
approach that combined two-dimensional microcapillary high-pressure liquid 
chromatography (HPLC) with electro spray ionization tandem mass spectrometry (ESI-
MS/MS) [216]. All tandem spectra were searched against H. Sapiens Open Reading 
Frame database (human.nci) using the SEQUEST algorithm [214]. For singly charged 
peptides, spectra with a cross-correlation score of greater than 1.5 were retained, while 
for multiply charged peptides, spectra with a cross-correlation score of greater than 2 
were retained [215]. The analysis was repeated three times for each granule subset and 
only proteins identified in at least two out of three experiments were assumed to be 
present on granules. 
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Quantitation of Granule Membranes and Western Blot analysis of Granules 
Whole granule fractions were resuspended in 2 ml of disruption buffer, and 
centrifuged at 100,000 x g for 20 minutes to obtain a solid pellet. Buffer was removed by 
aspiration and the pellets were resuspended in 100 III of disruption buffer. Sample 
volume was brought up to 1 ml by water and preincubated at 37°C. To quantitate 
phospholipid bilayers, TMA-DPH (Molecular Probes, Eugene, OR) was added at a final 
concentration of 1 x 10-7 M and fluorescence intensity was monitored continuously at 
excitation of 350 nm and emission of 430 nm for 20 seconds on Hitachi 4500 
fluorescence spectrometer. Proteins associated with equal amounts of membrane from 
each granule subset were loaded onto a gel for SDS-PAGE. Proteins were separated, 
transferred to nitrocellulose membrane, and probed with an anti-actin antibody. 
Results 
Prior to subjecting granules to proteomic analysis, the purity of each of the three 
granule subsets was determined. Granule subsets were analyzed by western blotting for 
CD66b (specific granule marker), and by ELISA for gelatinase and myeloperoxidase 
(MPO), markers for gelatinase and azurophil granules, respectively (Figure 3). The 
western blot showed that CD66b was present in the specific granule fraction, but 
essentially absent in gelatinase granule and azurophil granule fractions. ELISA for 
gelatinase showed that 75% of total gelatinase was present in gelatinase granules, 20% in 
specific granules and 5% in azurophil granules, while 73% of MPO was in azurophil 
granules, 20% in specific granules, and 7% in gelatinase granules. This distribution of 
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Figure 3. Assessment of purity of granule fractions. Granule fractions separated by 
centrifugation on Percoll gradients were analyzed for the content of CD66b (specific 
granule marker), gelatinase (gelatinase granule marker), and myeloperoxidase (azurophil 
granule marker). A) Western blotting analysis of CD66b content in granule fractions. 50 
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granule markers was similar to that reported by Kjeldsen et al. [10, 19]. Thus, optimal 
levels of granule subset enrichment were obtained. 
The initial analysis of granule subset proteomes was carried out by subjecting 
whole granules to 2DE. Figure 4A shows the separation of gelatinase granule proteins. A 
total of 38 proteins were identified by peptide mass fingerprint analysis of MALDI-MS 
spectral data. Thirty of these proteins were cytoskeletal and luminal proteins. The 2D gels 
of specific granule proteins were dominated by large amounts of luminal proteins, such as 
lactoferrin and lipocalin (NGAL), which were present in such high abundance that 
proteins focused poorly (Figure 4B). A total of 26 proteins were identified by peptide 
mass fingerprinting. The only cytoskeletal protein identified was actin (Figure 4B). 
Separation of azurophil granule proteins by 2DE revealed large amounts of highly basic 
proteins, such as myeloperoxidase, which focused poorly, leading to extensive smearing 
on the basic end of the gel (Figure 4C). Only 8 proteins were identified from the 
azurophil granule gel. 
To address the problem of overabundance of luminal proteins, granule proteins 
were fractionated by one of two methods prior to their separation by 2DE. First, the 
luminal contents of granules were separated from membranes by lysing the granules in 
0.1 M sodium carbonate, pH 11. At high pH luminal cationic proteins lose their positive 
charge and dissociate from negatively charged matrix [238,240,241]. Additionally, 
alkaline sodium carbonate treatment has been reported to remove the actin cytoskeleton 
from neutrophil membranes [242]. To determine what proteins were removed from 
granule membranes, carbonate-soluble proteins were also subjected to 2DE. Second, 
differential solubility of proteins in ammonium sulfate solutions was applied to granule 
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Figure 4. 2D gels of whole granules. Neutrophil granules were subjected to 2DE, gels 
were stained with colloidal Coomassie Blue dye, the spots were excised, in-gel digested 
with trypsin and the resultant peptides were analyzed by MALDI-TOF MS. A) Gelatinase 





proteins prior to 2DE. Whole granules were solubilized in a buffer containing 
Triton X -100, and proteins were separated based on precipitation at different 
concentrations of ammonium sulfate. The first sub fraction contained proteins precipitated 
in a 20% ammonium sulfate solution, while the second sub fraction contained the proteins 
soluble in 20% ammonium sulfate, but insoluble in 100% ammonium sulfate. 
Fractionation of gelatinase granules with sodium carbonate prior to 2DE resulted 
in identification of 26 proteins, of which eight proteins were not detected on whole 
gr'\Ilule gels (Figures 5A and 5B). On the other hand, 20 proteins identified by 2DE of 
whole granules were not observed on either carbonate-washed membrane or carbonate-
soluble protein gels. Most of these proteins were below 30 kDa, suggesting that low 
molecular weight proteins were lost during fractionation. Figures 5C and 5D show 2DE 
separation of ammonium sulfate precipitated proteins from gelatinase granules. This 
fractionation allowed identification of 38 proteins, 22 of which were not previously 
identified. Use of ammonium sulfate precipitation also identified all but three proteins 
detected following fractionation with sodium carbonate. Ten proteins seen in whole 
gelatinase granule gels were not detected after either fractionation method, indicating that 
protein fractionation is complementary to analysis of intact gelatinase granules. A total of 
62 proteins were identified from gelatinase granules by 2DE protein separation and 
MALDI-MS (Table 2). 
Fractionation of specific granule proteins with sodium carbonate resulted in 
identification of more proteins than extraction by ammonium sulfate precipitation. 
Sodium carbonate treatment prior to 2DE resulted in identification of 51 proteins from 
membranes and 27 proteins in the supernatant, of which 42 proteins were not detected on 
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Figure 5. ~D gels of gelatinase granule proteins fractionated by carbonate lysis and 
by ammonium sulfate precipitation of Triton x-tOO solubilized proteins. 
Fractionation of gelatinase granule proteins by carbonate lysis (A and B) and by 
ammonium sulfate precipitation (C and D). A) A 2D gel of proteins that remained on the 
membrane after granule lysis in 0.1 M sodium carbonate buffer. B) Proteins that were 
solubilized in 0.1 M sodium carbonate. C) Proteins precipitated in 20% ammonium 
sulfate solution. D) Proteins that remained in solution in 20% ammonium sulfate but were 
precipitated in 100 percent ammonium sulfate solution. 
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gels from whole specific granules (Figures 6A and 6B). Ammonium sulfate precipitation 
allowed identification of 45 proteins, only ten of which were not seen on gels from whole 
granules. Ammonium sulfate precipitation did not lead to identification of any protein not 
identified after fractionation with sodium carbonate (Figures 6C and 6D). Collagenase 
and cathepsin X were identified on the whole specific granule gels, but not after 
extraction by sodium carbonate. A total of 70 proteins were identified from specific 
granules (Table 2). 
Fractionation of azurophil granule proteins by sodium carbonate or by ammonium 
sulfate precipitation failed to improve visualization and identification of proteins. The 2D 
gels of carbonate-washed membranes were largely devoid of proteins (only 4 proteins 
were identified), while 2DE of carbonate-soluble proteins failed to reveal proteins not 
found on gels of whole granule proteins (data not shown). Likewise, fractionation of 
azurophil granule proteins by ammonium sulfate precipitation failed to improve the 
number of proteins visualized by 2DE (data not shown). Thus, only 8 proteins from 
azurophil granules were identified by 2DE (Table 2). 
For all granule subsets, the protein fraction precipitated by 100% ammonium 
sulfate contained primarily luminal proteins. Only two proteins remained in solution after 
precipitation of specific and gelatinase granule proteins with 100% ammonium sulfate, 
MRP-14 and MRP-8, while the corresponding sample from azurophil granules was 
devoid of protein (data not shown). To identify any proteins that failed to dissolve in the 
TX -1 OO-containing buffer and thus could not be detected in ammonium sulfate 
precipitated fractions, TX-lOO-insoluble pellets were also subjected to SDS-PAGE. Only 
actin, vimentin, CDllb, lactoferrin and gelatinase were detected in pellets from specific 
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Figure 6. lD gels of specific granule proteins fractionated by carbonate lysis and by 
ammonium sulfate precipitation of TX-IOO solubilized proteins. Fractionation of 
specific granule proteins by carbonate lysis (A and B) and by ammonium sulfate 
precipitation (C and D). A) A 2D gel of proteins that remained on the membrane after 
granule lysis in 0.1 M sodium carbonate buffer. B) Proteins that were solubilized in 0.1 
M sodium carbonate. C) Proteins precipitated in 20% ammonium sulfate solution, D) 
Proteins that remained in solution in 20% ammonium sulfate but were precipitated in 100 















Proteins identified from 2D gels of neutrophil granules 
Proteins Identified from 2D Gels 
Entrez Gene Entrez ID Protein N arne Granule Peptides % Coverage MOWSE 
MatchedIT otal score 
CA4 gij409725 Carbonic anhydrase IV GE 10/30 36 101 
CFL1 gil57099669 ("'ofilin 1 GE 16/53 70 153 
1F9PA gil34810160 Connective Tissue Activating Pept. GE 7/33 67 85 
EN01 gi14503571 Enolase GE 16/38 42 144 
GSN gij38044288 Gelsolin GE 15/58 26 83 
ATP5A1 gil50345982 H+-A TP-ase FO sub. IX GE 16/55 39 110 
IDH2 gij28178832 Isocitrate dehydrogenase GE 12/47 27 74 
MMM gil26892295 Methylmalonic Acidurea GE 7/14 16 69 
SOD2 2il7546412 Mn SOD chain b GE 8/52 57 72 
ARPC5 gil56204524 p16 Arc GE 11/22 58 142 
ARPC3 gil5031597 JIll Arc GE 6/20 40 68 
PPIA gil31615559 CyclophilinA GE 7/29 37 65 
RAB27A gi134485711 Rab27A GE 9/33 37 93 
RAP1A gil54696200 RaplA GE 9/30 43 105 
TAGLN gil55960374 Transgelin 2 GE 10/33 44 88 
VDAC2 JliL48146045 VDAC2 GE 7/31 32 65 
VIL2 gil46249758 Villin2 GE 28/58 41 170 
VIM gij340234 Vimentin 35 kDa GE 9/34 30 73 
YWHAZ gi149119653 14-3-31; GE,SG 9/21 36 106 
ACTB gil14250401 Actinll GE,SG 9/26 30 88 
ACTG1 gil178045 Actiny GE,SG 7/21 37 82 
ACTN1 gil4501891 IX-actinin GE,SG 11119 13 93 
ALB gij28592 Albumin GESG 19/35 30 161 
ANXA3 gil4826643 Annexin III GESG 8/12 28 104 
ACTR3 2il27806335 iARP3 GE,SG 9/20 23 83 
B2M gil1195503 11l2-Microglobulin GE,SG 8/22 77 107 
CALR gil30583735 Calreticulin GESG 8/21 19 79 
CAPZA1 gil12652785 CapZ GESG 11126 56 134 
CAPZA2 gil433308 Capping protein IX GE,SG 8/27 36 83 
ITGAM gil386975 CD11b GESG 10/16 10 85 
CLC gil17942629 Charcot-Leyden protein GESG 9/35 43 81 
FTL gil48145547 Ferritin Light Chain GESG 11120 53 143 
FCN1 M8051584 Ficolin 1 precursor GE,SG 14/24 46 156 
MMP9 gil22532481 Gelatinase GESG 11121 18 103 
GCA gi16912388 Grancalcin GESG 12/29 48 109 
PDIA3 gil7437388 Grp58 GE,SG 22/43 44 181 
HP gi147124562 Haptoglobin IX2 GE,SG 14/26 39 151 
HBB _J:il4504349 Hemoglobin GESG 12/26 93 184 
HSPA1A gil5123454 Hsp701A GE,SG 15/23 32 168 
HSPA5 gil1143492 Hsp70 SA GE,SG 20/50 37 149 
CST7 gil9836652 Leukocystatln GESG 7/16 28 74 
LCP1 gil4504965 L-Plastin GE,SG 9/19 17 84 
LSP1 gijl2804709 LSP-1 GE,SG 6/10 36 86 
S100A9 gil4506773 MRP-14 GE,SG 15/34 92 150 
S100A8 gil30583595 MRP-8 GESG 10/23 83 132 
MRCL3 gil5453740 Myosin Regulatory Light Chain GESG 10/36 65 90 
P4HB gi120070125 POI GE,SG 7/18 17 65 
PGLYRP1 gil37182990 Peptido21ycan reC02. prot. GESG 8/38 48 70 
PHB JliL49456373 Prohibitin GE,SG 10/37 47 100 
SDCBP gil55749523 Syntenin GESG 8/20 43 94 
TPM3 gil55665783 Tropomyosin 3 GESG 9/19 29 100 
TUBA3 gi118088719 Tubulins IX GE,SG 9/17 27 104 
TUBB1 gil57013276 Tubulins~ GE,SG 10/15 31 129 
VIM gil4507895 Vimentin 50 kDa GESG 14/19 36 168 
ANXA1 ~4696696 ~nnexin I SG 9/18 34 101 
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S100A12 gil5032059 Calgranulin C SG 4/11 40 65 
CTSZ Idl7546546 Cathepsin X SG 6/16 24 73 
ITGB2 gil46255730 CDI8 SG 7/14 12 64 
CHI3L1 gil4557018 IIP39 chitinase SG 20/37 55 195 
CHSY1 gil37182181 Chondroitin sulfate synthase SG 13/33 20 87 
MMP8 gil4505221 Collagenase SG 10/23 25 83 
DEFA1 gil4758146 Defensin a1 SG 5/22 28 68 
QPCT gil525241 Glutaminyl cyclase SG 9/17 41 123 
GNB2 gil29789261 GTP-bindinl! prot. 132 SG 7/23 20 67 
OLFM4 l!il29126831 GW112 SG 7115 20 78 
STXBP2 gil1944130 Hunc-18b SG 8/19 22 74 
SLPI fi13489087 Leukocyte Anti-elastase SG 7/15 25 72 
LTA4H gil4505029 Leukotriene A4 Hydrolase SG 7/12 14 76 
PPFIBP1 gil28278230 Liprin-Iike SG 7/19 40 71 
MAP2K11P1 gil11496277 MEK1 BP SG 5/16 62 75 
MYH9 l!il189036 Myosin Heavy Ch. SG 12/21 14 78 
PTX3 gil4506333 Pentaxin 3 SG 11/25 34 107 
PFC Idl3183860 Properdin P factor SG 14/30 33 134 
SEMG1 gil1147569 Semenol!elin I SG 16/38 38 146 
SEMG2 gil4506885 Semenogelin II SG 12138 25 84 
ST6GALNAC3 gil37182203 Sialyltransferase 3 SG 7/25 45 75 
EHD1 gil30240932 Testilin SG 15/26 25 138 
TOLLIP gi121361619 TOLLIP SG 8/33 36 65 
CRISP3 gil2136189 SGP-28 SG,AG 7/25 23 74 
CTSG gil2392230 Cathepsin G GE,SGAG 7/24 24 70 
CHIT1 gil47480958 Chitotriosidase GE,SG,AG 12126 30 113 
RETN Idl37183250 FIZZ-3 (Resisti& GESGAG 8/24 76 85 
CAMP gil39753970 hCAP-18 GE,SG,AG 9/22 45 109 
LTF gil640200 Lactoferrin GE,SG,AG 10/22 16 83 
LCN2 gil38455402 Lipocalin {NGALl GESGAG 12/27 64 163 
LYZ gil442591 Lysozyme GE,SG,AG 8/24 53 102 
MPO gil494396 Myeloperoxidase (MPO) Chain B,D GE,SG,AG 6/29 69 78 
gil494397 26/52 53 191 
Eighty-seven proteins were identified from all 2D gels of neutrophil granules usmg 
MALDI-TOF MS. The table lists the gene and protein designation, granule type, number 
of peptides matched, the percent protein coverage by these peptides, and the calculated 
molecular weight search (MOWS E) score for each protein. 
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and gelatinase granules (data not shown), while myeloperoxidase, cathepsin G, and 
lysozyme were found in the TX-I00-insoluble fraction of azurophil granules. A total of 
87 proteins were identified from granule subsets by the three 2DE approaches, of which 
56 were cytoskeletal or luminal proteins. Membrane proteins, except for CDllb and 
CDI8, were not visualized by 2DE. 
2DE-based approaches are biased against membrane proteins, low abundance 
proteins, and proteins at the extremes of isoelectric point and molecular mass. To address 
these issues, we used an approach that couples two-dimensional microcapillary HPLC 
(2D-HPLC) with ESI-MS/MS analysis [215,216]. This high-sensitivity mass 
spectrometry-based approach that allows direct analysis of complex protein mixtures was 
applied to granule membranes following removal of luminal and cytoskeletal proteins 
with sodium carbonate. Only proteins present in at least two out of three experiments or 
proteins also identified by 2DE-MALDI-MS were considered as valid granule proteins. 
By this criteria a total of 247 proteins were identified from all granule subsets, of which 
48 were also identified by 2DE. Table 3 lists identified proteins by granule subset, 
method of identification and functional classification of the protein. A total of 86 proteins 
were identified only from gelatinase granules, 28 proteins from only specific granules, 
and 26 proteins from only azurophil granules. A number of proteins were identified on 
multiple granule subsets, including 79 proteins from gelatinase and specific granules, 5 
proteins from specific and azurophil granules and 61 proteins from all three granule 
subsets. The peptide sequences detected by 2D-HPLC-ESI-MSIMS can be found in 
Supplementary Tables 1 and 2. Supplementary Table 1 lists the proteins identified at least 
twice out of three experiments and the sequences of corresponding peptides. Proteins 
58 
Table 3 
A complete list of proteins identified on neutrophil granules 
Rece_Jltors and Transmembrane Cytoskeletal Anchors 
Entrez Gene Entrez Protein Protein N arne Granule TypeMETHOD 
BZRP NP 000705 Benzodiazepine receptor GElCMS 
FCGR3B NP 000561 C016, FCIRlllb GElCMS 
CR1 NP_000564 C035, complement receptor-1 (CR1) GElCMS 
NP 000642 
SPN NP 003114 C043, sialophorin GElCMS 
CD9 NP 001760 ir.09, motility related protein GElCMS 
FLOT2 NP 004466 Flotillin 2 GElCMS 
LBR NP_919424 Lamin B receptor GElCMS 
NP 002287 
GP9 NP 000165 Platelet glycoprotein IX GElCMS 
SELPLG NP 002997 P-selectin glycoprotein liaand-1 GElCMS 
UNC84B NP 056189 Sad1 GElCMS 
SCAMP1 NP 004857 SCAMP1 GElCMS 
SCAMP2 NP 005688 SCAMP2 GElCMS 
CEACAM1 NP 001703 CAECAM-1 GElCMS,SPlCMS 
ITGAM NP 000623 C011 b, complement component receptor 3 (CR3) GE2D lCMS,SP2D lCMS 
ADAM8 NP 001100 C0156, AOAM-8 GElCMS, SPlCMS 
ITGB2 NP 000202 C018, macrophage antigen 1 (mac-1) beta subunit GElCMS,SP2D lCMS 
ITGA2B NP 000410 C041, platelet fibrinogen recl!jltor, alQha subunit GElCMS,SPlCMS 
ITGB3 NP 000203 C061, platelet glycoprotein ilia GElCMS,SPlCMS 
C5R1 NP 001727 C088, C5aR1 GElCMS,SPlCMS 
DSG1 NP 001933 Oesmoglein preproprotein GElCMS,SPlCMS' 
FPR1 NP 002020 FormylQl!J)tide recejJtor GElCMS, SPlCMS 
GP1BB NP 000398 Glycoprotein Ib beta precursor GElCMS,SPlCMS 
HLA-A NP 002107 HLA-A1 GElCMS, SPlCMS' 
ICAM3 NP 002153 ICAM-3 precursor GElCMS, SPlCMS' 
LAIR1 NP _002278 Leukocyte-associated Ig-like receptor 1 GElCMS, SPlCMS' 
NP _068352 
NP 068354 
LlLRB2 NP 005865 Leukocyte Ig-like receptor 2 GElCMS,SPlCMS 
CLEC12A NP _612210 Myeloid inhibitory C-type lectin-like receptor GElCMS,SPlCMS 
NP 963917 
SIGLEC5 NP 003821 Sialic acid binding Ig-like lectin 5 GElCMS,SPlCMS 
SDCBP NP 005616 Syntenin GE2D,SP2D 
VNN1 NP 004657 [vanin 1 precursor GElCMS,SPlCMS' 
VNN2 NP_004656 ~anin 2 GElCMS, SPlCMS' 
NP 511043 
CANX NP 001737 Calnexin GElCMS,SPlCMS,AZlCMS' 
FLOT1 NP 005794 Flotillin 1 GElCMS,SPlCMS·,AZccMS· 
FCER1G NP 004097 Fc receptor for IgE, high affinity I, gamma polypeptide GElCMS,SPlCMS,AZlCMS' 
ITGB5 NP 002204 Integrin, p_ 5 GElCMS·,SPlCMS·,AZlCMS 
LAMP2 NP _002285 LAMP2 GElCMS,SPlCMS·,AZlCMS· 
NP 054701 
STOM NP 004090 Stomatin GElCMS,SPlCMS,AZlCMS 
CD63 NP 001771 C063, LAMP-3 AZlCMS 
TM7SF3 NP 057635 Seven transmembrane rece)Jtor AZlCMS 
STOML3 NP 660329 Stomatin-like 3 AZlCMS 
Channels and Transporters 
EntrezGene Entrez Protein Protein N arne Granule T~eM~ 
SLC25A5 NP 001143 IAdenine nucleotide translocator 2 GElCMS 
SLC25A6 NP 001627 IAdenine nucleotide translocator 3 GElCMS 
SLC4A1 NP 000333 IAnion exchanger, member 1 GElCMS 
ATP5A1 NP_OO4037 IA TP synthase, H+ transporting, mitochondrial F1 GE2DlCMS 
!complex, alpha subunit 
ATP6V1C2 NP _653184 JATPase, H+ transporting, lysosomal 42kOa, V1 subunit GElCMS 
C isoform 2 
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ATP6VOA1 NP _005168 ATPase, H+ transporting, lysosomal VO subunit a GELCMS 
isoform 1 
ATP6VOA2 NP_036595 ATPase, H+ transporting, lysosomal VO subunit a GELCMS 
isoform 2 
SLC2A3 NP 008862 Glucose transporter type 3 GELCMS 
TMED9 NP 059980 gp25L2 protein, protein tran~rter GE CMS 
MTCH2 NP 055157 Mitochondrial carrier homolog 2 GELCMS 
SFXN1 NP 073591 Sideroflexin 1 GELCMS 
SLC04C1 NP _851322 Solute carrier organic anion transporter family, GELCMS 
member4C1 
VDAC2 NP 003366 ~oltage-dependent anion channel 2 GE2DLCMS 
SLC25A4 NP 001142 ~denine nucleotide translocator 1 GELCMS,SPLCMS 
ATP5F1 NP _001679 fA,TP synthase, H+ transporting, mitochondrial FO GELCMS,SPLCMC" 
complex, subunit b 
ATP5H NP_006347 ~TP synthase, H+ transporting, mitochondrial FO GELCMS,SPLCMS" 
~omplex, subunit d 
SLC25A24 NP 037518 Calcium-binding tran~orter GELCMS,SPLCMS' 
MVP NP_059447 Major vault protein GELCMS·,SPLCMC 
NP 005106 
SLC25A3 NP 005879 Mitochondrial phosphate carrier precursor isoform 1 GELCMS,SPLCMS' 
NP-002626 
PLSCR1 NP 066928 PhospholiJlld scramblase 1 GELCMS,SPLCMS' 






VDAC1 NP 003365 [\t'oltage-d~endent anion channel 1 GELCMS,SPLCMC" 
VDAC3 NP 005653 ~oltage-dependent anion channel 3 GELCMS,SPLCMC' 
ATP6VOD1 NP_004682 fA,TPase, H+ transporting, lysosomal, VO subunit D GELCMS,SPLCMS·,AZLCMS 
isoform 1 
TCIRG1 NP _006010 ~TPase, H+ transporting, 116kD, vacuolar, Tcell imune GELCMS,SPLCMS',AZLCMS 
rl!Jlulator 
ATP8A1 NP 006086 ~minophospholipid transporter ATPase AZLCMS 
VAT1 NP 006364 ~esicle amine transport protein 1 AZLCMS 
GTP-ases 
Entrez Gene Entrez Protein Protein N arne Granule~ 
HSPC121 NP_057479 Butyrate-induced transcript 1, GTPase activating GELCMS 
Iprotein 
IQGAP1 NP 003861 IQ motif containing GTPase activatirl{1JJrotein 1 GELCMS 
RAB7 NP 004628 RAB7 GELCMS 
RAB10 NP 057215 RAB10 GELCMS 
RAB11A NP 004654 RAB11A GELCMS 
RAB11B NP 004209 RAB11B GELCMS 
RAB14 NP 057406 Rab14 GELCMS 
RAB21 NP 055814 RAB21 GELCMS 
RAB32 NP 006825 RAB32 GELCMS 
RAP2A NP_066361 RAP2 GELCMS 
RAP2B NP_002877 
RAP2C NP 067006 
RAB31 NP 006859 RAB31 SPLCMS 
RAB2 NP 002856 RAB2 GELCMS,SPLCMS' 
RAB5C NP 958842 
NP-004574 
RAB5C GELCMS,SPLCMS 
CDC42 NP 001782 Cdc42 GELCMS,SPLCMS·,AZLCMS 
GNAI2 NP 002061 G;u2 GELCMS,SPLCMS,AZLCMS 
GNB1 NP_002065 G ~1,2 GELCMS·,SP2D LCMS',AZLCMS 
GNB2 NP 005264 
RAB1A NP 004152 RAB1 GELCMS,SPLCMS·,AZLCMS 
RAB1B NP-112243 
RAB3A NP 002857 RAB3 GELCMS,SPLCMS,AZLCMS 
RAB3B NP-002858 
RAB3C NP-612462 
RAB3D NP 004274 RAB3D GELCMS,SPLCMS,AZLCMS' 
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RAP1A NP _002875 RAP1 GE2D,SPLCMS,AZLCMS 
RAP1B NP 056461 
Structural Proteins and Adaptors 
EntrezGene Entrez Protein Protein N arne GranuleT~ 
AP2A1 NP 055018 jAdaptin GELCMS 
NP-570603 
CFL1 NP 005498 Cofilin 1 GE2DLCMS" 
NP-068733 
NP-619579 
CORO? NP 078811 Coronin 7 GELCMS 
ARPC5 NP 005708 Ip16 Arc GE2D 
ARPC3 NP 005710 1P21 Arc GE2D 




TAGLN NP 003177 Transllelin GE2D 
TUBB1 NP 110400 Tubulin beta 1 GELCMS 
URP2 NP 848537 UNC-112 related protein 2 GELCMS 
NP-113659 
VIL2 NP 003370 lViliin 2 GE2D 
RP2 NP 008846 ~RP2 GELCMS 
YWHAZ NP_003397 14-3-31; GE2D,SP2D 
NP 663723 
ACTN1 NP 001093 ~ctinin, alpha 1 GE2D LCMS,SP2D LCMS 
ANXA3 NP 005130 ~nnexin III GE2D,SP2D 
ACTR3 NP 005712 ~RP3 GE2D,SP2D 
CAPZA1 NP 006126 CapZ GE2D,SP2D 
CAPZA2 NP 006127 Capping protein a GE2D,SP2D 
COR01A NP 009005 Coronin 1A GELCMS,SPLCMS 
GSN NP _000168 Gelsolin GE2D LCMS,SPLCMS 
NP 937895 
TLN1 NP 006280 Talin 1 GELCMS,SPLCMS 
TPM3 NP 689476 ropomyosin 3 GE2D,SP2D 
TUBA2 NP 005992 Tubulin alpha 2,3 GELCMS,SPLCMS 
TUBA3 NP=524575 
NP 006000 
MRCL3 NP 006462 Myosin regulatory light chain GE2D,SP2D 
LSP1 NP 002330 LSP1 GE2D,SP2D 





CYLC2 NP 001331 Cylicin 2 SPLCMS 
MSN NP 002435 Moesin SPLCMS 
TUBA4 NP 079295 rrubulin alpha 4 SPLCMS 
ACTA1 NP 001091 jActin, alpha GELCMS,SPLCMS,AZLCMS 
ACTA2 NP=001604 
ACTB NP 001092 jActin, beta or gamma GE2D LCMS,SP2D LCMs.AZLCMS 
ACTG1 NP=001605 
ANXA1 NP 000691 ~nnexin I, (lipocortin I) GELCMS,SP2D,AZLCMS' 
FLNA NP 001447 Filamin 1 GELCMS,SPLCMS,AZLCMS' 
LCP1 NP 002289 L-plastin GE2D LCMS,SP2D LCMS,AZLCMS' 
MYH9 NP 002464 Myosin heavy chain GELCMS,SP2D LCMS,AZLCMS 
PFN1 NP 005013 Profilin 1 GELCMS,SPLCMS·,AZLCMS· 
TUBA1 NP 005991 Tubulin alpha 1 GE2D LCMS,SP2D LCMS,AZLCMS' 
TUBB2 NP 001060 Tubulin beta 3 GE2D LCMS,SP2D LCMs.AZLCMs 
VIM NP 003371 lVimentin GE2D LCMS,SP2D LCMS"AZLCMS 
HCLS1 NP 005326 Hematopoietic lineage cell-specific protein 1 AZLCMS 
ZYX NP 003452 lZyxin AZLCMS 
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Kinases and Phosphatases 
Entrez Gene Entrez Protein Protein N arne Granule TYPfMETHoD 
HCK NP 002101 Hck tyrosine kinase GELCMS 
FGR NP 005239 Far tyrosine kinase GELCMS,SPLCMS 
PTPRJ NP 002834 Protein tyrosine phosphatase, receptor type J GELCMS,SPLCMS 
PTPN7 NP_002823 Protein tyrosine phosphatase, non-receptor type 7 GELCMS,SPLCMS' 
NP 542155 
PTPNS1 NP_542970 Protein tyrosine phosphatase, non-receptor type GELCMS,SPLCMS 
substrate 1 
TTBK2 NP 775771 Tau tubulin kinase SPLCMS 
MAP2K11P1 NP 068805 MEK1 Binding Protein, MP1 SP2D 
PTPRC NP 002829 Protein tyrosine phosphatase, receptor type C GELCMS,SPLCMS,AZLCMS 
NP=563578 
NP 563579 
Luminal and Host Defense Proteins 
EntrezGene Entrez Protein Protein N arne Granule~ 
C10orf42 NP 612366 Chromosome 10 ORF 42 GELCMS 
SPCS2 NP 055567 KlAA0102 gene product (signal peptidase) GELCMS 




1F9PA NP 002695 Connective Tissue Activitatil19.. P~tide GE2D 
CLC NP 001819 Charcot-Leyden crystal protein GE2D,SP2D 
DEFA1 NP 004075 Defensin (Xi GE2D,SP2D 
DCD NP 444513 Dermcidin precursor GELCMS,SPLCMS 
FCN1 NP 001994 Ficolin 1 precursor GE2D LCMS·,SP2D LCMS 
HP NP 005134 Haptoglobin (X2 GE2D,SP2D 
PGLYRP1 NP 005082 Peptidoglycan recognition protein 1 GE2D,SP2D 
PADI4 NP 036519 Peptidyl arginine deiminase,!}tIle IV GELCMS,SPLCM" 
B2M NP 004039 1~2-Microglobulin GE2D,SP2D 
MGAM NP 004659 Maltase~lucoam}'lase GELCMS,SPLCMS 
MMP25 NP _071913 Matrix metalloprotease 25 (Ieukolysin) GELCMS,SPLCMS' 
NP 073209 
ANPEP NP 001141 Membrane alanine aminopeptidase GELCMS,SPLCMS' 
SIGLEC5 NP 003821 Sialic acid binding Ig-like lectin GELCMS,SPLCMS 
THBS1 NP 003237 Thrombospondin 1 precursor GELCMS,SPLCMS' 
CAT NP 001743 Catalase SPLCMS 
CHI3L1 NP 001267 Igp-39 chitinase SP2D 
CHSY1 NP 055733 Chondroitin sulfate synthase SP2D 
CHGA NP 001266 Chromogranin A SPLCMS 
QPCT NP 036545 Glutaminyl cyclase SP2D 
SLPI NP 003055 Leukocyte anti-elastase SP2D 
LTA4H NP 000886 Leukotriene A4 HIdrolase SP2D 
MMP8 NP 002415 Neutrophil collagenase SP2DLCMS 
PTX3 NP 002843 Pentraxin-3 SP2DLCMS 
PFC NP 002612 Properdin P factor SP2D 
T6GALNAC3 NP 694541 Sialyltransferase 3 SP2D 
AZU1 NP 001691 ~urocidin 1 preproprotein GELCMS·,SPLCMS.AZLcMS 
BPI NP 001716 Bactericidallpermeabilit}'-increasi~otein GELCMS,SPLCMS,AZLCMS 
CALR NP 004334 Calreticulin precursor GE2D,SP2D cMs"AZLCMS' 
CAMP NP 004336 hCAP-18 GE2D,SP2D LCMS,AZ2D LCMS 
CTSG NP 001902 Cathepsin G preproprotein GE2D LCMS,SP2D LCMS,AZ2D LCMS 
CHIT1 NP 003456 Chitotriosidase GE2D,SP2D LCMS"AZLCMS' 
EPX NP 000493 Eosinophil peroxidase GELCMS,SPLCMS,AZLCMS 
FTL NP 000137 Ferritin, light polypeptide GE2D,SP2D,AZLCMS 
RETN NP 065148 FIZZ-3, resistin GE2D,SP2D,AZ2D 
OLFM4 NP 006409 GW112 GELCM .. ,SP2D LCMS,AZLCMS' 
LTF NP 002334 Lactoferrin GE2D LCMS,SP2D LCMs.AZ2D LCMS 
CST? NP 003641 Leukocystatin; C},statin GE2D,SP2D,AZLCMS 
LCN2 NP 005555 Lipocalin 2; NGAL GE2D LCMS,SP2D LCMS,AZLCMS 
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LYZ NP 000230 Lysozyme precursor GE2D,SP2D LCMS,AZ2D LCMS 
MMP9 NP 004985 Gelatinase GE2D LCMS,SP2D LCMS,AZLCMS 
MPO NP 000241 Myeloperoxidase GE2D LCMS,SP2D LCMS,AZ2D LCMS 
PRTN3 NP 002768 Proteinase 3 GELCMS,SPLCMS,AZLCMS 
PRG2 NP 002719 Proteoglycan 2 GELCMS,SPLCMS,AZLCMS 
CTSZ NP 001327 Cathepsin Z (X) SP2D,AZLCMS' 
ELA2 NP 001963 Elastase 2 SPLCMS',AZLCMS 
CRISP3 NP 006052 ~gp-28 SP2D,AZ2D LCMS' 
PPGB NP 000299 Cathepsin A AZLCMS 
CTSC NP 001805 Cathepsin C AZLCMS 
TPP1 NP 000382 Tripeptidvl-peptidase I AZLCMS 
DPP7 NP 037511 Dipeptidyl peptidase 7 preproprotein AZLCMS 
GGH NP 003869 Gamma-glutamyl hydrolase precursor AZLCMS 
GUSB NP 000172 Glucuronidase, beta AZLCMS 
HEXA NP 000511 Hexosaminidase A preprop~otein AZLCMS 
HEXB NP 000512 Hexosaminidase B preproprotein AZLCMS 
HYAL3 NP 003540 Hyaluronidase 3 AZLCMS 
ACP6 NP 057445 Lysophosphatidic acid phosphatase AZLCMS 
ACP2 NP 001601 Lysosomal acid phosphatase 2 AZLCMS 
GAA NP 000143 Lysosomal alphalllucosidase AZLCMS 
MAN2B1 NP 000519 Mannosidase, alpha B, lysosomal AZLCMS 
Membrane Traffic and Fusion Proteins 
EntrezGene Entrez Protein Protein N arne Granule TypeMETHOD 
MBC2 NP_056107 KlAA0747 protein (membrane bound C2 domain- GELCMS 
containingj 
SNAP23 NP 003816 SNAP-23A GELCMS 
SACM1L NP 054735 Synaptojanin GELCMS 
UNC13D XP _113950 Unc-13 homolog 0 GELCMS 
NP 954712 
DYSF NP 003485 Dysferlin GELCMS,SPLCMS 
CLTC NP 004850 Clathrin heavy chain 1 SPLCMS 
STXBP2 NP 008880 Hunc18b SP2D 
DNAJC5 NP 079495 DnaJ (Hsp40) homolog, subfamily C, member 5 GELCMS,SPLCMS"AZLCMS' 
STX7 NP 003560 Syntaxin 7 GELCMS,SPLCMS"AZLCMS 
VAMP2 NP_004772 IVAMP2 GELCMS,SPLCMS"AZLCMS' 
NP 055047 
VAMP8 NP 003752 !VAMP 8 GELCMS,SPLCMS,AZLCMS 
SYTL1 NP 116261 Synaptotagmin-like 1 AZLCMS 
C20orf178 NP 789782 Snf7 homologue associated with Alix 1 AZLCMS 
Redox Proteins 
Entrez Gene Entrez Protein Protein N arne Granule TypeMETHOD 
DIA1 NP _000389 Cytochrome b5 reductase GELCMS 
NP 015565 
NQ03A2 NP 057327 Cytochrome b5 reductase 1 (B5R,1) GELCMS 
GSTK1 NP 057001 Glutathione transferase kajlJ)3 1 GELCMS 
SOD2 NP 000627 Mn SOD chain b GE2D 
NDUFB8 NP 004995 NADH dehydrogenase 1 beta subcomplex, 8 GELCMS 
ND5 NP_536853 NADH dehydrogenase subunit 5 GELCMS 
NP 776061 
NDUFB11 NP 061929 Neuronal protein 17,3 GELCMS 
HSD17B12 NP 057226 Steroid dehydrogenase homolC!Sl GELCMS 
SQRDL NP 067022 Sulfide dehydrogenase GELCMS 
TXNDC NP 110382 hioredoxin-related transmembraneJ)rotein GELCMS 
DHRS8 NP 057329 Dehydrogenase/reductase member 8 GELCMS,SPLCMS 
GAPD NP 002037 Glyceraldehyde-3-phosphate dehydrogenase SPLCMS 
PRDX5 NP_036226 Peroxiredoxin 5 precursor SPLCMS 
NP 857634 
CYBA NP 000092 Ip22-phox GELCMS,SPLCMS AZLCMS' 
PDIA3 NP 005304 Grp58 GE2D LCMS,SP2D LCMS',AZLCMS 
CYBB NP 000388 Igp91-phox GELCMS,SPLCMS,AZLCMS 
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Miscellaneous Proteins 
Entrez Gene Entrez Protein Protein Name GranuleT~ 
CA4 NP 000708 Carbonic anhydrase IV GE2D 
CGI-51 NP 056195 CGI-51 protein GElCMS 
EN01 NP 001419 Enolase GE2D 
FGG NP _000500 Fibrinogen y chain precursor GElCMS 
NP 068656 
GPI NP 000166 Glucose phosphate isomerase GElCMS 
E21G5 NP 055182 Growth and transformation-dependent protein GELCMS 
HNRPU NP_004492 hnRNP U protein GElCMS 
NP 114032 
ATAD3A NP 060658 Hypothetical protein FLJ 1 0709 GElCMS 
TNFAIP9 NP 078912 Hypothetical protein FLJ23153 GElCMS 
EFHA1 NP 689939 Hypothetical protein FLJ34588 GElCMS 
TMEM43 NP 077310 Hypothetical protein MGC3222 GElCMS 
LOC255809 XP 172995 Hypothetical protein XP 172995 GElCMS 
IDH2 NP 002159 Isocitrate dehydrogenase GE2D 
KlAA0792 XP 375848 KIAA0792~ene product GElCMS 
LAP1B NP 056417 Lamina-associated polypeptide 1B GElCMS 
LST1 NP 995309 
NP=995310 
Leukocyte specific transcript 1 GElCMS 
NP_995311 
NP 995312 
MMAA NP 758454 Methylmalonic acidurea GE2D 
PHB2 NP 009204 Prohibitin-like GElCMS 
RPN1 NP 002941 Ribophorin I GElCMS 
RPN2 NP 002942 Ribophorin II precursor GElCMS 
TMEM16F XP 113743 Similar to RIKEN cDNA F730003B03 GElCMS 
ALB NP 000468 IAlbumin GE2D lCMS·,SP2D lCMS' 
C20orf3 NP 065392 C20 ORF 3; adipocyte plasma membrane-associated GElCMS,SPlCMS 
DSP NP 004406 Oesmoplakin GElCMS,SPlCMS' 
FGB NP 005132 Fibrinogen (3 chain preproprotein GElCMS,SPlCMS' 
GCA NP 036330 Grancalcin GE2D lCMS,SP2D lCMS 
HBB NP 000509 Hemoglobin GE2D,SP2D 
HSPA1A NP 005336 Hsp701A GE2D lCMS·,SP2D 
LOC199675 NP 777578 Hypothetical protein LOC199675 GElCMS,SPlCMS 
.PHB NP 002625 Prohibitin GE2D lCMS,SP2D lCMS 
P4HB NP 000909 POI GE2D lCMS SP2D 
PKM2 NP_002645 Pyruvate kinase 3 isoform GElCMS,SPlCMS 
NP_872270 
NP 872271 





LOC388015 XP 370776 Similar to RTI1 GElCMS,SPlCMS 
HRNR XP_373868 Similar to hornerin GElCMS,SPlCMS' 
NP 001009931 
SEMG1 NP _002998 Semenogelin I GElCMS·,SP2D 
NP 937782 
SEM~2 NP 002999 Semenogelin II GElCMS·,SP2D 
B3GTL NP 919299 1(3 3.glycosyltransferase-like SPlCMS 
S100A12 NP 005612 Calgranulin C SP2D 
EP300 NP 001420 E1A binding protein ~300 SPlCMS 
GALIG NP 919308 Galectin-3 internal gene SPlCMS 
PPFIBP1 NP 003613 
NP-803193 
Llprin-like SP2D 
EHD1 NP 006786 Testilin SP2DlCMS' 
PPIA NP_066953 Cyclophilin A GE2D,SPlCMS·,AZlCMS· 
NP_982254 
NP 982255 
HCLS1 NP 005326 Hematopoietic cell-specific Lyn substrate 1 GElCMS·,SPlCMS·,AZlCMS 
HIST1H1C NP 005310 Histone H1 family GElCMS,SPlCMS',AZlCMS 
HIST1H2BG NP 003509 Histone H2B GElCMS,SPlCMS·,AZlCMS 
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HIST1H41 NP 003486 Histone H4 GELCMS,SPLCMS,AZLCMS 
HSPA5 NP 005338 Hsp705A GE2D,SP2D LCMs,AZLCMS· 
S100A8 NP 002955 MRP-8 GE2D LCMS,SP2D LCMS,AZLCMS• 
S100A9 NP 002956 MRP-14 GE2D LCMS,SP2D LCMs,AZLCMS· 
TOLLIP NP 061882 Toll-interacting protein GELCMS",SP2D,AZLCMS 
RPS27A NP 002945 Ubiquitin precursor GELCMS,SPLCMS,AZLCMS 
UBB NP=061828 
UBA52 NP 003324 
UBC NP-066289 
C9orf19 NP 071738 C9orf19, GAPR-1 SPLCMS,AZLCMS 
TMEM30A NP 060717 Hypothetical protein FLJ10856 SPLCMS,AZLCMS 
DDX4 NP 061912 DEAD (Asp-Glu-Ala-Asp) box--,,-oIYPeJ!tide 4 ~CMS 
ARL10B NP 620150 Hypothetical protein BC015408 AZLCMS 
FLJ22662 NP 079105 Hypothetical protein FLJ22662 AZLCMS 
SQSTM1 NP 003891 Sl!guestosome 1 AZLCMS 
All proteins identified on neutrophil granules by 2DE MALDI-TOF MS and 2D-HPLC 
ESI-MS/MS are listed. A total of 286 proteins were identified and proteins were 
catalogued by function based on a literature search for each protein in the PubMed 
database. The gene and protein designation, method of identification, and granule subset 
on which the protein was found are listed. To be listed as a component of the granule 
subset, a protein was either identified from a granule subset by MALDI-MS analysis of 
2D gels, detected by at least 2 of 3 2D-HPLC ESI-MSIMS experiments, or detected by 
2D-HPLC ESI MSIMS experiment once in one granule subset, and additionally detected 
by 2DE MALDI-MS or at least twice by 2D-HPLC ESI-MS/MS in a different granule 
subset (indicated by an asterisk near the method designation in "Granule TypeMETHoD" 
column of Table 2). In the method designation, LCMS is an abbreviation for 2D-HPLC 
ESI-MSIMS and 2D is an abbreviation for 2DE MALDI-TOF MS. 
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identified once in a given granule subset by 2D-HPLC ESI-MS/MS, and identified by 
either 2DE or at least twice by 2D-HPLC ESI-MS/MS in another granule subset, are 
listed in the Supplementary Table 2. Sequences of corresponding peptides and the percent 
coverage of identified proteins are also shown. 
To eliminate proteins present as contaminants of granule subsets, proteins that 
were detected by only one of the three 2D-HPLC-ESI-MS/MS experiments were 
classified as rejected proteins. Supplementary Table 3 lists the rejected proteins for each 
granule subset. A total of 344 proteins were rejected from gelatinase granules, 211 from 
specific granules, and 230 from azurophil granules. Most rejected proteins were of 
ribosomal, nuclear and mitochondrial origin, or were hypothetical proteins, suggesting 
that the granule isolation method resulted in contamination with small amounts of other 
subcellular organelles. That some contamination did occur is supported by identification 
of several proteins listed in Table 3. The benzodiazepine receptor was described 
previously to be present on mitochondria [243]. Lamin B receptor and Sad1 are of 
nuclear origin [244,245], suggesting that membranes from these structures contaminated 
granule preparations. The presence of signaling proteins (GRK6, PAK5, small GTPases 
of the Ras, Rab, and Rho family, and heterotrimeric G protein subunits) and membrane 
trafficking proteins (syntaxin 2, syntaxin 3A, syntax in 8, syntaxin 10, and syntaxin 11) in 
the list of rejected proteins suggests the exclusion criteria eliminated some proteins that 
are likely components of the granule proteome. Functional classification of proteins was 
performed by a literature search for each protein in the PubMed database. 
Receptors and Cvtoskeletal Membrane Anchors. This group included 
transmembrane proteins involved in adhesion, transmigration, cellular activation, and 
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cytoskeletal anchoring to the membrane, including components of lipid rafts. Of the 40 
proteins, 12 were identified only from gelatinase granules, 19 were found on both 
specific and gelatinase granules, 6 were found on all three granule types, and three were 
found only on azurophil granules. Proteins unique to specific granules were not found in 
this group. Formyl peptide receptors, CRl, CDllb, CDI8, SCAMPs Stomatin, CD63, 
and LAMPs have been identified previously as components of neutrophil granules 
[8,9,40]. 
Channels and Transporters. Proteins that function in facilitating the movement of 
solutes across lipid bilayers were included in this category. Thirteen proteins were 
identified only on gelatinase granules, 10 from gelatinase and specific granules, two from 
all three granule subtypes, and two only from azurophil granules. These proteins included 
proton pumps and transporters for metal ions, glucose, adenine nucleotides, amines, and 
steroids. Eleven of these proteins were described previously to be of mitochondrial 
ongm. 
GTPases. This group included both monomeric and heterotrimeric GTPases, and 
two GTPase-activating protein. Of the total of 21 identified proteins, 10 were found on 
gelatinase granules only, one was only from specific granules, two from specific and 
gelatinase granules, and 8 from all three granule subsets. Monomeric GTPases of the Rab 
family and Cdc42 have been shown to be involved in granule exocytosis in other cell 
types [246-248]. Of note, Rab27 A was shown previously to associate with many types of 
granules and play a crucial role in exocytosis by modulating granule binding with 
cytoskeleton and with proteins that control membrane fusion [249]. Rab27 A was a 
component of all three granule types. To our knowledge this is the first report of the 
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presence of Rab27 A in neutrophils. Cdc42 was also found on all three granule subsets. 
This Rho family GTPase stimulates exocytosis by activating the 1P3 and calcium second 
messenger signaling pathway [248]. 
Structural Proteins and Adaptors. We included cytoskeletal proteins and actin-
binding proteins in this group. Eleven proteins were identified only on gelatinase 
granules, 13 from gelatinase and specific granules, four from specific granules only, ten 
from all three granule types, and two from only azurophil granules. The presence of actin, 
tubulin, and vimentin on all three granule subtypes is consistent with a role for these 
cytoskeletal structures in neutrophil exocytosis [8,9,92,98]. Visual inspection of 2D gels 
suggested that greater amounts of cytoskeletal proteins were associated with gelatinase 
granules than specific granules, which in tum had more than azurophil granules. To 
confirm this observation, western blotting of whole granules for actin was performed 
following normalization for membrane content using a membrane-binding fluorescent 
dye (Figure 7). The amount of actin associated with gelatinase granules was dramatically 
greater than that associated with specific granules. A minimal amount of actin was 
associated with azurophil granules. 
Kinases and Phosphatases. This group included tyrosine kinases, tyrosine 
phosphatases, and one kinase scaffolding protein, MEK1-binding protein. Tyrosine 
kinases were previously identified on neutrophil granules, and inhibition of tyrosine 
kinase activity prevents neutrophil degranulation [152-155]. To our knowledge, this is the 
first report of a tyrosine phosphatase association with neutrophil granules. Tyrosine 
phosphatases are localized to granules in other cells, and they have been shown to 
participate in signaling leading to exocytosis [250-253]. 
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Figure 7. Assessment of actin content on neutrophil granules by western blotting. 
Membrane lipid content was quantitated in neutrophil granules by TMA-DPH lipophilic 
dye and granule proteins were loaded such that amounts of granule membranes loaded 
were equal among different granule subsets. Proteins were transferred to nitrocellulose 











Luminal and Host Defense. This group included proteins localized to granule 
lumens and luminal and membrane proteins that participate in host defense, such as the 
membrane proteases neprilysin and leukolysin. Four proteins were identified on 
gelatinase granules only, 13 proteins from gelatinase and specific granules, eleven 
proteins only from specific granules, 18 from all three granule subsets, three from 
specific and azurophil granules, and 13 from azurophil granules only. All of the luminal 
proteins in this list are annotated on the NCBI database as proteins destined either to 
lysosomal or to secretory compartments. Proteins of lysosomal origin were found 
previously in azurophil granules, in agreement with the hypothesis that azurophil 
granules are lysosome-related organelles [8,9]. Among the identified proteins in this 
group was calreticulin, a component of the endoplasmic reticulum [254]. Calreticulin 
may also be a bona fida granule protein, however, as it acts as a chaperone for neutrophil 
granule luminal proteins [255] and is present on the extracellular surface of the neutrophil 
plasma membrane [256]. Calreticulin was identified as a cytolytic component of T 
lymphocyte granules [257]. 
Membrane Traffic and Fusion. In this group 4 proteins were found on gelatinase 
granules only, one from gelatinase and specific granules, two from specific granules 
alone, four from all three granule types, and two from azurophil granules only. Runc 18b 
(Munc18-2) and Unc-13 homolog 3 (Munc-13), have not been previously identified in 
neutrophils. These proteins are members of a family of proteins that bind to and modulate 
the activity of membrane fusion proteins [47,57]. A hypothetical protein with a C2 
domain, which is known to be involved in membrane fusion events [258], was identified 
on gelatinase granules. Syntaxin 7 and V AMP 8 were expressed on all three granule 
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subsets. These two membrane fusion proteins have not been previously identified from 
neutrophil granules. 
Redox Proteins. Proteins involved in redox reactions, including a transmembrane 
protein related to thioredoxin and the components of the neutrophil NADPH oxidase, 
p22-phox and gp91-phox, were included in this group. Ten proteins were found only on 
gelatinase granules, one from gelatinase and specific granules, two from specific granules 
alone, and three from all three granules. Components of the NADPH oxidase were found 
on all three granule subsets. 
Miscellaneous Proteins. This group included proteins not classified into the other 
groups or for which no function has been described. Twenty-one proteins were identified 
on gelatinase granules, 16 from gelatinase and specific granules, 6 from specific granules 
only, 10 from all three granule types, two from specific and azurophil granules, and four 
from azurophil granules only. Among the proteins found were chaperones such as PDI 
and Hsp70 and 11 hypothetical proteins. Hemoglobin was also found on ge1atinase and 
specific granules, suggesting that hemoglobin from lysed red blood cells binds to 
phospholipid membranes. Hemoglobin was completely removed from granule 
membranes by sodium carbonate treatment. 
Discussion 
Using two approaches, 2DE followed by MALDI-MS and 2D-HPLC ESI-
MS/MS, 286 granule and granule-associated proteins from human neutrophils were 
identified. Only 87 proteins were identified by 2DE and MALDI-MS, of which 56 were 
abundant structural or luminal proteins. The only transmembrane spanning proteins 
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identified after 2DE were the integrins, CDllb and CD18, both of which have a single 
transmembrane domain. The limited protein identification using intact granules was 
marginally enhanced by fractionation of granule proteins using sodium carbonate 
treatment or ammonium sulfate precipitation. These results emphasize the recognized 
limitations to 2DE-based proteomics, namely, the bias against low abundance proteins, 
transmembrane proteins, and proteins at the extremes of isoelectric point and molecular 
mass [206,259]. Despite these limitations, 39 proteins were identified only by the 2DE-
based approach. 
The 2DE analysis of whole granules revealed that the quality of protein separation 
paralleled the density of the lumen matrix for each granule subset [8-10,19]. This is likely 
due to the presence of large amounts of basic proteins in the granule lumens that interfere 
with IEF and render the less abundant membrane-associated proteins unable to focus. 
This observation led to attempts to fractionate granule proteins with alkaline sodium 
carbonate or precipitation with various concentrations of ammonium sulfate. The sodium 
carbonate method fractionated granule proteins largely into luminal and membrane 
fractions. This method resulted in effective 2DE separation of specific granule proteins, 
possibly because these granules contain large amounts of moderately cationic luminal 
proteins that can be dissociated from the luminal matrix and granule membranes. The less 
dense granule matrix of gelatinase granules was associated with adequate protein 
resolution by 2D gels, resulting in minimal improvement after sodium carbonate 
extraction of luminal proteins. Sodium carbonate extraction did not improve separation 
and identification of proteins from azurophil granules, which contain a highly packed 
matrix of acid mucopolysaccharide and highly cationic myeloperoxidase [260]. Sodium 
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carbonate treatment of gelatinase, but not specific granules, also resulted in the 
significant loss of low molecular weight proteins, compared to 2DE of whole granules 
(compare Figure 4A with Figures 5A and 5B). 
The failure of sodium carbonate extraction to improve protein identification of 
gelatinase or azurophil granules prompted us to seek an alternative method of protein 
fractionation based on a different physical characteristic. Ammonium sulfate precipitation 
fractionates proteins according to their solubility in concentrated ammonium sulfate 
solutions. For neutrophil granules, this method separated cytoskeletal and cytoskeleton-
binding proteins from more hydrophilic luminal proteins. This fractionation method 
enhanced protein separation and identification of gelatinase granule proteins (Figure 5C 
and 5D). Fractionation of specific and azurophil granule proteins by ammonium sulfate 
precipitation did not improve protein separation or identification. This was likely due to 
the fact that most of the protein content in these granules was of luminal origin and, 
therefore, hydrophilic. Such proteins precipitate at high concentrations of ammonium 
sulfate and therefore they precipitated in the 100% ammonium sulfate solution. More 
hydrophobic proteins, which were mostly cytoskeletal and were less abundant, 
precipitated in the 20% ammonium sulfate solution. The use of other concentrations of 
ammonium sulfate did not result in improved fractionation of granule proteins (data not 
shown). Thus, sodium carbonate treatment was more effective for identification of 
specific granule proteins, while ammonium sulfate precipitation was more effective for 
identification of gelatinase granule proteins. Neither approach improved protein 
identification from azurophil granules. These results indicate that optimal protein 
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extraction and separation of granule proteins by 2DE IS highly dependent on the 
properties of the granule matrix and luminal proteins. 
To overcome the limitations of 2DE-based protein identification, granule proteins 
were also identified by strong cation exchange reversed-phase two-dimensional 
chromatography combined with ESI-MSIMS, commonly referred to as DALPC or 
MudPIT [214-216,261]. To enhance the sensitivity of this approach for membrane 
spanning and membrane-associated proteins, sodium carbonate extraction was used to 
remove luminal and cytoskeletal proteins [238,240-242,262]. As shown by the 
comparison of Figure 4 with Figures 5 and 6, the use of sodium carbonate significantly 
reduced high abundance luminal proteins, while the reduction in cytoskeleton was 
modest. 2D-HPLC ESI-MSIMS identified 247 proteins from the three granule subsets. 
The distribution of proteins among the granule subsets indicates that 
approximately half were present on more than one granule subset. The presence of 
proteins in more than one granule subset could be due to neutrophil granule biogenesis or 
to cross-contamination among the granule subsets following separation by Percoll 
gradient centrifugation. Granule biogenesis occurs during myeloid cell maturation, with 
different granules forming at different stages of differentiation. The protein content of 
these granules is determined by the timing of protein synthesis relative to formation of 
different granule subsets, not by selective targeting of proteins to different granules 
[8,9,24,31,32,231,232]. The relative purity of granule subset preparations was addressed 
to determine the quality of the proteome for each granule. The distribution of markers for 
each granule subset showed granule separation similar to that reported by other groups 
[10,19]. Western blot analysis for CD66b, a marker for specific granules, showed that 
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gelatinase and azurophil granules were not contaminated by specific granules. The 
presence of gelatinase in the specific granule preparation is consistent with a previous 
study showing that 60% of myeloperoxidase-negative granules contain gelatinase, in 
addition to a marker of specific granules, lactoferrin [8,9]. The presence of 
myeloperoxidase in specific and gelatinase granules may be due to the extremely basic 
nature of this protein, which allows myeloperoxidase released from azurophil granules to 
bind to phospholipid membranes of other granules. Based on current separation 
techniques and known granule markers, however, minimal cross-contamination among 
the granule subsets cannot be excluded. 
We attempted to establish a valid list of proteins for each granule type by 
rejecting proteins that were identified in only one of three 2D-HPLC ESI-MSIMS 
experiments. A total of over 500 proteins, including nuclear, mitochondrial, ribosomal, 
and cytosolic proteins were rejected using this exclusion criterion. A few contaminating 
proteins may have still been present in granule proteomes, as several mitochondrial 
membrane transporters were identified in more than one granule preparation, especially 
in the lighter gelatinase granule fraction. This is likely due to the fact that gelatinase 
granules sediment at a density of 1.08 glml in Percoll [10,19], while mitochondria 
sediment at a density of 1.05 glml [263]. Histones were also identified in all three granule 
subsets. Their presence may reflect nuclear contamination from the reported breakage of 
16% of nuclei during nitrogen cavitation of neutrophils [10,19] and subsequent non-
specific binding to granule membranes. Histones recently were described to co-localize 
with granule enzymes in neutrophil extracellular traps [264]. Subcellular fractionation 
showed that murine macrophage granules contained histones [265]. Histones were also 
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secreted by ammon cells [266]. Thus, histones may be components of neutrophil 
granules. The list of rejected proteins contained several proteins, including syntaxins and 
synaptobrevin-like proteins, that regulate granule membrane fusion. Although none of 
these proteins have been identified previously on neutrophil granules, these results 
suggest the possibility that some granule proteins may have been excluded by the criteria 
used in this study. The presence of false positive and false negative results indicates that 
defining subcellular organelle proteomes using highly sensitive mass spectrometry-based 
techniques is limited by the ability to purify these organelles. Ultimately, confirmation 
that a specific protein is present in an organelle will require histologic studies. 
Analysis of the distribution of proteins among the granule subsets revealed 
differences among the subsets that suggest functional heterogeneity. The total number of 
proteins and the number of proteins in each functional classification, except for luminal 
proteins, increased from azurophil to specific to gelatinase granules. The number of 
luminal proteins identified was greatest in specific granules (45 proteins) while azurophil 
(34) and gelatinase (35) granules contained similar number of proteins. Gelatinase 
granules are the most easily mobilized granules in neutrophils, and, therefore, these 
granules will undergo exocytosis at an earlier stage of neutrophil activation than specific 
or azurophil granules. Gelatinase granule membranes contain a large number of 
membrane receptors and adhesion molecules, as well as being associated with the largest 
amount of actin cytoskeleton and cytoskeletal regulatory proteins. These results support a 
role for gelatinase granules in enhancing the plasma membrane expression of molecules 
necessary for neutrophil adherence to and migration through inflamed vascular 
endothelium and for subsequent chemotaxis. On the other hand, azurophil granules 
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primarily fuse with phagosomes, while exocytosis is negligible. These granules contain 
the largest number of luminal bactericidal proteins, while there is a paucity of membrane, 
cytoskeletal, and GTP-binding proteins. The greater complexity of the specific granule 
lumen and the presence of a significant number of transmembrane and membrane-
associated proteins suggests that these granules represent a transitional phase that can 
contribute to neutrophil activation through exocytosis or provide bactericidal proteins to 
phagosomes. Our results also suggest a differential role of the actin cytoskeleton in 
regulation of granule exocytosis. Gelatinase granules, the most easily mobilizable granule 
subset, are associated with the largest amount of actin cytoskeleton. On the other hand, 
azurophil granules are associated with very little actin, and they fail to exhibit exocytosis 
unless the subplasma membrane actin cytoskeleton is disrupted [8,9]. Once again, 
specific granules represent a transition between these two extremes. Previous reports 
have emphasized the role of the subplasma membrane actin cytoskeleton as a barrier to 
granule exocytosis [79]. The present study suggests that the actin cytoskeleton associated 
with granules also plays an active role in mediating exocytosis. 
To our knowledge, this is the first proteomic study of neutrophil granules. The 
importance of regulated exocytosis in determining the activation state of neutrophils, and 
the use of regulated exocytosis by a large number of other cells, indicates the value of 
defining granule proteomes. The methodology described herein provides an approach to 
defining granule proteomes. In our experience, 2DE identified and revealed relative 
distribution of more abundant proteins in granules, while 2D-HPLC ESI-MS/MS 
identified less abundant proteins and hydrophobic proteins not amenable to detection by 
2DE. The sensitivity of this latter approach demands that granules be isolated to a high 
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degree of purity and/or experimental approaches be employed to eliminate false positive 
protein identification. Our data show that neutrophil granules are complex organelles. 
Analysis of the more than 200 proteins associated with neutrophil granules will allow a 




MYELOID-RELATED PROTEIN-14 IS A P38 MAPK SUBSTRATE IN HUMAN 
NEUTROPHILS 
Foreword 
Proteomic analysis of neutrophil granules revealed the presence of four confirmed 
MK2 substrates, 14-3-3s, LSP-l, pI6-Arc, and vimentin, on neutrophil granules. These 
proteins may play an indirect role in exocytosis by affecting actin polymerization, and 
thus are likely to influence a number of other cellular functions. No known p38 substrate 
was identified. To identify novel substrates, we screened granule proteome for MK2 and 
p38 MAPK-mediated phosphorylation by using recombinant active kinases and urea 
lysates of gelatinase granules [198,199]. We chose gelatinase granules due to the relative 
ease of separation of proteins from these granules on 2D gels, compared to specific or 
azurophil granules. Screening of gelatinase granule proteins for phosphorylation by MK2 
revealed two spots on autoradiographs that were specific to the presence of the kinase in 
the reaction mixture (Figure 8A). One of these spots matched to a spot on the Coomassie 
stained gel, and was identified as vimentin. A similar assay identified MRP-14 as a novel 
substrate of p38 MAPK (Figure 8B). Because of its novelty as a substrate, its ability to 
bind calcium and arachidonate (mediators involved in exocytosis), and its abundance in 
neutrophils, we decided to further study the phosphorylation of this protein. 
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Figure 8. Phosphorylation of urea-solubilized gelatinase granule proteins by 
MAPKAPK-2 and p38 MAPK in the presence of ['f2p]ATP. Granule proteins were 
solubilized in a kinase buffer containing 9 M urea, urea concentration was subsequently 
reduced by buffer exchange to 1 M and [l2p]ATP and a recombinant kinase were added 
to the reaction mixture [198,199]. Proteins were separated by 2DE, gels were stained with 
Coomassie blue dye and autoradiograms were obtained. Proteins were identified by 
MALDI-TOF MS. Panel A shows that only vimentin phosphorylation was observed 
when active recombinant MAPKAPK-2 (MK2) was included in the reaction mixture. 
When active recombinant p38 MAPK (P38) was included in the reaction mixture, MRP-
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Circulating neutrophils are relatively benign cells that undergo a senes of 
phenotypic changes in response to inflammatory stimuli, converting them into cells 
capable of adherence to vascular endothelium; migration to sites of infection; 
phagocytosis of bacteria; and rapid bacterial killing through exposure to proteolytic 
enzymes, antimicrobial peptides, and reactive oxygen species. A number of neutrophil 
responses, including chemotaxis, granule exocytosis, respiratory burst activity, and 
production of chemokines, are dependent on the activation of the p38 MAPK pathway 
[15,172-175,180,186,188,194,195,267,268]. MAPK pathways consist of three-kinase 
modules formed by the terminal MAPKs, which in turn are activated by dual-specificity 
serine-threonine/tyrosine kinases termed MAP2Ks, which in tum are activated by serine-
threonine kinases termed MAP3Ks [166,168,269]. For the p38 MAPK pathway MKK3 
and MKK6 serve as MAP2Ks, and MEKK2, MEKK3, ASKl, Tpl-2, and TAKI have 
been identified as MAP3Ks. [165,166]. The p38 MAPK pathway is activated in 
neutrophils by mediators of inflammation, including chemoattractants, cytokines, 
chemokines, bacterial lipopolysaccharide, tumor necrosis factor-a, and granulocyte-
macrophage colony-stimulating factor [172-175,180,267,268]. 
The signal transduction pathways that lead from p38 MAPK to specific neutrophil 
functional responses are not well defined. Delineating these signal transduction pathways 
requires identification of p38 MAPK substrates in neutrophils. A number of p38 MAPK 
substrates have been identified previously in other cell types, including transcription 
factors such as ATF2, kinases such as p38-regulated and -activated kinase (PRAK) and 
MAPK-activated protein kinase 2 (MAPKAPK-2), and cell cycle regulators such as 
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cyc1in D [270-273]. The only p38 MAPK substrates that have been identified in human 
neutrophils, however, are MAPKAPK-2 and p47phox [175,194,195,274]. The goal of the 
present study was to identify p38 MAPK substrates in human neutrophils using a 
functional proteomic approach developed in our laboratory that combines in vitro 
phosphorylation of neutrophil lysate by recombinant kinase, separation of proteins by 
two-dimensional gel electrophoresis, and phosphoprotein identification by MALDI-TOF 
mass spectrometry (MALDI-TOF MS) [198,199]. One of the proteins identified was 
myeloid related protein-14 (MRP-14), a member of the S100 protein family of calcium 
binding proteins [275,276]. MRP-14 and its binding partner, MRP-8, are highly 
expressed in neutrophils and monocytes, comprising up to 30% of the total cytosolic 
protein mass in neutrophils [277,278]. In addition to the unmodified protein of 114 amino 
acids, an isoform with deletion of the N-terminal four amino acids (MRP-14*) also exists 
[275-278]. Edgeworth et al. [279] reported that MRP-14 and MRP-14* were 
phosphorylated on Thr-113 in a PKC-independent manner in neutrophils and monocytes 
after treatment with ionomycin. Bengis-Garber and Gruener [280] also reported that 
MRP-14 was phosphorylated in neutrophils upon cell exposure to fMLP. Phosphorylation 
has been implicated in translocation of the MRP-14IMRP-8 heterodimer to membranes 
and cytoskeleton in monocytes [281]. MRP-14 was also reported to participate in the 
initiation ofNADPH oxidase activity in human neutrophils [282,283]. The present study 
showed that p38 MAPK phosphorylates MRP-14 on Thr-113. FMLP stimulation of intact 
neutrophils induced p38 MAPK-dependent phosphorylation and translocation ofMRP-14 
to Triton X-100 insoluble cytoskeleton. Thus, MRP-14 is a potential mediator of p38 
MAPK-dependent functional responses in human neutrophils. 
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Materials and Methods 
Neutrophil Isolation. 
Neutrophils were isolated from healthy volunteers using plasma-Percoll gradients 
as described by Haslett et al. [236]. Trypan blue staining showed that >97% of cells were 
neutrophils with >95% viability. After isolation, neutrophils were suspended in Krebs-
Ringer phosphate buffer (pH 7.2) (KRPB) at the desired concentration. The Human 
Studies Committee of the University of Louisville approved the use of human donors. 
Neutrophil Lysate Preparation 
Neutrophil lysate was prepared as previously described [198,199]. In brief, 108 
cells were lysed in 500 ~l of lysis buffer containing 2 M thiourea, 7 M urea, 65 mM 
CHAPS (3-[ (3-cholamidopropyl)-dimethylammmonio ]-I-propane-sulfinate), 58 mM 
dithiothreitol (DTT), and 4.5% ampholytes (pH 3 to 10). Lysates were cleared by 
centrifugation at 12,000 x g for 20 min at 15°C. Prior to addition of exogenous p38 
MAPK, lysate urea concentration was reduced to 1 M by size exclusion chromatography 
as previously described [198,199]. 
p38 MAPK Substrate Identification 
Neutrophil lysates (400 Ilg of total protein) were incubated with 10 IlCi of [y-
32p]ATP (lCN Biomedicals, Inc.) in the presence and absence of 400 ng of active 
recombinant p38 MAPKa (Upstate Biotechnology, Lake Placid, NY) at 30°C for 1 h. 
Kinase reactions were stopped by adding rehydration buffer (8 M urea, 2% CHAPS, 0.01 
M dithiothreitol, 2% ampholytes 3-10, and 0.01 % bromophenol blue) to give a total 
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volume of 450 Ill. Proteins were separated by isoelectric focusing with 18 cm, pH 3-10 
immobilized pH gradient (IPG) strips, followed by size separation with 10% DuracrylTM 
(Genomic Solutions, Ann Arbor, MI), as previously described [199]. Proteins were 
stained with SYPRO Ruby fluorescent stain (Molecular Probes, Eugene, OR), and 
phosphorylation was visualized by autoradiography. 
Identification of Proteins by Mass Spectrometry 
Protein spots were excised and digested with trypsin by modification of the 
method of Jensen et al. [284]. The excised gel pieces were incubated for 15 min in 100 
mM NH4HC03 and 50% acetonitrile and dried by vacuum centrifugation. Proteins were 
then reduced by incubation with 20 mM DTT at 56°C for 45 min, followed by alkylation 
with 65 mM iodoacetamide in the dark at room temperature for 30 min. Post-alkylation 
gel pieces were incubated for 15 min in 100 mM NH4HC03 and 50% acetonitrile and 
dried by vacuum centrifugation. Proteins were hydrolyzed by incubation in 20 ng/ml 
modified trypsin (Promega) at 37°C overnight. Trypsin-generated peptides were applied 
by a thin film-spotting procedure for MALDI-TOF MS analysis using (X-
cyanohydroxycinnamic acid as the matrix on stainless steel targets. Mass spectral data 
were obtained using a Tof-Spec 2E mass spectrometer (Micromass, Manchester, UK) and 
a 337-nm N2 laser at 20-35% power in the reflector mode. Spectral data were obtained by 
averaging 10 spectra, each of which was the composite of 40 laser firings. Mass axis 
calibrations were accomplished using peaks from tryptic auto-hydrolysis. Peptide masses 
obtained by MALDI-TOF MS analysis were used to search the National Center for 
Biotechnology Information database (NCBI, www.matrixscience.com) to identify the 
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intact proteins. A MOWSE score >71 was a priori assumed to indicate a significant 
match, indicating the probability that the match was not a random event. 
Isolation ofMRP-14IMRP-8 Complex for In Vitro Phosphorylation 
High solubility ofMRP-14IMRP-8 complex in concentrated ammonium sulfate 
solution was used to isolate these proteins [285]. Neutrophils (3 x 108 cells) were 
resuspended in 3 ml of lysis buffer containing 20 mM Tris, pH 7.2, 0.5% Triton X-100, 
0.5% NP-40, 150 mM NaCI, 20 mM NaF, 0.2 mM orthovanadate, 1 mM EDTA, 1 mM 
EGTA, 1 mg/mL AEBSF, 0.005 mg/ml leupeptin, and 0.02 mg/mL aprotinin, and 
disrupted by rotating the tube at room temperature for 15 minutes. Lysates were 
centrifuged at 14,000 x g for 15 min to pellet the insoluble material and supernatants 
were removed. Proteins in the supernatant were subjected to precipitation at room 
temperature by adding 100% saturated ammonium sulfate solution to reach the final 
concentration of 80% ammonium sulfate. Precipitated proteins were pelleted by 
centrifugation at 5,000 x g for 15 min and the supernatant was dialyzed overnight at 4°C 
against a buffer containing 0.1 M Tris-HCI, pH 7.4, 50 mM KCI and 20% glycerol. 
Protein concentration was adjusted to 1 mg/ml and aliquots were stored at -20°C. 
In Vitro Kinase Reactions 
Phosphorylation of purified MRP-14 by p38 MAPKa was performed by 
incubation of active recombinant p38 MAPK (1 flg) with 10 flCi of [y}2p]ATP and 12 flg 
of purified MRP-14IMRP-8 complex in 30 fll of kinase buffer containing 25 mM HEPES, 
25 mM ~-glycerophosphate, 25 mM MgClz, 2 mM dithiothreitol, and 0.1 mM NaV03, 
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pH 7.2. Reactions were incubated at 30°C for 30 min. Reactions were terminated with 
SDS sample dilution buffer, proteins were separated by SDS-PAGE on 4-12% Novex™ 
bis-tris gels (Invitrogen, Carlsbad, CA), gels were stained with Coomassie blue dye, and 
phosphorylation was visualized by autoradiography. 
Identification of the Phosphorylation Site in MRP-14 by Mass Spectrometry 
MRP-14IMRP-8 complex (40 Ilg protein) was incubated for two hours in 60 III of 
kinase buffer (50 mM Tris-HC1, pH 7.5, 30 roM MgClz) containing 5 mM NazATP in the 
presence or absence of active recombinant p38 MAPKa (1 Ilg). Proteins were transferred 
to 100 mM ammonium bicarbonate buffer by ultrafiltration using NanosepTM 3K Omega 
ultrafiltration devices (Pall, East Hills, NY) to the final volume of 100 Ill. Five 
nanograms of sequencing grade modified porcine trypsin (Promega, Madison, WI) were 
added to the protein solution and proteins were digested overnight at 37°C. Generated 
peptides were subjected to phosphopeptide enrichment by immobilized metal ion affinity 
chromatography (IMAC) using metal chelate ZipTipMc™ columns (Millipore, Bedford, 
MA) and FeCh as a source of metal ions, according to manufacturer's instructions. 
Resultant peptide solutions were dried by vacuum centrifugation and resuspended in 5 III 
of 50 mM ammonium bicarbonate. The matrix, a-cyano-4-hydroxycinnamic acid 
(HCCA), was prepared by dissolving 8 mg ofHCCA in 1 ml of acetonitrile/water (50:50, 
v/v) containing 0.1 % trifluoroacetic acid (TFA). The matrix solution was vortexed until 
all solids were dissolved. Samples were spotted as 1: 1 (v/v) of protein digest:HCCA 
directly onto MALDI sample targets. Samples were desalted by spotting 0.7 III 0.1 % 
TF A on each dried sample spot, followed immediately by pipetting off the surface liquid. 
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Samples were air-dried in the dark and were cleared of particulate matter with 
compressed gas prior to sample plate loading into the mass spectrometer. 
Positive ion MALDI-TOF mass spectra were acquired using an Applied 
Biosystems (Foster City, CA) AB4700 protein analyzer operating in reflectron mode and 
with ion source pressure ~0.5 pTorr. After a 400 ns time-delayed ion extraction period, 
the ions were accelerated to 20kV for TOF mass spectrometric analysis. A total of 600 to 
1000 laser shots (355nm Nd:YAG solid state laser operating at 200Hz) were acquired and 
signal averaged. Data was analyzed using Mascot assuming a) monoisotopic peptides 
masses, b) cysteine carbamidomethylation, c) variable oxidation of methionine, d) a 
maximum of one missed trypsin cleavage, and e) a mass accuracy of 100 ppm or better. 
Limitation of the original protein mass was not employed within the Mascot search. 
The protein candidates with Mascot significance scores of p<0.05 were a) 
analyzed for theoretical tryptic fragmentation masses using Peptide Cutter (EXPASY) 
and b) reanalyzed by Mascot using an additional Mascot scoring parameter of 
serine/threonine phosphorylation. Peaks identified within the acquired MALDI TOF 
spectrum matching to the predicted phosphopeptide masses were subjected MALDI TOF-
TOF analysis by collision- induced fragmentation (CID) using 1 KeV collision energy 
and atmospheric gases. Mascot search of the MALDI TOF-TOF data proceeded with 
search parameters listed above with the inclusion of a mass accuracy of 0.6 Da for 
peptide fragment masses. MALDI TOF-TOF spectra were used for combined 
MS/(MSMS) analysis using Global Protein Server software (Applied Biosystems, Forster 
City, CA) and Mascot. The resultant data were used to determine the presence or absence 
of phosphorylation and the sequence of the peptide. 
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Expression of Recombinant Wild Type and Mutant MRP-14 
Total RNA from human neutrophils was isolated using RNeasy Mini kit (Qiagen, 
Germantown, MD). RT-PCR primers were designed according to the cDNA sequence of 
human MRP-14. The forward primer (5'-CTGTGTGGATCCTCGGCTTTGG-3') 
incorporated a BamHI restriction enzyme site and the reverse primer (5' -
CACTGT AAGCTTAGGGGGTGCC-3') incorporated a HindIII restriction enzyme site. 
RT-PCR was performed using the SuperScript One-Step RT-PCR kit (Invitrogen) under 
following conditions: 30 min at 50°C for cDNA synthesis, 2 min at 94°C for strand 
denaturation, followed by 40 cycles of 30 sec steps at 94°C (denaturation), 55°C 
(annealing), and 68°C (extension), and the final extension step of 72°C for 10 min. The 
PCR product was digested with BamHI and HindIII (Promega) and ligated into pRSET-A 
plasmid (Invitrogen) using T4 DNA ligase (Promega). Plasmids were propagated in 
DH5a chemically competent E. coli cells (Invitrogen). Threonine 113 mutation to alanine 
was carried out using the Transformer Site-Directed Mutagenesis kit from BD 
Biosciences according to manufacturer's instructions. The mutation primer for Thr!!3 to 
Alal13 was 5'-GGGAGGGCGCCCCCTAAG-3' and the selection primer for pRSETA-
MRP-14 (mutating the XbaI site) was 5'-CAACGGTTTCCCTCCAGAAATA-3'. 
Cloning and mutation were confirmed by DNA sequencing. Expression ofpRSET-MRP-
14 and pRSET-MRP-14Tl !3A plasmids was carried out in BL21(DE3)pLysS chemically 
competent E. coli cells, and protein was purified using the ProBond Purification System 
(Invitrogen). 
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Assessment ofMRP-14 Phosphorylation Ex Vivo 
Neutrophils were loaded with e2p] orthophosphate, as previously described by 
Grinstein et ai. [286]. Briefly, 8 x 107 cells were suspended in 4 ml of loading buffer (6 
mM HEPES, pH 7.4,150 mM NaC!, 5 mM KCl, 1 mM MgCh, 0.25 mM CaCh, 10 mM 
Glucose) for 5 min and divided into four 1 ml tubes. Two mCi of e2p]orthophosphate 
was added to each tube, and the cells and were rotated at 37°C for 60 min. SB203580 was 
added to appropriate tubes to a final concentration of 3 IlM simultaneously with 
orthophosphate. After one hour, fMLP (final concentration 300 nM) was added to 
appropriate tubes. After 5 min, cells were pelleted at 500 x g, washed once in loading 
buffer, and the pellet was solubilized in 600 III of rehydration buffer (7 M urea, 2 M 
thiourea, 2% CHAPS, 0.01 M dithiothreitol, 2% ampholytes 3-10, and 0.01% 
bromophenol blue). The lysates were cleared by centrifugation at 14,000 x g, and 155 III 
of the supernatant was loaded onto pH 3-10 IPG Zoom ™ strips (Invitrogen, Carlsbad, 
CA) by overnight rehydration at 27°C. Strips were focused on Zoom IPG Runner™ using 
the following IEF protocol at 200 rnA maximum current setting: 200 V for 20 min, 450 V 
for 15 min, 750 V for 15 min, 2000 V for 30 min. After focusing, strips were sequentially 
incubated for 10 min in equilibration buffers I (6 M urea, 1% SDS, 2% dithiothreitol, 
30% glycerol) and II (6 M urea, 1 % SDS, 2.5% iodoacetamide, 30% glycerol). IPG strips 
were then applied to 4-12% Novex™ bis-tris gels (Invitrogen) and proteins were 
separated at 200 V for 1 h in X-Cell Sure Lock electrophoresis apparatus. Gels were 




Neutrophils were resuspended in KRPB supplemented with 1.2 mM Mg2+ and 0.5 
mM Ca2+ at a concentration of 5 x 106 cells/m!. Cells (200 ).1l) were added to each well of 
the Lab-Tek Chambered Coverglass (Nalge Nunc, Naperville, IL) and chambers 
incubated for 15 min at room temperature. SB203580 (3 ).1M) was added to appropriate 
wells, and the cells were incubated at 37°C for one hour prior to addition of 300 nM 
fMLP for 5 minutes at 37°C. Cells were washed with ice-cold KRPB, and 200 ).11 of 0.5% 
TX -100 in KRPB were added to each well for 5 min at room temperature to extract 
cytosolic MRP-14 from cells. Neutrophils were fixed with 3.7% paraformaldehyde for 30 
minutes at 4°C, blocked with 2% goat serum and 2% BSA in phosphate buffered saline 
(PBS), and incubated with mouse monoclonal anti-MRP-14 (Kamiya Biomedical, Seattle, 
WA) overnight at 4°C (1 :200 dilution in blocking buffers). Cells were washed with PBS 
and incubated at 4°C for one hour with rhodamine-conjugated goat anti-mouse IgG 
(Molecular Probes, Eugene, OR) for one hour at (1: 1000). Cells were also stained with 
BODIPY-conjugated phalloidin (Molecular Probes) for 1 hr at 4°C (to visualize F-actin). 
Imaging was carried out on a Zeiss Axiovert 100 M microscope using LSM51 0 software. 
Two-dimensional Electrophoretic Analysis of Granule and Plasma Membrane 
Fractions 
Neutrophil subcellular fractionation was carried out by the method of Kjeldsen et 
al [19]. Briefly, isolated neutrophils (8 x 108/ml) were pre-treated with 10 ).1M 
diisopropyl fluorophosphate, resuspended in disruption buffer containing 100 mM KCI, 1 
mM NaCI, 1 mM ATPNa2, 3.5 mM MgCh, 10 mM PIPES, 0.5 mM PMSF, and cells 
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were disrupted by nitrogen cavitation for 10 min at 380 psi and 4°C. Cavitate was 
collected into 1.5 mM EGTA, and nuclei and intact cells were removed by centrifugation 
at 500 x g for 5 minutes. The postnuclear supernatant was layered onto a Percoll gradient 
formed from three 9 mllayers of Percoll, of density 1.090 glml, 1.050 glml and 1.120 
glm!. Percoll solutions were prepared in buffer containing 100 mM KCI, 3 mM NaCI, 1 
mM Na2ATP, 3.5 mM MgCh, 1.25 mM EGTA, 10 mM PIPES, and 0.5 mM PMSF. The 
gradient was centrifuged at 37,000 x g for 30 minutes in SS-34 fixed angle rotor in a 
Sorvall RC-5B centrifuge. The separated granules were recovered from the gradient 
interfaces by aspiration, and the Percoll removed by ultracentrifugation at 100,000 x g for 
90 minutes using the Ti-50.3 rotor (Beckman, Fullerton, CA). Granule and plasma 
membrane/secretory vesicle devoid of Percoll were washed in disruption buffer by 
centrifugation. Washed material was dissolved in 300 ~l of rehydration buffer, and 
lysates were cleared by centrifugation at 14,000 x g. Supernatant was loaded onto pH 3-
10 IPG Zoom ™ strips by overnight rehydration at 27°C. Proteins were separated by 2DE 
using Zoom IPG Runner™ IEF apparatus and X-Cell Sure Lock electrophoresis 
apparatus, as described above. Gels were stained with Coomassie blue dye. 
Purity of granule fractions was determined by immunoblot analysis for CD66b (a 
marker of specific granules) and an ELISA for gelatinase and myeloperoxidase (a marker 
of azurophil granules). CD66b was found only in specific granule fractions. Distribution 
of gelatinase was 75% in gelatinase granules, 18% in specific granules, 5% in plasma 
membrane/secretory vesicles, and 2% in azurophil granules. Myeloperoxidase 
distribution was 76% in azurophil granules, 20% in specific granules, 3% in gelatinase 
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granules, and 1% in plasma membrane/secretory vesicles. This degree of granule 
enrichment is similar to that previously reported [19]. 
Association ofMRP-14 With Neutrophil Granules and Plasma Membranes 
Neutrophils (9 x 108 cells) were resuspended in Krebs-Ringer buffer 
supplemented with Ca2+ and Mg2+, and incubated with or without 300 nM fMLP for 5 
minutes with or without pretreatment with 3 )lM SB203580 for 40 min. Cells were 
subjected to subcellular fractionation, as described above. Granule and plasma 
membrane/secretory vesicle proteins were separated by SDS-P AGE on 15% gels, the gels 
were cut at the level of the 25 kDa marker, and the lower portions of gels were subjected 
to immunoblotting using standard methods. Blotted membranes were probed with mouse 
monoclonal anti-MRP-14 (Kamiya Biomedicals, Seattle, WA) at 1:500 dilution and 
HRP-conjugated goat anti-mouse IgG (Upstate Biotechnology) at 1 :2000 dilution. To 
ensure equal protein loading, upper portions of the cut gels were stained with Coomassie 
blue dye, and the staining intensities of protein bands were compared. 
F -actin Co-sedimentation Assay. 
F-actin filaments (500 )lg of 5-10 )lm length) were generated using the Actin 
Filament Biochem Kit (Cytoskeleton, Denver CO) according to manufacturer's 
instructions. MRP-14IMRP-8 complexes (150 )lg of protein) prepared from human 
neutrophils were incubated overnight at 30°C in 100 )ll of kinase buffer containing 25 
mM HEPES, 100 mM KC1, 40 mM MgCb, pH 7.2 and 5 mM Na2ATP (pH adjusted to 
7.4), in the presence or absence of 2 )lg of active recombinant p38 MAPK. After 
94 
overnight incubation, unphosphorylated (no kinase) and phosphorylated (kinase added) 
MRP-14IMRP-8 complexes (100 Ill) were mixed with 350 III F-actin filaments (250 Ilg 
of actin) in the Actin Polymerization Buffer supplied with the kit. To determine the 
amount of nonspecific MRP-14IMRP-8 sedimentation, 100 III of unphosphorylated and 
phosphorylated complexes were added to 350 III of Actin Polymerization Buffer without 
actin. All solutions were incubated at 37°C for 30 minutes and centrifuged at 100,000 x 
g for 1 hr in a Ti55 rotor (Beckman) at 37°C. Supernatants (450 Ill) were removed 
completely, and pellets were dissolved in 100 III of SDS-PAGE gel loading buffer. 
Twenty III of the dissolved pellets and 20 III of supernatant were loaded onto 4-12% Bis-
Tris SDS-P AGE gels (Invitrogen), proteins were separated, and the gels were stained 
with colloidal Coomassie blue dye (Genomic Solutions). Gels were scanned and the 
intensities ofMRP14 bands were measured by densitometry. 
Results 
Identification of p38 MAPK Substrates 
To screen for p38 MAPK substrates, human neutrophil lysates were incubated 
with [y_32p]ATP in the presence and absence of active recombinant p38 MAPKu. 
Proteins were separated by two-dimensional gel electrophoresis, gels were stained with 
Coomassie blue dye, and phosphorylated proteins were visualized by autoradiography. 
Autoradiographs were compared with Coomassie stained gels to identify proteins that 
were p38 MAPK substrates. Protein phosphorylation was not observed on 
autoradiographs ofneutrophillysates incubated with [y)2p]ATP in the absence of active 
recombinant kinase, indicating that method of neutrophil lysate preparation eliminated 
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endogenous kinase activity (data not shown). In the presence of active recombinant p38 
MAPK, autoradiography demonstrated at least 15 phosphorylated proteins. Three of these 
could be matched to Coomassie blue-stained protein spots, while no stained protein spots 
could be visualized for the remainder. Figure 9 shows the location on two dimensional 
gels of the three proteins identified by MALDI-TOF MS, MRP-14, coronin, and Ly-GDI. 
MRP-14 is a known phosphoprotein that binds Ca2+ [275-281] and arachidonic acid 
[287,288]. MRP-14 also acts as a binding partner for the cytosolic factors of the NADPH 
oxidase [282,283]. As these findings suggest MRP-14 may mediate some p38 MAPK-
dependent neutrophil responses, additional experiments were performed to confirm that 
MRP-14 is a true substrate ofp38 MAPK. 
In Vitro Phosphorylation ofMRP-14 by p38 MAPK 
The possibility that MRP-14 phosphorylation represented a false positive was 
addressed by performing in vitro kinase reactions under non-denaturing conditions. In 
cells, MRP-14 is predominantly found in a heterodimeric complex with MRP-8 
[277,278]. In order to assess the ability ofp38 MAPK to phosphorylate MRP-14 while 
complexed with MRP-8, MRP-14IMRP-8 complexes were purified from human 
neutrophils under non-denaturing conditions. Purified complexes were incubated with 
active recombinant p38 MAPK and [y_32p]ATP, after which proteins were separated by 
SDS-PAGE. Figure 10 shows a Coomassie blue-stained gel and the corresponding 
autoradiograph demonstrating that MRP-14, but not MRP-8, was phosphorylated by p38 
MAPK. These data show that MRP-14 is a p38 MAPK substrate while complexed with 
MRP-8. 
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Figure 9. Identification of p38 MAPK substrates in human neutrophil lysate. 
Candidate p38 MAPKa substrates were identified by incubation of neutrophil lysates 
with [y)2PJATP in the presence of active recombinant p38 MAPKa. Proteins were 
separated by two-dimensional gel electrophoresis, and phosphoproteins were detected by 
autoradiography. Corresponding proteins were located by matching the autoradiograph 
with the image of the SYPRO Ruby-stained gel. Phosphoproteins were identified using 
in-gel trypsin digestion and MALDI-TOF MS of tryptic peptides followed by protein 
database analysis of obtained spectra. A SYPRO Ruby-stained gel and its corresponding 
autoradiograph are shown. The arrows show the three proteins identified from the gel, 
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Figure 10. In vitro phosphorylation of MRP-14 by p38 MAPK. MRP-14IMRP-8 
complexe~ purified from neutrophil lysates were incubated with [y)2p]ATP in the 
presence or absence of active recombinant p38 MAPKa and proteins were separated by 
SDS-PAGE. Kinase alone (K), MRP-14IMRP-8 alone (P14/8), and kinase plus MRP-
141MRP-8 (K+pI4/8) were added to separate lanes and subjected to SDS-PAGE. The 
Coomassie blue-stained gel and its corresponding autoradiograph are shown. The figure 






MRP-14 Phosphorylation by p38 MAPK in Intact Neutrophils 
To assess whether MRP-14 is phosphorylated by p38 MAPK in intact cells, 
isolated neutrophils were loaded with e2p]orthophosphate in the absence or presence of 
the p38 MAPK inhibitor SB203580 prior to stimulation of cells with fMLP. Cells were 
lysed and proteins separated by two-dimensional electrophoresis. Coomassie blue-stained 
gels were compared with autoradigraphs to identify phosphorylation events. Figure 11 
shows that some phosphorylation ofMRP-14 was detected in unstimulated cells, and this 
basal phosphorylation was reduced by pre-treatment with 3 IlM SB203580. Stimulation 
with 300 nM fMLP for 5 minutes markedly enhanced phosphorylation ofMRP-14, while 
pre-treatment with SB203580 abolished fMLP-induced phosphorylation. These data 
indicate that MRP-14 is a substrate ofp38 MAPK in human neutrophils. 
p38 MAPK Phosphorylates Threonine-113 on MRP-14 
MRP-14 was reported previously to be phosphorylated on Thr-113, although the 
kinase was not identified [279]. To determine if Thr-l13 is phosphorylated by p38 
MAPK, mass spectrometry was used to identify the phosphorylated residue on MRP-14. 
MRP-14IMRP-8 was incubated with ATP in the presence or absence of active 
recombinant p38 MAPK. Following phosphorylation, proteolysis by trypsin was 
performed, and the peptide solution was SUbjected to phosphopeptide enrichment using 
metal ion affinity chromatography. MALDI-TOF MS analysis of the tryptic digests 
confirmed the presence ofMRP-14 (Mascot p<0.05) in all digests. The unphosphorylated 
C-terminal 21 amino acid peptide containing Thr-113 was predicted to have a mass to 
charge ratio (m/z) of2176.2, while the phosphorylated peptide was predicted to be 
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Figure 11. Phosphorylation of MRP-14 by p38 MAPK in intact neutrophils. Neutrophils 
were load~d with e2p]orthophosphate prior to stimulation of cells with fMLP in the absence or 
presence of 3 J.lM SB203580. Cells were lysed and proteins separated by two-dimensional 
electrophoresis. Coomassie stained gels and corresponding autoradiographs used to identify 
phosphorylation events are shown. MRP-14 was identified from gels using MALDI-TOF MS. 
The figure shows that basal MRP-14 phosphorylation was increased by treatment with 300 nM 
fMLP, and pretreatment of cells with SB203580 reduced basal phosphorylation levels and 
abolished fMLP-induced phosphorylation. The arrows identify the full length and N-terminal 
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2256.0 m/z, due to the 80 Da mass addition of a phosphoryl group (HP03) [289]. 
Analysis of peptide mass spectra showed a peak at 2177.3 mlz in samples from p38 
MAPK treated and untreated MRP-14 (Figure l2A and B). An ion of 2257.2 mlz was 
observed only in the digest from the sample incubated with p38 MAPK (Figure 12B). 
These results suggest that the C-terminal 21 amino tryptic peptide of MRP-14 was 
modified by phosphorylation. 
To confirm the phosphorylation of this peptide, timed ion selection of 2257 ± 3 
m/z precursor ions, followed by collision induced dissociation fragmentation, yielded a 
fragmentation pattern with a Mascot ion score of 31 (significant homology (p<0.05) at a 
score >18 and identity at a score of >33) for a sequence of 
94MHEGDEGPGHHHKPGLGEGTp1l4. The TOF-TOF spectrum analysis included an 
ion of 2158.6 mlz, which corresponds to the neutral loss of 98 mlz (the mass of 
phosphoric acid, H3P04) from the parent phosphorylated ion (Figure 12C). Appearance 
of a peptide with this mass to charge ratio in addition to the MH+80 precursor ion 
confirms that the post-translational modification on the peptide was phosphorylation 
[227,290-292]. As Thr-1l3 is the only residue in the peptide that could serve as a 
phosphate acceptor from p38 MAPK, these data suggest that p38 MAPK phosphory1ates 
MRP-14 on Thr-l13. 
To confirm that Thr-1l3 is the residue phosphorylated by p38 MAPK, a mutant 
recombinant protein was created in which alanine was substituted for Thr-113. Wild-type 
MRP-14 and mutant MRP-14 were expressed and incorporated in an in vitro kinase 
reaction with recombinant active p38 MAPK. Figure 13 shows that wild type MRP-14 
was strongly phosphorylated under the conditions employed, while no phosphorylation 
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Figure 12. p38 MAPK phosphorylates MRP-14 on Thr-113. To define the site ofp38 
MAPK phosphorylation, purified MRP-14/MRP-8 complexes were incubated with 
Na2ATP in the presence or absence of recombinant p38 MAPK. Following proteolysis by 
trypsin, the peptide solution was subjected to phosphopeptide enrichment using metal ion 
affinity chromatography. MALDI-TOF MS analysis of the tryptic digests confirmed the 
presence ofMRP-14 in digests from incubation with and without p38 MAPK. Panel A 
shows the mass spectra of peptides from digests of the MRP-14IMRP-8 complex alone, 
which included a peptide with mlz of 2177, corresponding to the C-terminal 21 amino 
acid tryptic peptide of MRP-14 (MHEGDEGPGHHHKPGLGEGTP) (arrow). Panel B 
shows the mass spectra for digests of the MRP-14/MRP-8 complex incubated with p38 
MAPK. A new major peak at 2257 mlz was found, corresponding to the hypothetical 
mass (2256.4) of the phosphorylated C-terminal 21 amino acid peptide containing Thr-
113. 
The peak with the mlz of 2257 was sequenced using the timed ion selection and 
collision induced dissociation (CID) fragmentation. Panel C shows the spectra of the ions 
from this fragmentation. Included in this spectra was an ion with a mass of ~2159 mlz 
(shown with an asterisk on threonine), which corresponds to the neutral loss of 
phosphoric acid (H3P04) from the parent phosphorylated ion (theoretical mass of 2158). 
The increase in 80 Da with phosphorylation and the loss of 98 Da with CID confirm that 
the post-translational modification on the peptide was phosphorylation. Observation of 
multiple peaks with IDa differences in mlz (for example, observation of peaks with mlz 
of 2257, 2258, 2259) arises from the natural presence of isotopes of carbon, nitrogen, 
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Figure 13. P38 MAPK phosphorylates wild type hrMRP-14, but not the T113A 
mutant. Twenty micrograms of purified recombinant human wild type and TI13A 
mutant MRP-14 were incubated with [y_32p]ATP in the presence or absence of the 50 ng 
active recombinant p38 MAPK for 30 min at 30°C. The upper panel shows a Coomassie 
stained gel, and the lower panel shows the corresponding autoradiograph. Wild type 
MRP-14 was phosphorylated, while no phosphorylation of the TI13A mutant was seen. 
The mass of the recombinant MRP-14 is about 4.5 kD higher than that of human 











was observed when alanine replaced Thr-l13. Taken together, these results finnly 
establish that p38 MAPK phosphorylates MRP-14 on Thr-l13. 
p38 MAPK-Dependent Translocation ofMRP-14 in Intact Neutrophils 
Phosphorylation of MRP-14 in monocytes results in increased calcium binding 
and translocation from cytosol to membranes and cytoskeleton [281]. To detennine if a 
similar translocation occurred in human neutrophils, confocal microscopy was used to 
detennine co-localization of MRP-14 and F-actin in fMLP-stimulated and unstimulated 
cells. Initial studies showed that the large amount of cytosolic MRP-14 resulted in intense 
staining of the whole cell, which obscured visualization of any changes in intracellular 
distribution (data not shown). Therefore, control and fMLP-stimulated neutrophils that 
had been plated on confocal microscope slides were penneabilized with TX-100 to 
remove cytosolic MRP-14. Cells were then fixed and stained for F-actin using BODIPY 
650/665-conjugated phalloidin and stained for MRP-14 with monoclonal anti-MRP-14 
and rhodamine-conjugated secondary antibody. Figure 14A shows that minimal staining 
for MRP-14 associated with cortical F-actin was observed in unstimulated cells. FMLP 
stimulation resulted in a marked increase in MRP-14 staining and in F-actin fonnation, 
both of which were associated with lamellipodia. MRP-14 staining was localized at the 
base of F-actin within lamellipodia, and excluded from the leading edge (Figure 14B). 
The increased intensity of MRP-14 staining and localization at lamellipodia were 
completely prevented by pre-treatment with SB203580, while fonnation of lamellipodia 
and increased F-actin fonnation were not affected. These results suggest that MRP-14 
translocates to the stable actin cytoskeleton at the base of lamellipodia following fMLP 
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Figure 14. Phosphorylation-induced redistribution ofMRP-14in intact neutrophils. 
Control and tMLP-stimulated neutrophils were plated on confocal microscope slides and 
permeabilized with Triton X-lOO prior to fixation and staining. Panel A shows cells 
stained for F-actin using BODIPY 650/665-conjugated phalloidin (shown in green), and 
with monoclonal anti MRP-14 and rhodamine-conjugated anti-mouse IgG (shown in red), 
and the merged pictures of the two. Unstimulated cells show minimal staining for MRP-
14, confined to the periphery of the cell and colocalized with cortical F-actin (Control). 
Neutrophil stimulation with tMLP resulted in increased F actin staining primarily 
localized to lamellipodia. An increase in MRP-14 staining was seen at the base of 
lamellipodia. Increased MRP-14 staining and association with lamellipodia were 
completely reversed by incubation of cells with SB203580 prior to tMLP treatment 
(tMLP+SB), while F-actin staining and lamellipodia formation was not affected. 
Panel B shows analysis of single cell staining profiles using LSM510 software 
(green lines correspond to the intensity of actin staining and red to MRP-14 staining). 
This analysis demonstrates colocalization of F-actin and MRP-14 under basal condition 
(control). Following tMLP stimulation F-actin staining was most prominent in 
lamellipodia. MRP-14 did not co-localize with the leading edge of F-actin, but was 
present at the base of lamellipodia. Preincubation with 3 f..lM SB203580 (tMLP+SB) 
blocked translocation of MRP-14. Distance in the graphs (the x-axis) corresponds to the 
distance measured from the base to the tip of the line traversing cells. These results 
indicate that MRP-14 translocates to Triton X-lOO insoluble structures at the base of 
lamellipodia in human neutrophils upon tMLP treatment, and that the translocation is p38 
MAPK-dependent. 
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stimulation of human neutrophils, and this translocation is dependent p38 MAPK 
activity. 
We and others reported previously that neutrophil exocytosis depends on p38 
MAPK activation [15,186,188,195]. Therefore, localization of MRP-14 to neutrophil 
granule subsets and the effect of iMLP-stimulation on this localization were examined. 
Two-dimensional electrophoretic separation of neutrophil granule and plasma 
membrane/secretory vesicle fraction proteins revealed that MRP-14 was present in 
pl8$ma membrane/secretory vesicle fractions, on gelatinase granules and specific 
granules, but was absent from azurophilic granules (Figure 15). The amount of MRP-14 
associated with plasma membrane/secretory vesicle and granule fractions in control and 
iMLP-activated neutrophils was examined using western blotting (Figure 16). The 
amount of MRP-14 associated with specific granules was greater than that associated 
with plasma membrane/secretory vesicles or gelatinase granules. FMLP stimulation 
resulted in a significant increase in the amount of MRP-14 associated with plasma 
membrane/secretory vesicle fractions and gelatinase granules, while no change was 
observed in MRP-14 association with specific granules. This translocation was abolished 
by pre-treatment of cells with SB203580. MRP-14 did not associate with azurophilic 
granules under either basal or stimulated conditions (data not shown). In separate 
experiments the ability of anti-MRP-14 antibody to recognize both the non-
phosphorylated and the phosphorylated form of MRP-14 was examined. Both purified 
MRP-14IMRP-8 complexes and recombinant MRP-14 were incubated with ATP in the 
presence and absence of p38 MAPK. Immunoblot analysis showed that phosphorylated 
and non-phosphorylated MRP-14 were detected equally (data not shown). These results 
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Figure 15. Association of MRP-14 with neutrophil granule and plasma 
membrane/secretory vesicle fractions. Neutrophil subcellular fractionation was 
performed to isolate plasma membrane/secretory vesicle fraction and granules. The figure 
shows a portion of Coomassie blue-stained two-dimensional gels, after separation of 
proteins from each fraction, showing the area in which MRP-14 is located. Proteins were 
identified usmg MALDI-TOF MS. MRP-14 was identified m plasma 
membrane/secretory vesicle, gelatinase granule, and specific granule fractions, but was 





Figure 16. Translocation of MRP-14 to neutrophil gelatinase granule and plasma 
membrane/secretory vesicle fractions in tMLP-stimulated neutrophils. Plasma 
membrane/secretory vesicle and granule fractions were obtained from control (basal) and 
tMLP-stimulated cells (tMLP) without or with pretreatment with SB203580 (tMLP/SB). 
Gelatinase granule, specific granule and plasma membrane/secretory vesicle fraction 
proteins were separated by SDS-PAGE on 15% gels. The gels were cut at 25 kDa marker. 
The figure shows immunoblots for MRP-14 of lower portions of gels. To ensure equal 
protein loading, upper portions of each gel were stained with Coomassie blue dye, and 
the staining intensities of abundant proteins were compared. Actin, gelatinase and 
lactoferrin bands were confirmed by MALDI-TOF MS and peptide mass fingerprinting 
as described above. FMLP stimulation resulted in a significant increase in the amount of 
MRP-14 associated with plasma membrane/secretory vesicle fractions and gelatinase 
granules, while no change was observed in MRP-l4 association with specific granules. 
This translocation was abolished by treatment of cells with SB203580. A greater amount 
of MRP-14 was associated with the specific granule fraction than with plasma 
membrane/secretory vesicle or gelatinase granule fractions (equal amounts of protein 
were loaded on gels for each fraction). MRP-14 did not associate with azurophilic 
granules under either basal or stimulated conditions (data not shown). 
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suggest that p38-MAPK-dependent phosphorylation induces translocation ofMRP-14 to 
plasma membrane and gelatinase granules, possibly due to increased association with the 
actin cytoskeleton. 
To determine ifMRP-14 phosphorylation regulates its binding to actin, an in vitro 
F-actin co-sedimentation assay was performed. MRP-14/MRP-8 complexes were 
incubated with ATP in the presence and absence of recombinant active p38 MAPK. 
Equal amounts of phosphorylated and non-phosphorylated MRP-14IMRP-8 were added 
to F -actin filaments, then F -actin was pelleted by ultracentrifugation. Protein in the 
pelleted F-actin and supernatant were separated by 4-12% gradient electrophoresis. 
Figure 17 A shows a Coomassie blue-stained gel demonstrating increased association of 
phosphorylated MRP-14IMRP-8 with actin. Figure 17B presents the densitometric 
analysis of three separate experiments. The data indicate that p38 MAPK phosphorylation 
doubles the amount ofMRP-14IMRP-8 complex associated with F-actin. In the absence 
ofF-actin, MRP-14IMRP-8 complexes failed to pellet following ultracentrifugation (data 
not shown). These data suggest that phosphorylation by p38 MAPK regulates the 
translocation ofMRP-14IMRP-8 to lamellipodia and granules by mediating binding to F-
actin. 
Discussion 
The p38 MAPK pathway participates in a number of neutrophil functions critical 
to generation and regulation of the inflammatory response, including chemotaxis, 
adherence, respiratory burst activity, degranulation, and cytoskeletal reorganization 
[15,172-174,180,186,188,194,195,267 ,268,]. Understanding the molecular mechanisms 
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Figure 17. Phosphorylation by p38 MAPK enhanced actin binding of MRP-
14IMRP-8. Purified MRP-14IMRP-8 was incubated overnight with 5 mM ATP in the 
presence 9r absence of 2 Ilg p38 MAPK. Phosphorylated (K+MRP) and non-
phosphorylated (MRP) complexes were then incubated with F-actin for 30 min at 37°C. 
Following centrifugation ofF-actin at 100,000 x g, pelleted proteins were separated by 4-
12% gradient gel electrophoresis. Panel A shows a Coomassie blue stained gel 
demonstrating increased binding of phosphorylated MRP-14IMRP-8 to actin. Panel B 
shows the mean ± S.D. densitometric analysis of MRP-14 bands from three separate 
experiments, demonstrating that p38 MAPK-mediated phosphorylation of MRP-14 
resulted in a 100% increase in actin binding. 
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by which p38 MAPK participates in these responses is hindered by the limited number of 
targets ofp38 MAPK identified to date in neutrophils. MAPKAPK2 and p47phox are the 
only clearly identified p38 MAPK targets in human neutrophils [175,194,195,274]. A 
previous study by Lewis et al. [203] determined that 20 of 25 ERK targets identified in a 
global screen were not previously known. Thus, it is likely that a number of important 
targets of p38 MAPK that participate in regulation of neutrophil responses remain to be 
identified. The goal of the present study was to apply a recently developed proteomic 
approach that allows simultaneous identification of multiple substrates of a single kinase 
to defining p38 MAPK substrates in human neutrophils. This approach involves in vitro 
phosphorylation of cellular lysate by active recombinant kinase in the presence of [y-
32p]ATP, followed by protein separation by two dimensional gel electrophoresis, 
alignment of autoradiogram with stained gel, and subsequent identification of 
phosphoproteins by MALDI-TOF MS. Using this approach, three potential p38 MAPK 
substrates were identified, MRP-14, Ly-GDI, and coronin. 
The identification of only three of more than 15 phosphorylated proteins by the 
current approach indicates sensitivity remains a limitation to this method. For a number 
of phosphorylation events identified by autoradiography, no corresponding protein spot 
was found or an insufficient mass spectrum was obtained for successful protein 
identification. The limited sensitivity may result from low abundance of these proteins, 
inadequate transfer of proteins from IPG strips to the second dimension gels, incomplete 
in-gel digestion of the protein by trypsin, or inefficient processing and ionization of 
phosphopeptides during mass spectrometric analysis. 
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All three of the proteins identified as targets of p38 MAPK have the potential of 
participating in neutrophil functional responses. Coronins are a family of actin binding 
proteins that directly regulate actin nucleation by Arp2/3 complexes [293], participate in 
chemotaxis of Dictyostelium [294], associate with the phagocytic cup [295], and bind the 
cytosolic components of the NADPH oxidase [296]. Ly-GDI inhibits dissociation ofGDP 
from Rho GTPases, including Rac and Cdc42, maintaining them in the inactive state and 
controlling distribution between cytosol and membrane [297,298]. MRP-14 and its 
heterodimeric partner, MRP-8, are members of the S 1 00 family of calcium binding 
proteins. The heterodimer constitutes up to 30% of neutrophil and 1 % of monocyte 
cytosolic proteins [277,278]. The MRP-14IMRP-8 complex was reported to undergo 
phosphorylation-dependent translocation to the plasma membrane and cytoskeleton in 
monocytes following cell stimulation [281]. The MRP-14IMRP-8 complexes were also 
found to bind arachidonic acid [287,288], and to participate in the activation ofNADPH 
oxidase [282,283]. MRP-14/MRP-8 increased the affinity ofp67phox for cytochrome b558, 
and oxidase activity was enhanced [283]. Targeted disruption of the MRP-14 gene in 
mice does not produce consistent phenotypic changes [299,300], although Manitz et al. 
[300] reported impaired in vitro chemotaxis and up-regulation of CD 11 b. Because of its 
abundance in human neutrophils, further studies were performed examining MRP-14. 
The artificial conditions used for in vitro kinase reactions with neutrophillysates 
may permit p38 MAPK phosphorylation of proteins that would not be targets in intact 
neutrophils. The use of cell lysate may permit access of exogenously added kinase to 
proteins with restricted localization in intact cells. Urea denaturation may expose 
phosphorylation sites that are inaccessible in properly folded proteins. Disruption of 
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protein-protein interactions may result in dissociation of signaling modules that restrict 
kinase-substrate interaction. Finally, protein spots may contain more than one protein, 
which could lead to identification of false substrates. For these reasons, experiments were 
performed in which MRP-14 was confirmed to be a p38 MAPK substrate both in vitro 
and ex vivo. The MRP-14IMRP-8 complex was isolated under non-denaturing conditions 
and subjected to an in vitro kinase reaction with active recombinant p38 MAPK. Under 
these conditions, MRP-14, but not MRP-8, was phosphorylated. In intact neutrophils 
loaded with e2p]orthophosphate, MRP-14 demonstrated basal phosphorylation that was 
dramatically increased by fMLP stimulation. Basal and fMLP-stimulated phosphorylation 
ofMRP-14 was dependent on p38 MAPK activity. These findings indicate that MRP-14, 
while in a heterodimeric complex with MRP-8, is a direct target ofp38 MAPK in human 
neutrophils. This conclusion is supported by a recent report by Vogi et ai. [301] showing 
that MRP-14 is phosphorylated by p38 MAPK in arsenite-stimulated human monocytes 
and in vitro, using recombinant proteins. 
To identify the p38 MAPK phosphorylation site in MRP-14, a combination of 
phosphopeptide enrichment using immobilized metal affinity chromatography (IMAC) 
and tandem mass spectrometry was used [227,290-292]. Edgeworth et at. [279] showed 
that the penultimate residue, Thr-113, was the single phosphorylated residue on MRP-14 
in ionomycin-activated neutrophils and monocytes, and this phosphorylation was 
independent of protein kinase C activity. Our data demonstrated that in the presence of 
p38 MAPK, the 21 amino acid C-terminal MRP-14 tryptic peptide that contains Thr-113 
showed an 80 Da increase in mass, as compared to MRP-14 tryptic peptides in the 
absence of p38 MAPK. This is consistent with phosphorylation of this peptide, as the 
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mass of a phosphoryl group (HP03) is 80 Da [289]. Use of tandem mass spectrometry 
allowed us to observe the p-elimination, neutral loss of 98 mlz from the precursor peptide 
ion, which is the mass of phosphoric acid (H3P04) [289,290]. Peptide tag sequencing of 
the phosphopeptide using collision-induced dissociation showed that the sequence 
corresponded to that of the 21 amino acid C-terminal peptide of MRP-14. Confirmation 
that Thr-l13 was the amino acid residue phosphorylated by p38 MAPK was obtained by 
showing that mutation of Thr-113 to alanine prevented phosphorylation. Similarly, Vogl 
et al. [301] identified Thr-l13 as the site of p38 MAPK-mediated phosphorylation. 
Despite being the most abundant protein in human neutrophils, the functional role 
of MRP-14 has not been determined. The MRP-14IMRP-8 complex translocates to the 
plasma membrane and cytoskeleton in monocytes in a phosphorylation-dependent 
manner following cell stimulation [281]. The present study used confocal microscopy to 
determine the location of MRP-14 after neutrophil stimulation with fMLP, and to 
determine if changes in location were dependent on p38 MAPK activity. The abundance 
of MRP-14 in human neutrophils resulted in marked staining of the entire cell, preventing 
detection of differences in MRP-14 localization between control and stimulated cells 
(data not shown). We presumed that the large amount of cytosolic MRP-14 was 
obscuring any changes in localization that could have occurred as the result of 
phosphorylation following cell activation. Permeabilization of cells with Triton X-I 00 
prior to fixation and staining resulted in loss of cytosolic MRP-14. Under basal 
conditions, only a small amount of MRP-14 was present in the sub-plasma membrane 
area occupied by cortical actin. FMLP stimulation prior to permeabilization resulted in a 
significant increase in MRP-14 staining that localized to the base of the actin 
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cytoskeleton forming lamellipodia. The increased staining for MRP-14 and its 
localization at the base of lamellipodia were dependent on p38 MAPK-mediated 
phosphorylation, as both were inhibited by SB203580 at concentrations specific for p38 
MAPK inhibition [302]. These data suggest that phosphorylation by p38 MAPK results 
in MRP-14 association with long, unbranched actin filaments that form at the base of 
lamellipodia. This conclusion is supported by our data demonstrating enhanced F-actin 
binding of phosphorylated MRP-14. Thus, the MRP-14IMRP-8 complex may playa role 
in stabilization of the actin network at the base of lamellipodia [303]. Manitz et al. [300] 
reported that neutrophils from mice with targeted deletion of MRP-14 demonstrated 
impaired chemotaxis to IL-8 and LTB4• MRP-14-1- neutrophils exhibited increased basal 
levels of F-actin that did not increase with IL-8 stimulation. Impaired CDllb up-
regulation in IL-8-stimulated MRP-14-1- neutrophils suggested that MRP-14 plays a role 
in exocytosis. Vogi et al. [301] reported that deletion of the MRP-14 gene in mice 
inhibited granulocyte migration, suggesting a functional role for the MRP-14IMRP-8 
complex. Thr-l13 is absent from the mouse isoform of MRP-14, however, preventing 
any conclusions regarding the role ofp38 MAPK-mediated phosphorylation in MRP-14 
functions from studies in mice. 
Permeabilization with Triton X-100 prior to confocal microscopic visualization of 
MRP-14 and F-actin solubilizes many cell structures, thereby preventing detection of 
translocation of MRP-14 to these structures. However, using two-dimensional gel 
electrophoresis and MALDI-TOF MS, MRP-14 was shown to be associated with plasma 
membrane/secretory vesicles, gelatinase granules, and specific granules, but not with 
azurophilic granules, in resting human neutrophils. Based on previous reports indicating 
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p38 MAPK regulates neutrophil granule exocytosis [15,186,188,195], the effect ofMRP-
14 phosphorylation on its association with these structures was determined. The data 
indicate that MRP-14 translocated to the plasma membrane/secretory vesicle fraction and 
gelatinase granules following fMLP stimulation, and that this translocation was 
dependent on p38 MAPK activity. The failure of MRP-14 to translocate to specific and 
azurophilic granules upon cell activation may be related to the small amount of actin 
associated with these granules (unpublished observations). The quantitative difference in 
MRP-14 association with specific granules, compared to gelatinase granules and plasma 
membrane/secretory vesicle fractions, under basal conditions remains to be explained. 
Taken together, the results of the present study suggest the hypothesis that 
phosphorylation of MRP-14 by p38 MAPK contributes to p38 MAPK regulation of 
cytoskeletal reorganization necessary for exocytosis. Association of MRP-14 with 
granule subsets may also provide a mechanism by which MRP-14 is released 
extracellularlyat sites of inflammation [304-306]. 
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CHAPTER IV 
SUMMARY AND FINAL CONCLUSIONS 
Proteomic analysis of neutrophil granules with 2DE revealed that for each granule 
subset, the quality of protein separation by 2DE paralleled the density of the lumen 
matrix and the amount of cationic proteins in the granule lumen. Proteins from gelatinase 
granules, which had the least dense lumen, were the most amenable to analysis by 2DE. 
Azurophil granule proteins on the other hand, were dominated by large amounts of highly 
cationic proteins that make up the dense matrix of these granules and did not separate 
well by 2DE. Specific granules have intermediate density and content of cationic proteins 
in the lumen, and the quality of specific granule protein separation by 2DE was 
intermediate to those of gelatinase and azurophil granules. To improve protein separation 
by 2DE, we fractionated granule proteins prior to analysis by 2DE using either the 
separation of luminal proteins from membranes by sodium carbonate, or differential 
precipitation of proteins by ammonium sulfate. We found that the success of each of 
these two methods depended on the granule subtype. Thus, sodium carbonate treatment 
removed large amounts of basic luminal proteins from granule membranes, and allowed 
for improved separation of both membrane-associated cytoskeletal proteins and the 
luminal proteins. However, it led to losses of low molecular weight proteins and luminal 
proteins from gelatinase granules. Ammonium sulfate precipitation was most useful at 
improving the separation of gelatinase granule proteins, which had more cytoskeletal 
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proteins and fewer basic luminal proteins than specific granules. Neither method 
succeeded at improving the separation of proteins from azurophil granules, which 
contained very little cytoskeleton and large amounts of acidic mucopolysaccharide and 
highly cationic proteins that do not resolve well on 2D gels. 
Similarly to other proteomic studies, we found that transmembrane and 
membrane-associated proteins were strongly underrepresented among the proteins 
identified by 2DE. To overcome the limitations of 2DE-based protein identification, we 
used a much higher sensitivity proteomic method, namely, strong cation-exchange 
reversed-phase two-dimensional chromatography combined with ESI-MSIMS (2D-HPLC 
ESI-MSIMS). To enhance the sensitivity of this approach for membrane-spanning and 
membrane-associated proteins, we used sodium carbonate extraction of granules. Based 
on 2D gels of carbonate treated granule membranes, this treatment allowed for granule 
membrane-associated proteins to largely remain bound to the membrane, but effectively 
removed luminal proteins. 
The high sensitivity of 2D-HPLC ESI-MSIMS and the resultant identification of 
proteins from subcellular organelles that contaminated isolated granules, led us to 
establish a valid list of proteins for each granule type by repeating the 2D-HPLC ESI-
MSIMS experiments for each granule subtype three times, and rejecting proteins that 
were identified in only one of the three experiments. We identified a total of 286 proteins 
on the three granule subsets, 87 of which were identified by 2DE and MALDI-MS and 
247 were identified by 2D HPLC ESI-MSIMS. 
Proteomic analysis of neutrophil granules resulted in identification of a number of 
proteins not previously described in neutrophils, but have been implicated in granule 
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exocytosis of other hematopoietic cells. Among these proteins were SNARE proteins 
V AMP-8 and syntaxin 7, SNARE-modulating proteins Munc-18-2 and Munc-13-4, 
GTPase Rab27 A, and synaptotagmin-like protein SIp-I. V AMP-8 associates with, and 
participates in exocytosis of platelet dense core granules and RBL-2H3 mast cell granules 
[307,308]. Syntaxin 7 was found on platelet granules [309]. In addition, it was shown that 
syntaxin 7 interacts with V AMP-8 and may act in granule-to-granule and granule-to-
phagosome fusion [310-312]. SNARE modulating protein Munc-18-2 (Hunc-18b) is 
found on mast cell granules, interacts with microtubules, and participates in compound 
exocytosis of granules [100]. Munc-18-2 also associates with a complex that contains 
SNAP-23 and VAMP 3 and participates in platelet exocytosis [313]. Munc-13-4 and 
synaptotagmin-like protein 1 (SIp-I) are effectors of the GTPase Rab27A. Rab27A 
regulates granule secretion in a number of cell types, and mutations in Rab27 A gene have 
been found in a human disorder known as Griscelli syndrome characterized by aberrant 
pigmentation and immunodeficiencies [314]. Munc-13-4 regulates granule secretion in 
platelets and mast cells by directly binding to GTP-Rab27 A and enhancing exocytosis 
[315,316]. The function of synaptotagmin-like proteins is not known, but they interact 
with GTP-Rab27A and contain tandem calcium C2 domains found in many proteins 
involved in exocytosis [317,318]. 
The identification of a number of proteins on neutrophil granules that are involved 
m granule exocytosis in other hematopoietic cells suggests a common exocytotic 
machinery for all hematopoieteic cells. However, signaling pathways that lead to 
exocytosis are unique for each cell. In neutrophils the p38 MAPK pathway plays a central 
role. We screened neutrophil granule proteins for substrates of p38 MAPK and its 
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downstream kinase MAPKAPK-2 (MK2). Novel substrates were not identified for MK2, 
however, we identified MRP-14 as a novel p38 MAPK substrate and a component of 
neutrophil granules. Upon phosphorylation by p38 MAPK, MRP-14 translocated to 
plasma membranes and gelatinase granules. No increase was seen in the amount ofMRP-
14 associated with specific granules, which had more MRP-14 bound to them under basal 
conditions than gelatinase granules or plasma membranes. Additionally, confocal 
microscopy revealed colocalization ofMRP-14 and F-actin at the base oflamellipodia in 
cells stimulated with :fl\1LP and extracted with TX-I00. P38 MAPK and its substrate 
Hsp27 also localized at the base of lamellipodia in migrating aortic smooth muscle cells 
[319]. Our confocal micrographs revealed punctate distribution of colocalized F-actin and 
MRP-14 in small round structures at the base of neutrophillamellipodia. Whether these 
structures were granules that have been immobilized by binding to TX-I00-insoluble 
cytoskeleton, is not known. MRP-14 also bound to F-actin in vitro in phosphorylation-
dependent manner. Thus, MRP-14 may be translocating to F-actin present on granules 
and plasma membranes. Increased translocation of MRP-14 to gelatinase granules and 
plasma membranes, but not to specific granules, may reflect an earlier observation of the 
presence of more actin on plasma membranes and gelatinase granules than on specific 
granules. Presence of significant amounts of MRP-14 on specific granules under basal 
conditions, and the lack of change in MRP-14 content upon cell stimulation, suggests that 
non-phosphorylated MRP-14 binds an unknown membrane component that is abundant 
in specific granules. 
Phosphorylation of threonine 113 of MRP-14 by p38 MAPK is interesting from 
the standpoint of substrate recognition by this proline-directed kinase. Threonine 113 is a 
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penultimate residue at the highly disordered C-terminus of the protein [320]. Although it 
is followed by a proline, it lacks a basic residue at -2 position and its proximity to the 
protein C-terminus makes it dramatically different from other p38 MAPK 
phosphorylation sites that are followed by a proline [321]. 
The MRP-14IMRP-8 complex binds arachidonic acid and can transport it through 
hydrophilic cytosol and extracellular fluids that would otherwise prevent the diffusion of 
this hydrophobic signaling molecule [287,322,323]. MK-2, a substrate of p38 MAPK, 
phosphorylates 5-lipoxygenase (5-LO), an arachidonate-metabolizing enzyme of the 
leukotriene synthesis pathway [324]. This phosphorylation is augmented in vitro by a 
direct addition of arachidonate to the reaction mixture containing 5-LO, MK2 and 
MgATP [324]. Thus, p38 MAPK may modulate arachidonate metabolism by inducing 5-
LO activity, as well as transport of arachidonate through cytosol. This process may be 
involved in granule exocytosis, since arachidonate augments membrane fusion between 
specific granules and phospholipid vesicles [134,135], and MRP-14 may act in the 
delivery of this lipid mediator to neutrophil granules during exocytosis. 
Using proteomic approaches, we identified a number of proteins that are likely to 
be involved in neutrophil granule exocytosis, and a novel p38 MAPK substrate that could 
participate in exocytosis and/or other neutrophil effector functions. Thus, we have 
provided targets for the studies that may lead to elucidation of the mechanism neutrophil 
degranulation, as well as improved understanding of the role of p38 MAPK in neutrophil 
exocytosis or other aspects of neutrophil biology. 
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Supplementary Table 1 
Peptides used for identification of proteins from more than one 2D-HPLC ESI-
MS/MS experiment 
GELATINASE GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
BZRP NP 000705 Benzodlazeplne receptor RFVHGEGLRW 1 R.FVHGEGLR.w 
CEACAM1 NP_001703 ~AECAM-1 1 RTL TLlSVTRN 1 R.OLTEHKPSVSNHTQOH$NDPPNK.M 1 R DL TEHKPSVSNHTOOHSNOPPNK.M R.TL TlLSVTR.N R.IL TLLSVTR.N 
CANX NP _001737 ~alneXln 1 K.APVPTGEVYFADSFDRG 1 KIPDPEAVKPDDWDEDAPAK.I 1 K.lPNPDFFEDLEPFR.M KJPOPEAVKPODWOEDAPAKI K.IPNPDFFEDLEPFR.M R.IYODWANDC3VY'GLK.K 
K.lPNPDFFEDLEPFR.M R.KIPNPDFFEDLEPFR M R.KIPNPDFFEDLEPFR.M 




ITGAM NP_000623 1C011 b, complement component receptor 1 ROHVFQVNNFEALK.T 1 R.DHVFQVNNFEALK T 1 R.OHVFQVNNFEALK.T R.EOOIQSWTYDLALDSGRPHSR.A K.EFVSTVMEQLKK S K EFVSTVMEOLK.K 3 (CR3) R.FGAALTVLGDVNGDK.L K.ERlPSHSDFlAElR.K K.FGDPLGYEDVIPEADRE 
K FGDPU3YEDVIPEADR.E K.FGDPLGYEOVIPEAORE RGFGQSWQLQGSRV 
RGAVYLFHGTSGSGISPSHSQR I ~ ~:~~~~i~~~~~~~~;~~~R:' K.ILWITOGEK.F R GFGQSWOLQOSRV R.LPSHSOFLAELR K 
RLPSHSOFLAELR.K R.OFOOSWQLQGSR.V K.LTOVAIGAPGEEONRG 
KL TOVAIGAPGEEONRO ~,K.ILWITOOEKFOOPLOYEOVIPEAORE R.QELNTIASKPPRO 
R.QELNTIASKPPR.O VIR.Y RSLVKPITQLLGRT 
10 RONTOMWESNANVK.G R.LPSHSOFLAELRK 10 RTOVTFFFPLOLSYRK 
11 R.SLVKPITOLlGRT 10 R.QNTGMNESNANVK.G 11 RVQSLVLGAPRY 
12 K.TEFQLELPVKY 11 R.SLVKPITQLLGR.T 12 RWVGAPOEIVAANOR G 
13 K.TLFSLMOYSEEFR.I 12 R.VMCHQYOVSNLOQRS 13 K.YAVYMVVTSHGVSTK.Y 
14 R.vMQHQYQVSNLGQRS 13 R.VQSLVLGAPR.Y 
15 R.WVGAPQEIVAANQRG 14 RWVGAPQEIVAANORG 
15 R.WIOVGDAFR.S 
ADAM8 NP _001100 je0156, AOAM-8 1 R GPOELVPTTHPOQPARH 1 ROPOELVPnHPOQPARH 
R.SNPLFHQAASR V 
R.VlEWNHVDKL 
FCGR3B NP 000561 1c016 FCYRlllb 1 K.AWFlEPQWYSVLEKO 1 K.YFHHNSDFHIPK.A 
ITGB2 NP _000202 1C018, macrophage antigen 1 (mac-1) 1 K.LAENNIQPIFAVTSR.M 1 R.LLVFATDDOFHFAGDOKL 1 RALNEITESGR.I 
R.LLVFATDOOFHFAGDGK.L K.SAVGELSEOSSNVVHLIK.N R.IGFGSFVDK.T beta subunit K SAVOELSEDSSNWHUK.N R.SNEFDYPSVGQLAHK.L K.LAENNIQPIFAVTSRM 
R.SNEFDYPSVGQLAHK.L K.SOWNNDNPLFK.S K.LGAIL TPNDGRC 
K.TVlPFVNTHPDKL K.TVLPFVNTHPOK.L K.LGGOLlRA 







CR1 NP 000564 [;035, complement receptor-1 (CR1) 1 R.HTGTPSGDIPYGK.E 1 RHTGTPSGOIPYGK.E 1 R.ENFHYGSWTYR.C 
NP-000642 R VLFPVNLOLGAK.v R.HTGTPSODIPYGK.E R.VLFPVNLOLGAK.V 
ITGA2B NP _o00410 041, platelet fibrinogen receptor, alpha 1 R.OGYNOIAVAAPYGGPSGRG 1 RVAIVVGAPR.T 1 R.OGYNDIAVAAPYOGPSGR.O 
R.EQNSLOSWGPK.V R FGSAIAPLGOLDR 0 








ITGB3 NP_000203 ~061, platelet glycoprotein ilia 1 K DDLWSIONLGTK.L 1 K.GSGOSSQVTQVSPQRI 1 K.GSGDSSQVTOVSPORI K.GSGDSSQVTQVSPORI R.NDASHLLVFTTOAK.T K.lGOTVSFSIEAK.V 






C5R1 NP _001727 p088, C5aR1 1 R.NVL TEESWRE 1 KDTLDLNTPVOK.T 
R.NVLTEESWR.E 
CD9 NP 001760 "'09, motility related protein 1 K.KOVLETFTVKS 1 K.KOVLETFTVK.S 
DSG1 NP _001933 Oesmogleln preproproteln 1 R.ISGVGIDOPPYGIFVINQKT 1 K.vGOFVATOLDTGRPsTTVRY 
K.VGDFVATDLDTGRPSTTVR.Y K.YQGTILSIDDNLOR T 
K.YOGTILSIODNLQR.T 
FCER1G NP _004097 Fc receptor for IgE, high affinity I, 1 K.SOOVYTGLSTR.N 1 K.SDGVYTGLSTR.N 1 R.OOETYETLK.H 
klamma polypeptide K SDGVYTGLSTR.N 




FLOT2 NP _004466 FlotUlin 2 1 KNWLOTLEGHLR.S K.NWLOTLEGHLR.S 
KTAEAQLAYElQGAR.E RSILGTLTVEQIYODRD 
K.VDEIWLSGDNSK.V 
FPR1 NP 002020 Formvl DeDtlde receptor 1 RLIHAlPASLERA 1 R.UHALPASLER.A 
GP1BB NP 000398 IGlycoproteln Ib beta precursor 1 RTAHLGANf'YoIRC 1 R.TAHlGANPWR.C 
HLA-A NP 002107 HLA-A1 1 R APWIEOEGPEVWDOETRN 1 R.SWTAAOTAAOITOR K 
ICAM3 NP _002153 CAM-3 precursor 1 RQPAVEEPAEVTATVLASR.D 1 R.TFVlPVTPPR.L 1 R QPAVEEPAEVTATVLASRD 
RWEEELSROPAVEEPAEVTATV RTFVlPVTPPRL 
SR.D R.TSL TWLLRW 
LBR NP_919424 Lamln B receptor 1 K.ENDIKPL TSFRQ 1 KWEGTPltDGR.R 
NP 002287 K.WEGTPUDGR.R 
LAMP2 NP 002285 LAMP2 1 K.YLOFVFAVK N 1 K.YLDFVFAVK.N 
LlLRB2 NP_005865 Leukocyte Ig-like receptor 2 RKAOFOHPAGAVGPEPTOR.G 1 K.NGQFHIPSITWEKTGRY 
K.NOOFHIPSIT'vVEHTGR.Y 




CLEC12A NP _612210 Myeloid Inhibitory C-type lectin-like 1 RSYDYWLGlSPEEDSTRG 1 RSYDYWLGLSPEEOSTR (3 
NP_963917 receptor R.VDNIINSSAWVIRN 
NP 963919 
Gpg NP 000165 Platelet glycoprotein IX 1 R.GHGLTALPAlPAR.T 1 RTPEALlOVR.C 
SELPLG NP 002997 P-selectln alvcoproteln lIaand-1 1 K SPGLTPEPR.E 1 K.SPGL TPEPRE 
UNC84B NP_056189 lSad1 1 K.EGVIGVTEEQVHHIVK.a 1 R.DSSPHFQAEORV 1 RQGAPGQGGGGGLSHEDTLALLEG R.LEOOLAGLQQELAALALK Q K.EGVIGVTEEQVHHIVK.Q VSR.R 
R.QGAPGOOGGGGLSHEDTLAllEG K.lL THVAEMQGK,S 
VSRR RLEDQLAGLOOELAALAlK Q 
R.RLEDOLAGLOOELAALAlK.Q R.RPDEGWEAR.O 
R.RPDEGWEAR.D 
SCAMPl NP 004857 ISCAMP1 1 K.EHALAQAElLK.R 1 KEHALAQAELLK.R 
SCAMP2 NP_005688 !SCAMP2 1 RELQNTVANLHVR.Q 1 R.ElQNTVANLHVR Q 1 R.ELQNTVANlHVR.Q 
R.TGASFQQAQEEFSQGIFSSRT R.TGASFQQAOEEFSQGIFSSR,T 
SIGLEC5 NP_003821 !SIalic acid binding Ig-like lectin 1 R.KKPNPDSPGOOASPPGDAPPLEE pt KPNPDSP(300ASPPGDAPPLEE 1 K.OQEAPSTIEYSEIKT K.E KE 
RMEDTGSYFFR.V 
SPN NP _003114 !Slalophorln (CD43) 1 R.TGALVLSRG 1 R,NGWDAWAQPAaVPEEGAVTVTVG 1 R.NGWDAWAGPAOVPEEGAVlVlVG SGGDK,G ~SGGCKG 
RTGALVlSRG 
STOM NP _004090 !Stomatln 1 R.AKVIAAEGEMNASR.A 1 K.OSVTISVOOVVVYR.v 1 K.DSVTISVOGVVVYR.V K.EASMVITESPAALQLRY RLLAQTILR.N K.EASMVITESPAALQLRY 
RLLAQTTLR.N K.NLSQILSORE REEIAHNMQSTLOOATOAWGIK.V 
K,LPVQLQR.A ~~K.NlSQILSOREEIAHNMQSTLOOATOA RLLAQTTLR.N 
W~·NLSQILSOREEIAHNMQSTLOOATOA GIK.V K.LPVQLQRA 
GIK.V K.NSTIVFPLPIOMLQGIIGAKH K.NLSQILSORE 
~~.NLSQILSOREEIAHNMQSTLOOATOA Is R.TISFOIPPQEIL TK.O R.TISFOIPPQEILTK 0 
GIKVERV ~ R.VQNATLAVANITNAOSATRL KVIAAEGEMNASRA 
R.TISFDIPPOEIL TK.O RYLQTLTTIAAEK.N RVONATLAVANITNAOSATR.L 
K.VIAAEGEMNASRA 10 R.YLQTLTIIAAEK N 
R.VQNATLAVANITNAOSATRL 




VNN2 NP _004656 Vanln 2 1 K.ONSIYVLANLGDK.K 1 K .ONSIYVLANLGOK ,K 1 K EENEVYVLGAFTGLHGR.R 
NP 511043 K.EENEVYVLGAFTGLHGR.R K TETP\lSQEOALNLMNENI01LETAIK.Q 
Channels and Transporters 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
SLC25A4 NP _001142 jAdenlne nucleotide translocator 1 1 K.LLLQVQHASK.Q 1 R.GNLANVIRY 
RyFPTQALNFAFK.O 
SLC25A5 NP _001143 iAdenlne nucleotide trans locator 2 1 KDFLAGGVAAAISK T 1 K OFLAGGVAAAISK.T 
K.EOGVLSF'NR.G 
SLC25A6 NP 001627 IAdenlne nucleotide translocator 3 1 K,OFLAGGIAAAISK.T 1 K.OFLAGGIAAAISKT 1 K.OFLAGGIAAAISK.T 





ATP5Fl NP _001679 iATP synthase, H+ transporting, 1 K.EQEHMINWVEK.H 1 K.OASIOHIQNAIOTEK S 
mitochondrial FO complex, subunit b K.QASIOHIQNAIOTEK.S K TGVTGP'r'\II...GTGULYALSKE 
ATP5H NP_006347 IATP synthase, H+ transporting, 1 R.LAALPENPPAICM'AYYK.A 1 K,YPYWPHOPIENL.· 
K.NLIPFDOMTIEDLNEAFPETK.L ~Itochondrlal FO complex, subunit d K.TID'v'NAFAEIIPQNQK.A 
K,YPYWPHOPIENL.-
ATP5Al NP_004037 IATP synthase, H+ transporting, 1 RNVQAEEMVEFSSGLK G 1 REAYPGDVFYLHSRL 
mitochondrial F1 complex, alpha subunit K.HALlIYDDLSK.O 
TCIRGl NP_006010 IATPase, H+ transporting, 116kD, 1 RLGALQQLOQQSQELQEVLGETER.F RTPLLQAPGGPHODLRV 1 ROLNASVSAFORR 




ATP6V1C2 NP _653184 ~TPase, H+ transporting, lysosomal 1 K.UTEDKEGGLFTVTlFRK 1 K UTEOKEGGLFTVTLFRK 
2kDa, V1 subunit C Isoform 2 
ATP6VOAl NP _005168 IATPase, H+ transporting, lysosomal VO 
~ubunlt a Isoform 1 
1 RDLNPOVNVFQRK 1 RDLNPDVNVFQR K 
ATP6VOA2 NP_036595 IATPase, H+ transporting, lysosomal VO 1 RAOIPLPEGEASPPAPPLK.Q 1 RADIPLPEGEASPPAPPLK.O 
ubunlt a Isoform 2 
ATP6VODl NP _004682 JATPase, H+ transporting, lysosomal, VO 1 RFFEHEVK.L 1 RFFEHEVK.L 
Isubunlt 0 Isoform 1 
SLC25A24 NP 037518 alclum-blndlng transporter 1 K.HEGLGAFYK.G 1 ROLLAGGIAGAVSRT 
SLC2A3 NP _008862 !Glucose transporter type 3 t =:t~~i~~~~g:~~~~gESAR.M ~ ~·~~~~~~:~~~~K.D 1 RLWGTOOVSODIOEMK.D K.OVTVLELFRV 
R.TFEOITRA 
MTCH2 NP_055157 Mitochondrial carrier homolog 2 R.EEGILGFFAGLVPR L 1 R.GLFTGL TPR.L 1 R.GLFTGL TPR.L 
KVLOHYOESDKGEELGPGNVOK.E K VlIQVGYEPLPPTIGR.N 
SLC25A3 NP 005879 Mitochondrial phosphate carrier 1 RLPRPPPPEMPESLK,K ~ K.GIFNGFSVTLK,E 
NP-002626 IDrecursor Isoform 1 R.lOTOPGYANTLRD 
PLSCRl NP 066928 Phospholipid scramblase 1 1 R.EAFTDAONFGIOFPLOLOVK.M 1 REAFTOADNFGIOFPLDLDVKM 1 R.EAFTOADNFGIOFPLDLDVK,M 
ATP2A3 NP 005164 ~~rco/endoPlasmlc reticulum Ca2+ - 1 KAVGVAVATGLHTELGK.I K.NMLFSGTNITSGK.A 
NP-777613 RHFSVTAEGGlSPAOVTGAR.E R.vDOSIL TGESVSVTK.H TPase RIVENLOSFNEITAMTGOOVNDAPA 
NP-777614 K.K 
NP-777615 K.NMLFSGTNITSGK.A RVDOSll TGESVSVTK.H 
NP-777617 RYGPNELPSEEGK.S 
NP-777618 
SFXNl NP_073591 ISlderoflexln 1 1 K.IOESHPELRR 1 R.NILL TNEOLESARK 1 R.NILLTNEOlESAR.K ~ =:~~::~P~L~::E~~RA K.OAITQVWSRI R.QGIVPPGLTENELWRA 
SLC04Cl NP _851322 ~olute carrier organic anion transporter 1 K.SPEPSLPSAPPNVSEEKL Ii ~:~~~~~~~~~~~.L 
amlly, member 4C1 
VDACl NP_003365 ~oltage-dependent anion channell 1 K.SENGlEFTSSGSANTETTK.V 1 K.WNTONTLGTEITVEDOLARG 1 K.SENGLEFTSSGSANTETIKV 
K.TOEFOLHTMINOOTEFGGSIYOK.V K,TDEFOLHTNVNOOTEFGGSIYOK.V 
SLC04Cl NP _003366 lVoltage-dependent anion channel 2 1 R TGOFQlHTNVNOGTEFGGSIYQKV 1 R.TGOFQLHTNVNDGTEFGGSIYQK 
K.VNNSSLlGVGYTOTLRPGVK.L 





Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
HSPC121 NP_057479 Butyrate-Induced transcript 1 GTPase 1 R.VELSDVQNPAISITENVLHFK.A t ~:~~~~:~:~isriENVlHFK.A 
ctlvatlna Droteln 
CDC42 NP 001782 dc42 K.NVFDEAILAALEPPEPK.K 1 K,NVFOEAILAALEPPEPK.K 1 K.NVFDeAILAALEPPEPK.K 
GNAI2 NP _002061 jGla2 1 KAMGNLQIDFADPSRA RIAQSDYIPTQOOVLR.T 1 K.EFADSLGIPFlETSAKN RIAOSOYIPTOOOVLR.T K YDEAASYlOSK.F R GAHGIIWYDVTDQESFNNVK 
IQGAP1 NP_003861 Q motif containing GTPase activating ~ K.LPYOVTPEQALAHEEVK.T 1 KTVlELMNPEAOLPaVYPFAADl yaK 
IProteln 1 
K.TLINAEDPPMVVVRK 
RAB10 NP _057215 RAB10 1 K EPNSENVDISSGGGVTGWK.S 1 KEPNSENVDISSGGGVTGWKS K.TPVKEPNSENVOISSGGGVTGWK,g 
RAB11A NP 004654 RAB11A 1 RENDMSPSNNWPIHVPPTTENKPK.V 1 RENDMSPSNNWPIHVPPTTENKPK 




RAB14 NP_057406 Rab14 1 R.NL TNPNTVIILIGNKA RNL TNPNTVItLIGNKA 12 KTGENVEDAFLEAAK.K K.QFAEENGLLFLEASAK.T 
KTGENVEDAFLEAAK.K 
RAB1A NP _004152 RAB1A 1 K.EFADSLGlPFLETSAKN 1 KEFADSLGIPFLETSAK.N R.OAHOIIWYOVTOOESFNNVK.Q R.OAHOIIVVYDVTOOESFNNVK 
RAB1B NP _112243 RAB1B 1 RMGPGAASOGERPNLK.I 1 R.OAHOIIVVYDVTOOESYANVK.Q 1 R.OAHOIIVVYOVTOOESYANVKQ 
K.NATNVEQAFMTMAAEIK.K K.NA TNVEQAFMTMAAEIK.K 
RAB2 NP_002856 RAB2 1 R.OTFNHL TTWLEOARQ 1 K.IQEOVFDINNEANOIKI 
K IQEOVFOINNEANOIK.I K.TASNVEEAFINTAK.E 
RAB21 NP 055814 RAB21 R.HVSIOEAESYAESVOAK.H 1 RHVSIOEAESYAESVGAK.H 
RAB2?A NP 899057 RAB27A 1 KFLALODSGVGKT 1 K.FlALODSOVOKT 1 K.FLALGDSGVGK.T 
NP-899058 tz R.IHLOLWDTAGOER.F ~ =:~:~~i:~~~~F R.lHLOLWDTAGOERF J3 K.TSVLYOYTDGKF 
NP-899059 R.WKEEEAIALAEK.Y 
NP-004571 
RAB32 NP _006825 RAB32 1 K.lL VNHQSFPNEENDVDK.I ~ ~:~~~~!~~E~SAK.O 
K1LVNHOSFPNEENDVDKI 
RAB3A NP 002857 RAB3 1 K.LOIWDTAGOERY 1 K.lUIGNSSVOK.T 
RAB3B NP-002858 
RAB3C NP-612462 
RAB3B NP 002858 RAB3B 1 K.TYSWDNAOVILVGNK.C 1 K.TYSWONAOVILVONKC 
RAB3D NP_004274 RAB3D 1 R.DAAOONFOYMFK.L ROAAOONFDYMFK.L 1 R DAAOONFDYMFK.L 
R.LAOOLGFEFFEASAK.E RLADOLGFEFFEASAK.E 
RAB5C NP 958842 RAB5C 1 R.AVEFQEAQAYAOONSLLFMETSAK.T 1 RGVDlOENNPASR.S 1 R.GVDLQENNPASR.S 
NP-004574 R.OVDlOENNPASRS 
RAB? NP _004628 RAB7 1 RDPENFPFWLGNK.I 1 RDPENFPFWLONKI 
K.EAINVEOAFQTIAR.N 
K.OETEVELYNEFPEPIK.L 
RAP2A NP 066361 RAP2 K EIEVDSSPSVLEILDTAGTEOFASMR 1 K.VWLOSGOVGK S 
RAP2B NP-002877 
RAP2C NP-067006 
Structural Proteins and Adaptors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
ACTA1 NP 001091 Actin, alpha 1 R.OL TOYLMK.I 1 RAVFPSIVGRPRH 1 K.AOFAODOAPRA 
ACTA2 NP=001604 RHOOVMVGMOOKD RHOGVMVGMGOK 0 RAVFPSIVGRPR.H K.SYELPDGQVITIGNER.F K.IKIIAPPERK K.EITALAPSTMKI 
K.YP1EHOIITN'NDDMEK.1 K.IWHHTFYNELRV KYPIEHGIITMNDDMEK.I 
K.YPIEHGIITNWDDMEKI 
ACTB NP 001092 Actin, beta or gamma 1 K.OEYDESGPSIVHR.K 1 R.GYSFTTTAER.E 1 RGYSFTTTAERE 
ACTG1 NP=001605 R.TTONMDSGDGVTHTVPIYEGYALPH K.OEYDESGPSIVHRK RKOl YANTVLSGGTTMYPGIAOR.M ILRL K.OEYDESGPSIVHRK.C K.QEYDESGPSIVHR.K 
R.VAPEEHPVU TEAPLNPK.A RTTC3IVMOSGOC3VTHTVPIYEGYALPH R.VAPEEHPVLL TEAPLNPK.A 
ILRl 
R.VAPEEHPVLL TEAPLNPK A 
ACTNl NP_001093 IActlnln, alpha 1 1 R.DHSGnOPEEFK.A 1 KLVSIOAEEIVOQNVK.M 




AP2Al NP_055018 jAdaptln 1 K.LLC3FOSAlLONVOPNPENFVGAGIIQ f.< ~LLGFGSAUDNVDPNPENFVC3AOIIQ 
NP 570603 K.A 
ANXAl NP 000691 IAnnexln I, (l/Docortln II 1 K.GVOEATIiDILTK.R 1 K.GTDVNVFNTIL TTR.S 










NP _001447 Fllamln 1 
NP _o00168 "elsolin 
NP _937895 
NP _o78811 ~oronln 7 
NP _o02289 L-plaslin 
NP _o02464 Myosin, heavy chain 
NP _o05013 Profilin 1 




NP _006280 alin 1 
NP _o05991 !Tubulin alpha 1,2 
NP 005992 
NP-524575 
NP 006000 ubulln alpha 3 
ubulln beta 1 
































~ K.VTAQGPGLEPSGNIANK T 























I~ K HWPNEVVVORL 
























KLQVELDNVTGlLSQSOSKS RIAEFTINLTEEEEK 5 
R.LTEMETLQSQLMAEK.l RIAQLEEELEEEQGNTELINDR.L 
10 K.LTKOFSALESQLQOTQELLQEENRQ 10 K.lAQlEEQLONETK.E 
11 RNWOWWRL 11 RIMGIPEEEQMGLLRV 
12 RQAQQEROELAOEIANSSGKG 12 KKEEELOAALARV 
13 K TElEOTLOSTAAQOELR S 13 RKLEGOSTDLSOQIAELQAQIAELK.M 
14 R.TEMEOLMSSKOOVGK.S 14 K.LEGOSTDLSOOIAELQAQIAELK.M 
15 K.THEAQIQEMRQ 15 RLOOELDOLLVDLOHQR.Q 
16 KTLEEEAKTHEAQIQEMRO 6 R.LTEMffiQSOLMAEK.L 





























































TUBB2 NP_001060 ubulln beta 3 1 R.AILVDLEPGTMDSVRS 1 K.EVDEQMlNVQNK.N 1 R.FPQOlNADLR K K.EVOEQMLNVQNK.N RFPGOlNADLR.K 




URP2 NP 848537 UNC-112 related protein 2 1 K EKEPEEEL YDLSKV ~ RVFVGEEOPEAESVTLR.V 






VIM NP_003371 IVlmenlin 1 K.FADLSEAANRN 1 K.FAOLSEAANR.N K.ILLAELEOLKGQGK.S K.llLAELEQLKGQGKS 
RLlQDSVDFSLAOAINTEFKNTR.T R.LLQDSVOFSLADAINTEFKNTRT 
RP2 NP 008846 P<RP2 1 K.APDFlPLlNK.G 1 K.APDFlPLlNK.Q 
Kinases and Phosphatases 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
HCK NP 002101 Hck tyrosine kinase 1 RJPYPGMSNPEVIR.A 1 RIPYPGMSNPEVIR.A 
FGR NP _005239 Fgr tyrosine kinase 1 K.FHILNNTEGDVoJWEAR.S 1 RJPYPGMNKR 1 ROLLSPGNPQGAFlIRE 
ROLLSPGNPOGAFLlR.E 
RSYGAAOHYGPOPTK.A 
PTPNS1 NP_542970 Protein tyrosine phosphatase, non- 1 RVPPTLEVTQQPVR.A 1 RVPPTLEVTOOPVR.A 
eceptor-type substrate 1 
PTPN7 NP 002823 Protein tyrosine phosphatase, non- 1 RRGSNVALMLDVRSLGAVEPICSVNT 1 RRGSNVALMLDVRSLGAVEPICSVNT 
NP-542155 receptor type 7 PR.E PR.E 
PTPRJ NP _002834 Protein tyrosine phosphatase, receptor ~.AGSPTAPVHOESLVGPVDPSSG ~.AGSPTAPVHOESLVGPVDPSSG 1 K KOFIATQGPLPNTLK.D 
!tYpe J 




PTPRC NP 002829 Protein tyrosine phosphatase, receptor 1 K.DLQYSTDYTFK.A 1 K.DLOYSTDYTFK.A 
NP-563578 jtYpeC RDPPSEPSPLEAEFOR.L REVTHIQFTSWPDHGVPEDPHLLLK.L K.ELlSMIQWK.Q K.KRDPPSEPSPlEAEFORL 










Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
BPI NP _001716 BacterlcldaUpermeabillty-lncreaslng 1 K.FFGTFlPEVAK.K 1 K.GLDYASQQGTAALOK.E 1 K.FSISNANIK.I 
Iproteln precursor, BPI K.GLDYASQQGTAALOK E K.GLDYASQQGTAALQK.E 
CTSG NP _001902 ~athepsln G preproproteln 1 R.NVNPVALPRA 1 R.IFGSYDPRR Q 1 RIFGSYDPRR R.TlQNDIMLLOLSRR RNRNVNPVALPRA RNVNPVALPR A 
RVSSFLPWIR.T R.NVNPVALPR.A R.TIQNOIMLLQLSR R 
R.TlQNDIMllQlSRR R VSSFlPWIR.T 
R.VSSFlPWIRT 
C10orf42 NP_612366 ~hromosome 10 ORF 42 1 R.DLLSHENAATLNDVK.T 1 ROLLSHENAATLNDVK.T 
R.DPlOVHLPLR.Q RDPLQVHLPlR.Q 
RLEDLKEOLAPlEK.V R VAASTGIOlllLDDFK.L 
DCD NP _444513 Dermcldln precursor 1 R.SSLLEKGLDGAKK.A 1 K.DAVEDLESVGK.G 1 K DAVEDlESVGK.G 
K.LGKDAVEDlESVGK.G 
EPX NP_000493 Eosinophil peroxidase 1 R.IGLDLAALNMQRS 1 R.IGLDLAALNMQRS 1 R NGFlLPLVRA 
RIVYEGGIDPILR.G R.IVYEGGIOPILR.G R.NOINALTSFVDASMVYGSEVSLSLR.L 
RNGFlLPLVR.A RNGFLLPlVRA R.TNYLGLLAINQR.F 
R.RPLLGASNQALAR W R.TNYlGLLAINQRF 
R.TNYLGLLAINOR.F RVANVFTlAFR.F 
R.VANVFTLAFR.F 
MMP9 NP _004985 ~elatlnase 1 R.AFALWSAVTPlTFTR.V 1 R.FTEGPPlHK.O 1 R.FTEGPPlHK.O R FTEGPPLHK.D R.KLDSVFEEPLSK.K R KLDSVFEEPlSK.K 
R.FTEGPPLHKDOVNGIR.H K.LGLGADVAQVTGALRS K SLGPALLLLQK.O 
R.GSRPQGPFLIADK.W K.QLSLPETGElDSATLK.A 
RKlDSVFEEPLSK.K R.OSTLVlFPGDlRT 
K.OLSlPETGELOSA TLK.A K.SlGPAlLLLOK.O 
ROVWVYTGASVLGPR.R 
K.SL<3PALlLlOK.Q 
SPCS2 NP_055567 KlAA0102 gene product (signal 1 R.lHOSLAIER.K K.FFDHSGTlVMOAYEPEISR.l 
!Peptidase)" K.SIFLVAHR.K 
LTF NP _002334 Lactoferrln 1 K.GGSFOLNELQGLK.S 1 K.EDAIWNUR.Q 1 R.OGAGDVAFIRE 
R.THYVAVAWK.K K.FQLFGSPSGOK 0 K.EDAIWNLLRO 
K.GGSFOLNELOGlK 5 K.FOLFGSPSGQK.D 






LCN2 NP 005555 Lipocalln 2; NGAL 1 K.VPlQQNFOONQFQGK.W 1 K.VPLQQNFQDNOFQGKW 
MGAM NP _004659 Maltase-glucoamylase 1 R.DASLNHPPYMPHlESR.O 1 R DASlNHPPYMPHLESRD 1 K DPNNLAFNEIK.I 
R.EIEELYNNPQNPER.S RlPSTNVYGLGEHVHQQYR.H R.EIEEl YNNPQNPER.S 








MMP25 NP 071913 Matrix metalloprotelnase 25 (Ieukolysln) 1 R.DlSLWEGAPPSPOOVlVSNAGOTY 1 ROLSLWEGAPPSPDOVlVSNAGDTY 1 R.DGLQQl YGK A 
NP-073209 FFK.G FFK.G 
ANPEP NP _001141 Membrane alanine aminopeptidase 1 R.DHSAIPVINR.A 1 R DHSAIPVINR.A 1 ROHSAIPVINR.A 






MPO NP _000241 Myeloperoxldase 1 R.FPTDOLTPDOER.g 1 R.DHGLPGYNAWR R RDHGlPGYNAWR.R R.IANVFTNA.FR.Y R.FPTOOLTPDQERS R fPTOOl TPDOER.S 
R.NOINALTSFVDASMVYGSEEPLAR.N R.lGLOLPAlNMORS RIANVFTNAFRY 









PADI4 NP _036519 Peptldyl arginine delmlnase IV 1 R.ELGLAESDIIOIPOLFK.L 1 R.ElGLAESDIIDIPOLFK.L R.GPOTGGISGLDSfGNLEVSPPVT R.GPQTGGISGLDSFGNLEVSPPVT 
R.G R.G 
K.LFQeOONEGHGEAlLFEGIKK K.LFQEQQNEGHGEALLFEGIK.K 
PRTN3 NP _002768 Proteinase 3 1 R.TQEPTQQHFSVAOVfLNNYOAENK.L 1 R.LVNVVLGAHNVR.T R.TQEPTOOHFSVAQVFLNNYDAENK.L 
PRG2 NP 002719 Proteoglycan 2 1 R.GNlVSIHNFNINYR.I 1 R.GNLVSIHNFNINYR.I 1 RGNLVSIHNFNINYRI 
THBS1 NP_003237 hrombospondln 1 precursor 1 R.FTGSaPFGQGVEHATANK.Q 1 R.ODDYAGFVFGYOSSSRF 1 RFTGSOPFGOGVEHATANKO K.GPOPSSPAFR.I K,DHSGOVFSWSNGK.A RIEDANLIPPVPDDKFODLVDAVRA 







10 R KDHSGOVFSWSNGK.A 
11 KMENAELDVPtOSVFTRO 
12 R.NALWHTGNTPGOVRT 
13 KOHWSVEEALLATGQWK S 
14 RT1VTTLQDSIRK 
15 KVTEENKELANELR R 
Membrane Traffic and Fusion Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
DNAJC5 NP _079495 DnaJ (Hsp40) homolog, subfamily C, 1 K.APEGEETEFYVSPEDLEAQLQS 1 KYHPDKNPDNPEAAOKFK E 1 K.APEGEETEFYVSPEDLEAQLQS 
member 5 OERE DERE K.EINNAHAILTDATK,R 
DYSF NP_003485 Dysferlln 1 RAEDLPQMDDAVMDNVK.Q KEYSIEEIEAGRIPNPHLGPVEER.L 1 K.OSFSDPYAIVSFLHClSQK.T K,OSFSDPVAIVSFLHQSOK.T K.H'NVPAEK.M ROVILDDLSL TGEK.M 
REFTGFPDPYTELNTGKG K.lGETWDLENRL R.EFTGFPDPYTELNTGKG 
RIETONOllGtADRL R.IPNPHLGPVEER.L RGSQPSGELLASFELIQR.E 
R.IPNPHLGPVEER.L K.lYPlPEDPAIPMPPRQ RIETQNOLLGIAOR.L 
KJYPLPEOPAIPMPPR.O KLGHSELPAALEQAEOWLLR.L K.IGETWDLENRL 
R KDPSECKEOIESNLLRPTGVALRG KLVEHSEQKVEDLPADDILR.V K IYPLPEDPAIPMPPR.Q 
KLGHSElPAALEOAEOWLLR L R LEAGLEQVHLAlK.A 
KNLVDPFVEVSFAGK.M K.NLVDPFVEVSFAGKM 
10 RRPOTSFLWFTSPYK.T 10 RSLGGEGNFN'NRF 
11 K.TGPAAVFALEGAlGGVMOOKS 11 RTDAlLGEFR.M 
12 RTHHLSOITEAALAUU 12 K.TGPAAVFALEGALGGVMOOK.S 
3 KTQEETEOPSV1GEFK.G 13 K.TOEETEOPSVIGEFK.G 
14 R.VPAHOVLFSR.R 
TMED9 NP 059980 lao25L2 oroteln 1 RVHLOIQVGEHANOYAEIAAKD 1 R.VHlDlOVGEHANOYAEIAAK.D 
MBC2 NP _056107 KlAA0747 protein 1 RIHVLEAQDUAK.O 1 RKPHTESlELQVRG 
R LLVPlVPDLQOVAQlRS R.LLVPLVPOLOOVAQlR.S 
RL THVOSPLEAPAGPLGQVK.l 
K.VLQASVLOOlNFPLQGGQGQVHlRL 
SNAP23 NP 003816 ~NAP·23A 1 K.QPGPVTNGQLQQPTTGAASGGYIK.R 1 K.QPGPVTNGOLOOPTTGAASGGYlKR 
SACM1L NP 054735 Svnaotolanln 1 RGIOSEGHAANFVETEQIVHYNGSK.A RELSAQPEVHRF 
STX? NP_003560 ~yntaxln 7 1 RTLNOLGTPQOSPELRQ 1 RTlNOlGTPODSPELR.Q 1 RLVAEFTTSlTNFQK.v RTLNQlGTPQOSPElR.Q 
UNC13D XP _113950 Unc·13 homolog D 1 RlGHPEPNHVTEASELlR.Y 1 R.EVPGLSGSEEPGEVPOTRL 




YAMP2 1 RAOAlQAGASOFETSAAKl 1 RAOALQAGASOFETSAAKl 1 R AOALOAGASQFETSAAK.L 
VAMPB NP _003752 VAMP 8 1 R.NKTEDLEATSEHFKT ~ ~:~~g~::iSGEVHK~.T 
1 K.NIMTONVERJ 1 KNIMTQNVER.I ~ =:~~~~~SK~~FK.T 
K.TEDLEATSEHFK.T 
Redox Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
DIA1 NP 000389 jeytochrome b5 reductase 1 KDILLRPELEELRN 1 RAPEAWOYGQGFVNEEMIR.O 1 R.GPSGLLVYQGK.G 




NQ03A2 NP _057327 ytochrome b5 reductase 1 (B5R.1) 1 RGPSGLLTYTGKG 1 RGPSGLL TYTGKG R RPOVTlLOPNEKY 
DHRSB NP _057329 Dehydrogenase/reductase member 8 1 K.NPSTSLGPTlEPEEVVNRL 1 KNPSTSLGPTLEPEEWNRL 1 K.NPSTSLGPTlEPEEWNR.L K.SVTGEIVLlTGAGHGIGR.L K.SVTGE1VLITGAGHGIGR.L 
PDIA3 NP_005304 prp58 1 RTAOGIVSHLKK 1 RTAOGIVSHLK.K K TFSHELSDFGLESTAGEIPVVA1R.T 
GSTK1 NP 057001 Glutathione transferase kaooa 1 1 R.NEDITEPOSILAAAEK.A 1 K.OSGNKPPGLLPR K 
CYBB NP _000388 ~p91.phox 1 K.DVITGLK.O 1 RGVHFIFNKE 1 K LLGSALALAR A ~ =.~~L~~~~~RA R GVHFIFNKENF- K.MEVGQYIFVK.C KLLGSALALARA 
~ KLLGSALALAR A KTlYGRPtN-JONEFK.T 
KTIELQMK.K 
NDUFBB NP 004995 NADH dehydrogenase 1 Bsubcomolex 8 1 R.DPNYSWOQPGLR.L ROPWYSNOOPGLR.L 
NDS NP 536853 NADH dehydrogenase subunit 5 1 RFPTlTNINENNPTlLNPIK.R ~ RFPTLTNINENNPTLLNPIK.R 1 RFPTLTNtNENNPTLLNPIKR 
NP-776061 K.TISQHQ1STSIITSTOK.G K TISQHQISTSIITSTQK.G 
NDUFB11 NP 061929 Neuronal protein 17.3 1 K.RPPEPTTPWQEDPEPEDENL YEK.N 1 K.RPPEPTTPWOEOPEPEDENL YEK.N 
CYBA NP _o00092 p22-phox 1 RERPQIGGT1K.Q ~.::~~~~~~~GGPPGGPQVN ~.RKKPSEEEAAAAAGGPPGGPQVN 
PIPVTOEW- IPVTOEW.-
HSD1?B12 NP_057226 I>terold dehydrogenase homolog 1 K.GVFVOSVLPYFVATK.L ~ =:~:VL::SS:~~~,S 
1 R.SKOKLOCIVSSEIK.E 
167 
SQRDL NP _067022 !Sulfide dehydrogenase 1 K.YADALQEIIQER.N t R.HFYQPIWTLVGAGAK-Q 1 K.EGNAIFTFPNTPVK.C K.VGAENVAIVEPSER.H 
TXNDC NP _110382 t,hlOredOXln-related transmembrane 1 R.RPOPYPYPSK.K RRPQPYPYPSK.K 1 K.OFINFISDK.E 
roteln 
Other Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
C20orf3 NP _065392 jc20 ORF 3; adlpocyte plasma R.DYLUVMEGTDDGR.L RLFENOlVGPESIAHIGDVMFTGTAD 1 RDYLLLVMEGTDOGR.L K.EPPLlLGVLHPNTK.L RV K.EPPLLlGVLHPNTK.l 




CGI-51 NP 056195 GI-51 protein 1 K.OWVQHVHFOGLGRT KDVWQHVHFDGLGR T 
DSP NP_004406 iDesmoplakln ~ RLLEAQIATGGIIDPK,E ~ R.AVTGYNOPETGNIISLFQAMNK.E R.QLQNIIQATSR.E R.LKNTLTQTIENLR.R 
R.LlEAQIATGGtlDPK.E 
FGB NP _o05132 Fibrinogen ~ chain preproproteln ~ ~:~~~~~:;:~~~~YR.A 
K.QGFGNVATNTOGK N 
1 K.DNENWNEYSSELEK.H 
FGG NP _000500N Fibrinogen y chain precursor 1 RL TIGEOQQHHLGGAK.Q 1 K.EGFGHLSPTGTIEflNlGNEK.I 
P 068656 Iz K.YEASll THDSSIRY 
GPI NP_000166 iGlucose phosphate Isomerase 1 KTlAOlNPESSlFIIASK.T 1 K.HFVAlSTNTTKV 
Rw.tYVSNIDGTHIAK.T 
GSTK1 NP 057001 IGlutathlone transferase kappa 1 K.DSGNKPPGllPRK RNEOITEPOSllAAAEK.A 
GCA NP _036330 iGrancalcln ~ ROHlOOGSANFIYOOFlOGTMAI.· ~ K.ENFMTVOODGSGTVEHHElRO 1 RLSPOTl TTIVK.R 
K ElWAAlNAWK.E R.lSPOTl TTIVK.R 
K.ENFMTVOOOOSGTVEHHElR.O 
E21G5 NP _o55182 iGrowth and transformation-dependent 1 K.EOEIPETVSlEMlDAAK.N 1 K.EDEIPETVSlEMlOAAK.N 
Iproteln 
HIST1H1C NP _o05310 Histone H1 family 1 KAlAAAGYDVEK.N 1 K.KALAAAGYDVEK.N 
K.AlAAAGYDVEKNNSR I RKASGPPVSElITK.A 
KGTGASGSFKlNK.K 
HIST1H2BG NP_003509 Histone H2B 1 K.AMGIMNSFVNDIFERI ~ RKESYSVYVYK.V 
K HAVSEGTKAVTKYTSSK.· RllLPGELAK H 
K.QVHPOTGISSK.A 
K.VLKOVHPDTGISSK.A 
HIST1H41 NP _o03486 Histone H4 1 R.DNIQGITKPAIR.R 1 RDNIOGITKPAIRR 1 R.ONIQGITKPAIRR 
RTlYGFGG.· RISGLiYEETR.G R ISGLIYEETR.G 
K.TVTAMDWYALK.R K.RISGLlYEETRG RTLYGFGG.· 
K.YFLENVIR.O K.TVTAMOWYALK.R 
K.YFLENVIRO 
HNRPU NP 004492 hnRNP U protein 1 K.EKPYFPIPEEYTFIQNVPLEDR.Y 1 K.EKPYFPIPEEYTFIQNVPlEOR.V 
NP-114032 
ATAD3A NP _o60658 Hypothetical protein FlJ10709 1 KGEGAGPPPPLPPAOPGAEGGGDRG 1 RNILMYGPPGTGK.T 
R.INEMVHFDLPGQEERE 
TNFAIP9 NP 078912 Hypothetical protein FlJ23153 1 RNLGLTPMOQGSLMAAK.E 1 K.TTlLPSGAEVLSYSEAAK.K 




EFHA1 NP 689939 HYDothetlcal Droteln FlJ34588 1 K.YATGQELSNNllDTVFK.I 1 K.TNETGYQEAIVKEPEINTTLQMR.F 
LOC199675 NP _777578 Hypothetical protein lOC199675 1 R LETTLAGIK.N 1 RGWDSVQQSITMVR.S 
K.NQGAHOPDYENITLAFK.N RLETTlAGIK.N 
K.NOGAHDPDYENITLAFK.N 
LQC255809 XP 172995 Hypothetical protein XP _172995 1 R.GGQVVQLLQAPTOORG 1 RGGQVVQLLOAPTOQR.G 
K.RPTSTSSSPETPEFSTFR.A 
KlAA0792 XP 375848 KlAA0792 Ilene Droduct 1 R.TLFITGLPR.O 1 RTlFITGLPR 0 
LAP1B NP _o56417 lamina-associated polypeptide 1 B 1 RISHLVLPVOPENAlKR 1 RFESFPAGSTlIFYK Y 1 R.ISHLVLPVQPENALK.R 
R.lSHLVLPVQPENALK R 
RQVTGOPONASFVK R 




S100A9 NP _002956 MRP-14 1 K.DLQNFLK.K 1 KlGHPOTLNOGEFK.E 1 R NIETIINTFHQYSVK L 









P4HB NP_000909 POI 1 RTGPAATILPOOAAAESlVESSEVA 1 KVOATEESDLAQQYGVR.G 
IGFFK.D 
PHB NP_002625 Prohlbltln 1 RIFTSIGEDYDERV 1 RFDAGELITORE 1 RNITYLPAGOSVLLOlPQ.· 
R.NITYLPAGQSVLlQLPO.· 
PHB2 NP _o09204 Prohlbltin-like 1 R.IGGVaaOTILAEGLHFRI 1 RIGGVQODTILAEGLHFRI 1 KFNASQlITQR.A 
RIPWFQYPIIYDIRA RIPWFQYPlIYDIR A RIGGVaaOTILAEGLHFRI 
RIPNFQYPllYDIRA 
PKM2 NP 002645 Pyruvate kinase 3 Isoform 1 K.GAOFLVTEVENGGSLGSKK 1 K.GVNlPGAAVOLPAVSEK.O 1 RLAPITSOPTEATAVGAVEASFK.C 
NP-872270 R TATESFASOPILYRPVAVALOTKG K.KGVNLPGAAVDlPAVSEK.O R TATESFASOPILYRPVAVALOTK.G 
NP-872271 




NP - 997404 














HRNR XP _373868 ISlmllar to hornerln 1 RGPYESGSGHSSGLGHRE 1 RGPYESGSGHSSGLGHR.E RHGSGSGQSSSYSPYGSGSGWSSSR 
196527 XP_113743 Islmllar to RIKEN cDNA F730003B03 1 K.LPLKPNOLK.N 1 K.VlSVDESIIKPEaEFFTAPFEK.N K.VlSVCESIIKPEQEFFTAPFEK.N 
LOC388015 XP 370776 islmllar to RTll 1 R.NFIEfVFPYRH 1 RNFIEFVFPYR.H 
RPS27A NP 002945 Ublqultln precursor 1 K.ESTLHLVLR.L 1 K.eSTLHLVLR.L ~ ~:~~~i~~~~IENVK.A ~ NP-061828 K.lQDKEGIPPOQQR.L K.TITLEVEPSDTIENVK.A K.TITLEVEPSDTIENVK.A 
UBA52 NP-003324 RTLSOYNIQK.e 
UBC NP-066289 
SPECIFIC GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
ADAMS NP _001100 ~DAM-8 (CD156) 1 R.GPOElVPTTHPGQPAR.H 1 RGPOELVPTTHPGQPARH RHlHDNVQLITGVDFTGTTVGFARV 
R,VLEWNHVOKL 
CANX NP _001737 ~alnexln K APVPTGEVYFADSFDR.G 1 R.IVDDWANOOWGLK K 1 KJPOPEAVKPDOoNOEDAPAK.1 K.IPDPEAVKPDONDEOAPAK.I R.KIPNPDFFEDLEPFR M 
K.IPNPDFFEDLEPFR.M 
K.TPELNLOOFHDK.T 
CEACAM1 NP _001703 (;AECAM-l R.TL TLLSVTR.N ROL TEHKPSVSNHTQDHSNDPPNK M 1 RDLTEHKPSVSNHTQDHSNDPPNK.M 
RTL TLLSVTRN R.Tl TlLSVTR N 
ITGAM NP_000623 (;Dllb 1 R.DHVFQVNNFEAlK.T 1 RDHVFQVNNFEAlK.T 1 K.AIMEFNPR.E 
K.ERlPSHSDFlAElRK K.FGDPlGYEDVIPEADR.E RDHVFQVNNFEALK.T 
K.FGDPLGYEDVIPEADRE RGAVYLFHGTSGSGISPSHSQRI K.EFVSTVMEQlK.K 
K.FGDPlGYEDVIPEADREGVIR.Y RGFGQSWQlQGSR.V K.FGDPlGYEDVIPEADR.E 
RGAVYlFHGTSGSGISPSHSQRI R lFTAlFPFEK.N RGAVYlFHGTSGSGISPSHSQRI 
R.GFGQSWOlQGSR.v RlPSHSDFLAElRK RGFGQSWQlQGSRV 
RlPSHSDFLAElRK R.QELNTIASKPPRD K.ll WITDGEK F 
R.QElNTIASKPPR.D KTEFQlElPVK.Y RlFTALFPFEK.N 
R.QNTGMoNESNANVKG RVQSLVlGAPRY K.lTDVAIGAPGEEONRG 
10 RVMQHQYQVSNU3QRS 10 RWVGAPOEIVAANOR.G 10 RQNTGMoNESNANVK.G 
11 RVQSlVlGAPR.Y 1 RYVIGVGOAFR.S 11 RSlVKPITQllGRT 




115 R YVIGVGOAFR.S 
ITGB2 NP _000202 IeD18 1 RIGFGSFVDK T 1 RALNEITESGR.I 1 RIGFGSFVOK.T K.LAENNIQPIFAVTSRM RIGFGSFVOK.T K.LAENNIQPIFAVTSRM 
K.lGAll TPNDGR.C RllVFATDDGFHFAGDGK l K.lGAll TPNDGRC 
RLlVFATDOOFHFAGDGK.l K.lTEIIPK.S K.lGGOLlR.A 
K.SAVGElSEDSSNVVHUK.N K RSNEFDYPSVGQLAHK.L RlLVFATODGFHFAGDGK.l 
R.SNEFDYPSVGQLAHK.L K.SAVGELSEOSSNVVHLIK.N K.lTEIIPK.S 
K.SQWNNONPLFK.S RSNEFDYPSVGQLAHKl K.SAVGELSEDSSNVVHUK.N 
R.vFlOHNALPDTLK v K.SQWNNDNPLFK.S R.SNEFOYPSVGQLAHK.l 
K.TVlPFVNTHPOK.L K.SQWNNDNPlFK.S 
10 RVFLDHNALPDTLK.v 10 RVFlOHNAlPDTLK.v 
C5R1 NP 001727 D88 C5aRl 1 RNVL TEESWRE 1 RNVlTEESWRE 1 R.NVlTEESWRE 






ITGB3 NP _000203 ~D61 1 K.GSGOSSQVTQVSPORJ 1 K.GSGOSSQVTQVSPOR.I K.HVLTLTOOVTR F 
RNOASHLLVFTTOAK.T 
K.SFTIKPVGFK..O 
FCER1G NP 004097 FCERl G gene product 1 K.SDGVYTGLSTRN 1 K.SOGVYTGLSTRN 1 K.SOGVYTGLSTR.N 
FPR1 NP 002020 Formvl peptide receptor 1 R.UHAlPASLERA 1 RUHAlPASLERA 
GP1BB NP 000398 KOlycoproteln Ib beta precursor 1 R.TAHLGANP'NR.C 1 RTAHlGANP'NR.C 
LlLRB2 NP 005865 Leukocyte Ig-like receptor 2 1 R.KADFQHPAGAVGPEPTDRG 1 K.NGQFHIPSITWEHTGRY 
CLEC12A NP 612210 Myeloid Inhibitory C-type lectin-like 1 R.SYDYWlGLSPEEOSTR.G 1 R.SYDYWLGLSPEEOSTR.G 
NP-963917 eceptor Isoform 
SIGLEC5 NP _003821 Islallc acid binding Ig-like lectin 5 1 RKKP'NPOSPGOOASPPGOAPPlEE ~IR.KKP'NPOSPGOOASPPGDAPPlEE K.E KE 
R.MEOTGSYFFRV 
STOM NP_004090 !Stomatln 1 K.EASMVITESPAAlQlRY 1 K.EASMVITESPAALQlRY 1 K.EASMvrTESPAALQLRY R.llAQTTLR.N RllAQnlR.N t =:~~~~~~TlODATDAWGIK.V 
K.LPVQLQR.A RLPDSFKOSPSK.G 
K.NlSQILSDRE KVIAAEGEMNASR.A 15 K.lPVQLQRA 
RTISFOIPPOEll TK.D R.VQNATtAVANITNAOSATR.l K.NlSOllSDRE 





Channels and Transporters 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
SLC25A4 NP _001142 "'denlne nucleotide trans locator 1 1 RlWGTQOVSOOIOEMK.D 1 RLWGTQDVSQOIQEMK.D 1 RLWGTOOVSQOIQEMK.O 
K.QVTVLELFR.V K.QVJVLElFR v K.OVTVLELFR.Y 
RTFEOITRA 






MVP NP _059447 Major vault protein 1 R.LAQOPFPL YPGEVLEK.D 1 K.AQQLAEVEVK.K RLAOOPFPl YPGEVLEK.O NP 005106 K.LKAQAlAIETEAElQR v 
169 
GTP-ases 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
RAB3A NP 002857 RAB3 1 R.YADDSFTPAFVSTVGIDfK.Y 1 K.L.QIWOTAOQER.Y 
RAB3B NP-002858 
RAB3C NP-612462 
RAB3D NP_004274 RAB3D 1 R.LADDLOFEFFEASAK.E 1 R.LADDLGFEFFEASAK.E 1 RDAADQNFOYMFK.L RLADOLGFEFFEASAK.E 
K.LLLIGNSSVGK.T 
K.MNESLEPSSSSGSNGK.G 
RAB5C NP 958842 RAB5C 1 RGVDLQENNPASRS 1 RGVDlQENNPASR.S 
NP-004574 




GNAI2 NP_002061 1<>1 .. 2 1 K.AMGNLQIDfADPSRA 1 K.AMGNLOIDFADPSR.A 1 K.AMoNlQIDFADPSR.A RIAOSOYIPTQQOVLR.T R.IAQSDYIPTQQDVLR.T R.IAQSDYIPTQQDVlR.T 
K.YDEAASYIQSK.F 
RAP1A NP 002875 RAP1 1 K.LWLGSGGVGK.S 1 K.LWlGSGGVGK.S 1 K.SAL rvQFVQGIFVEK.Y 
RAP1B NP-056461 
RAB31 NP 006859 RAB31 1 K.NAINIEElFOGISR.Q 1 K.NAINIEELFQGISR.Q 
Structural Proteins and Adaptors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
ACTN1 NP _001093 IActlnln, alpha 1 1 R.FAIQOISVEETSAK.E 1 R.FAIQDISVEETSAK E 1 R.TlNEVENQll TR.O R.LAllGIHNEVSK.t 
R.VGWEOLL TTIAR.T 
ACTA1 NP 001091 IActln, alpha 1 K.EITALAPSTMK.I 1 K SYElPDGQVITIGNERF 1 K.AGFAGDDAPRA 
ACTA2 NP-001604 K.YPIEHGIITtNoJDDMEK.1 RVAPEEHPTlL TEAPlNPK.A K SYElPDGOVITIGNER.F K YPIEHGIITtNoJDDMEK.I 
ACTB NP 001092 IActln, beta or gamma 1 R.GYSFTTTAER.E 1 RGYSFTTTAERE 1 R GYSFTTTAERE 
ACTG1 NP=001605 K.OEYDESGPSIVHR K K.OEYOESGPSIVHRK f.tA7·nGIVMDSGDGVTHTVPIYEGYAlP R VAPEEHPVllTEAPlNPK.A 
IlR.l 
RVAPEEHPVlL TEAPLNPK.A 





CYLC2 NP 001331 yllcln2 1 K.AOEKKOEOOKKDANK.G 1 K.AOEKKDEDGKKOANK.G 
COR01A NP _009005 poronln 1A 1 R AAPEASGTPSSOAVSR.l 1 R.AAPEASGTPSSDAVSRl 
R HVFGOPAKA ROAGPLlISLK.O 


















GSN NP 000168 Gelsolln 1 K.HWPNEVWOR.L 1 KTGAOElLR.V 1 KAGALNSNOAFVlK.T 
NP-937895 KTPSAAYLWVGTGASEAEK.T REVQGFESATFLGYFK.S 




MSN NP _002435 Moesln 1 K.APDFVFYAPRL 1 K.ESEAvewQQK.A 1 K.FYPEOVSEELIOOITOR.L K.KAPOFVFYAPRL 
MYH9 NP _002464 Myosin heavy chain 1 RAGVLAHLEEERO 1 KDFSALESQLOOTOELLQEENROK.L K.ANLOIOOINTDLNLERS K.ANlOIDQINTDLNLER.S KFOOLLAEEK T KDFSALESOlODTQELLOEENR 0 
K.DFSALESOLOOTQELLQEENR 0 R.IAEFTTNLTEEEEKS KEOADFAIEALAK.A 
RFLSNGHVTIPGQQ[)K.O R.KKVEAQLOELOVKF K.IAOLEEOLDNETK.E 








13 K.TElEDTLDSTAAQQELR S 
14 K.TOLEELEDELQATEOAK.L 
5 K.VSHLLGINVTDFTRG 
TLN1 NP_006280 alln 1 R.IGITNHOEYSLVR.E 1 RIGITNHOEYSLVR.E KNlGTALAELR.T KNLGTALAELR.T 






TUBA4 NP 079295 ubulln alpha 4 1 R.OIFHPEOLITGKE 1 R.QIFHPEQlITGK E 
TUBB2 NP_001060 ubulln, beta 3 1 R.FPGQLNADLR.K 1 R.FPGQLNADLR.K 1 R.SIJPfIJQlfRPDNfVfGQSGAGNN K.NSSYFVEWIPNNVK.T AKG 
170 
Kinases and Phosphatases 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
FGR NP 005239 Far tvroslne kinase 1 RQUSPGNPOGAFLlR.E R.QUSPGNPOGAFLIR.E 1 K.FHILNNTEGt:rNWEAR.S 
PTPNS1 NP_542970 Protein tyrosine phosphatase, non- 1 R VPPTLEVlQOPVR.A 1 RAKPSAPWSGPAAR.A 
eceptor-type substrate 1 
PTPRC NP 002829 Protein tyrosine phosphatase, receptor 1 K.KRDPPSEPSPlEAEFQR.L 1 R.DPPSEPSPLEAEFQR.L 1 K.ATVIVMVTR.C 











TTBK2 NP 775771 lTau tubulln kinase 1 K.LALOIKIATYR.K 1 K.LALDIKIATYR.K 
Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
AZUl NP 001691 lAzurocldln 1 preproproteln 1 RQFPFLASIQNQOR H 1 R.OFPFLASIONQGR.H 1 R.OFPFLASIONOGR.H 
BPI NP _001716 Bactericidal/permeability-Increasing 1 K.FFGTFlPEVAK.K 1 K.OLOYASQQGTAAlOK.E 1 K FFOTFlPEVAK.K 
protein K.GLOYASOOOTAALOK.E K.IOSVAGINYOLVAPPATTAETLOV MK.O 
R.IKIPOYSDSFK.I 
CAT NP 001743 icatalase 1, K.LNVITVGPRO 1 RFNTANOONVTOVRA 
CAMP NP 004336 hCAP-18 1 RFALLGOFFRK 1 RFALLGOFFRK 1 RFALLGOFFRK 
CTSG NP _o01902 Fathepsln G preproproteln RIFOSYDPR R 1 RIFGSYOPRR RNVNPVALPRA R.NVNPVALPR.A 
R.TIONDIMLLOLSRR R TIONOIMUOLSRR 
R.VSSFLP'NIRT RVSSFLP'NIR.T 
CHGA NP 001266 lehromoaranln A 1 RRPEOOELESLSAIEAELEK.V 1 R.RPEOOELESLSAIEAELEK.V 
llid2 NP _444513 Dermcldln precursor 1 K.LOKDAVEDLESVOK.G 1 K.DAVEDLESVOK.O K.DAVEDLESVOK.O RSSLLEKOLOOAKKA 
EPX NP_000493 Eosinophil peroxidase 1 RIGLDLAALNMORS RDfLPLVLGK.A 1 RIVYEOOIDPtLR.G 
RtlCDNTGITTVSRD RIOLDLAALNMORS R.RPLLOASNOALAR.w 
RIVYEGGIDPILRO R.IVYEGOIOPILR.G R.TNYLOLLAINQRF 
R.NOFLLPLVRA K.LNRQDAMLVDELR 0 
R.RPLLGASNQALARW RNOFLLPLVR.A 
RTNYLGLLAINQRF RRPLLOASNQALAR.w 
R.YANVFTLAFRF R TNYLGLLAINQR.F 
FCNl NP_001994 Flcolln 1 precursor 1 RVOLVOFEGNHOFAK.Y 1 K.LVLOAFVOOSAGNSLTOHNNNFFS KO 
MMP9 NP_004985 ~elatlnase RAVIDDAFAR.A 1 R FTEGPPLHKD 1 R KLDSVFEEPLSK.K 
R.FOTFEODLK.w R.KLOSVFEEPLSK.K K.LGLOADVAOVTGALR.S 
RFTEGPPLHK.D K.LOLOADVAOVTOALR.S K.OLSLPETOELDSAnK A 
R FTEOPPLHKDDVNOIRH K.OLSLPETGELDSATLK.A 
RGSRPOOPFLIADK.W ROSTLVLFPGDLR T 




OLFM4 NP _006409 ~Wl12 1 K.LDIVMHK.M 1 K.L YVYNDOYLLNYDLSVLOKPO.-R LEFTAHVlSOK.F 
K.L YVYNOOYUNYDLSVLQKPQ-
R TEEI FYYYDTNTGK.E 
K.VQSINYNPFOOK.L 
LTF NP_002334 Lactoferrin 1 ROOAODVAF1RE 1 ROOAGOVAFIRE 1 RDOAODVAFIR.E 
KDSAIOFSR.V K.DSAIGFSR.V K.OSAIOFSRV 
K.EDAIWNLlR.Q R.ESTVFEDlSDEAERD RESTVFEOlSDEAER 0 
K GGSFQLNElQGlK.S K.FQLFOSPSOOK.D K.FQlFOSPSOOK.D 
R.IOSOl YLGSGYFTAIQNlR.K K.KGOSFQLNElOGlK S KOGSFOlNELOGLK.S 
K.KOOSFOlNElOOLK.S KlRPVAAEVYGTER.O R.lOSGlYlOSOYFTAIQNLR.K 
K.LRPVAAEVYGTER.Q RTHVYAVAWK.K KYLGPQYVAGITNlK.K 
RRSDTSL TWNSVK 0 
R SVNGKEDAIWNLLR.O 
10 RTHVYAVAWK.K 
LCN2 NP 005555 Llpocalln 2; NGAL 1 K.YPlOONFOONOFOGK.W 1 K.VPLOQNFQDNQFOGK.w 1 K VPlQQNFOONQFQOK.w 
LYZ NP _000230 Lysozyme precursor 1 K.RLOMOGYR.O 1 R.STDYGIFOINSRY 1 RSTOYGIFOINSR.Y 
RSTOYOIFQINSR.Y 
MGAM NP _004659 Maltase-glucoamylase 1 R EIEELYNNPONPERS 1 R.DASLNHPPYMPHlESR.O 
K.FAGFPALlNRM K.DPNNLAFNEIK.I 
R.EIEELYNNPONPER.S 
~r K.NLPSSPVFOSNVONVlL TAEYQTS 
R.F 
K.YEMELPGOKJ 
MPO NP_000241 Myeloperoxldase 1 RFPTOOLTPDQER.S 1 ROHGLPGYNAWRR 1 R.DHOLPOYNAWR.R 
R QNQIAVOEIR.E R.FPTOOL TPOOERS RFPTOOL TPOQER.S 
RIANVFTNAFR.Y R.IANVFTNAFRY 
R.OALAOISLPRI ROALAQISLPR.I 
MMP8 NP _002415 Neutrophil collagenase 1 K.DISNYGFPSSVOAIDAAVFYRS 1 RNYTPOLSEAEVERA 
K.FYOLPSN:!YOSTR.K 
RNYTPOLSEAEVERA 
PTX3 NP _002843 Pentraxln-3 1 R.ADLHAVQGWAARS R.ADLHAVOOWAARS 
R.LTSALOElLOATRD 
PRTN3 NP_002768 Proteinase 3 1 R.TOEPTOOHFSVAQVFLNNYOAENK.l RLVNVVLGAHNVR.T 
PRG2 NP _002719 Proteog Iyca n 2 1 R.FOWVOOSRW 1 RRFQWVDGSRW 1 RFQWVOGSR.w 
R GNlVSIHNFNINYR.1 RGNlVSIHNFNINYR.1 
RRFOWVOGSR.W 
SIGLEC5 NP_003821 [sIalic acid binding Ig-like lec1ln ~t R.KKP'NPDSPGOOASPPGOAPPlEE ~tRKKP'NPOSPGDQASPPGDAPPLEE 
K." K.E 
R.MEDTOSYFFRV 
Membrane Traffic and Fusion Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
CLTC NP _004850 lathrln heavy chain 1 1 R.NNLAGAEELFAR.K t ~:~~~~:C~~C~;:E~YQALR.T 1 K.lLYNNVSNFGRL 
171 
DYSF NP _003485 Dysferlln 1 R EFTGFPOPYTELNTGK.G 1 REFTGFPDPYTELNTGK.G 1 ROVILDDLSL TGEK,M K.HWVPAEKM K.lGETVVDLENR.L R.GSQPSGEu.ASFEUORE 
K.LGHSELPAALEQAEDWLLR.L RTOALLGEFR.M R.lETQNOLlGIADR L 





VAMP8 NP _003752 IVAMP8 1 K.NIMTQNVER I ~ KNIMTQNVER.I RNKTEDLEATSEHFK.T RNKTEOLEATSEHFK.T 
P ~.~~:~i:E~F~.T 
Redox Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
DHRSB NP_057329 Dehydrogenase/reductase member 8 1 K.NPSTSLGPTLEPEEWNRl 1 KNPSTSLGPTLEPEEWNR.l 
CYBB NP _000388 ~p91-phox 1 RGVHFIFNKE 1 RGVHFIFNK.E 1 KDVITGLK.Q K.LLGSALALAR.A R.GVHFIFNKENF.- RGVHFIFNKE 
K.MEVOQVIFVK C Kn YGRPI'Nv'ONEFK.T R.VNNSDPYSVALSElGDR.a 
R.VNNSOPYSVALSELGDRQ 
GAPD NP_002037 Glyceraldehyde-3-phosphate 1 K.LlSWYONEFGYSNRV 1 R.GALQNIIPASTGAAKA R.GALONIIPASTGAAK.A 
dehvdrollenase K LVINGNPITIFOER.O K.LVINGNPITIFOERD K VGVNGFGRI 
CYBA NP_000092 p2211hox 1 R.ERP01GGTlK.O 1 RERPOIGGTlK.O RKKPSEEEAAMAGGPPGGPOVN R.KKPSEEEAAAAAGGPPGGPOVN IPVTDEW.-
PIPVTDEW· 
PRDX5 NP_036226 Peroxlredoxln 5 precursor 1 KVGDAIPAVEVFEGEPGNKVNLAEL 1 K.THLPGFVEOAEALK.A FK.O 
Other Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
B3GTL NP _919299 P 311lycosyltransferase-like 1 R IOIPKLLETlR.R 1 R1OIPt<LLETLR.R 
C9orf19 NP _071738 [C90rf19, glioma pathogenesis-related 1 KASASDGSSFWARY 1 K.ASASDGSSFWAR Y 
Iproteln R.EAOQYSEALASTRI 
C20orf3 NP _065392 F20 ORF 3; adlpocyte plasma 1 K.GLFEVNPNKR 1 RRPLRPOWTDDOOQAPEAK.O 
membrane-associated K.LLLSSETPIEGK.N 
EP300 NP 001420 E1A binding protein p300 1 RLOEWYKK.M 1 R.LOEWYKK.M 
GALIG NP 919308 Galectln-3 Internal Dene 1 K.LEPCFSSSRFGKKARO 1 KLEPCFSSSRFGKKARO 
GCA NP 036330 Grancalcln 1 K.ENFMTVOOOOSGTVEHHELRO KENFMTVOOOOSGTVEHHELRO 
HIST1H41 NP _003486 Histone H4 1 R.ONIOGITKPAIR.R 1 RISGLlYEETRG 1 K.VFLENVIR 0 R.ISGLlYEETR.G K.vFLENVIR.D 
K.RISGLlYEETRG 
K.vFLENVIRD 
HSPA5 NP 005338 Hsp705A 1 K.ELEEIVOPIISK L 1 K.ELEEIVOPIISK.L 1 RIiNEPTAAAIAYGLDK.R 
TMEM30A NP _060717 Hypothetical protein FLJ10856, 1 K.FRNPPGGONLEER.F 1 RKSDLHPTLPAGRY 
ransmembrane protein 30A 
LQC199675 NPJ77578 Hypothetical protein LOC199675 1 R GWOSVQQSITMVRS 1 RGWDSVOQSITMVRS 1 RGWDSVOOSITMVR S K.NOGAHOPDYENITLAFK.N R.LETTLAGIKN 
PHB NP 002625 Prohlbltln 1 R.FDAGELlTQR.E 1 RFDAGEL1TORE 
PKM2 NP 002845 Pyruvate kinase 3 Isoform 1 K.GAOFLVTEVENGGSLGSKK 1 K.GVNLPGAAVOLPAVSEK.D 
NP-872270 
NP-872271 
S100AB NP_002955 MRP-8 1 K.ALNSIIOVYHKY 1 K.ALNSIIDVYHK.Y 1 K.ALNSIIOVYHK.Y K.GAOV'NFK.E 
K.GNFHAVYRD 
S100A9 NP_002956 MRP-14 1 K.LGHPDTLNQGEFK.E 1 K.LGHPOTLNOGEFK.E 1 K.VIEHIMEOI..DTNADK.O RNIETIINTFHOYSVK.L R.NIETIiNTFHOYSVK.L 
K.vIEHIMEDLOTNAOK.O 
LOC388015 XP 370776 Similar to RTI1 1 R.NFIEFVFPVRH 1 R.NFIEFVFPYR.H 
RPS27A NP 002945 Ublqultln precursor 1 KTITLEVEPSDTIENVKA 1 KESTLHLVLR.L ~ K.TITLEVEPSDTIENVK.A 
UBB NP=061828 R.TLSDYNIQK.E K.TITLEVEPSDTIENVK.A R.TLSOYNIQK.E R TLSOYNIOK.E 
UBA52 NP 003324 
UBC NP-066289 
AZUROPHIL GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
CD63 NP 001771 063, LAMP-3 K.VMSEFNNNFRO 1 K.VMSEFNNNFR.O 
ITGB5 NP 002204 ntegrln a 5 RLGFGSFVDK.D 1 RLGFGSFVDK.O 
TM7SF3 NP 057635 Seven transmembrane receDtor 1 RVTNILOPSYHIPPLRE 1 R.VTNILDPSYHIPPLRE 
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STOM NP_004090 ~tomatln 1 RAKVIAAEGEMNASRA 1 R.AKVIAAEGEMNASR.A 1 R.AKVIAAEGEMNASR.A R.DSEAQRLPDSFKOSPSK.G R.ALKEASMVITESPAALQLRY R.AlKEASMVITESPAALOLRY 
K.EAS~ITESPAALQlR.Y K.EASMVITESPAAlOLRY K.EASMVITESPAALQLR.Y 
R.LLAQTTLR N K.VIAAEGEMNASR.A R.LPDSFKOSPSK.G 
K.VlAAEGEMNASR.A K.NLSQILSDR.E 







11 R.YLon TTIAAEK.N 
STOML3 NP 660329 iStomatln-like 1 R.lPVQLQR.S 1 R.IPVQLQR.S 
Channels and Transporters 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
ATP6VOD1 NP _004682 ~TPase, H+ transporting, lysosomal, VO 1 K.LLFEGAGSNPGDK.T 1 KlLFEOAGSNPGDK.T 
"ubunlt D, Isoform 1 
TCIRG1 NP_006010 ~TPase, H+ transporting, 116kD, 1 R.AGlVLPPPK.G 1 RAGLVLPPPK.G R.LGALQQlQOQSOELOEVLGETERF RLGALQQLOOQSOELaEVLGETERF ~acuolar, T celilmune regulator R.TPLLQAPGGPHOOLR.V RTPLLQAPGGPHQDLRV 
RVLQLLPPGQVQVHK.M R VLQLLPPGQVQVHK.M 
R.VNFVAGAVEPHKA RVNFVAGAVEPHK.A 






RTSNLNEELGOVK Y RTSNLNEELGOVK.Y 










Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
CDC42 NP 001782 CDC42 1 K.NVFOEAILAALEPPEPK.K 1 KNVFDEAILAALEPPEPKK 
GNAI2 NP _002061 Gla2 1 R.IAQSDYIPTQQDVlRT 1 R.IAQSOYIPTQQDVLRT 1 K.AMGNLQIDFADPSRA RIAQSDYIPTQQOVLRT 
GNB1 NP 002065 G ~ 1,2 1 KIYAMHWGTOSRL 1 K IYAMHWGTOSRL 
GNB2 NP-005264 





RAP1A NP 002875 RAP1 1 K.INVNEIFYDLVR.O 1 K.INVNEIFYDLVRQ 1 K.INVNEIFYDLVR.Q 
RAP1B NP-056461 K.LWLGSGGVGK.S K.LWLGSGGVGK.S 
RAB1A NP 004152 RAB1A 1 K.NATNVEQSFMTMAAEIK.K 1 K.NATNVEOSFMTMAAEIK.K 1 K.NATNVEQSFMTMAAEIK.K 
RAB1B NP 112243 RAB1B 1 K.NATNVEQAFMTMAAEIK K 1 K.NATNVEOAFMTMAAEIK.K 
RAB3A NP 002857 RAB3 1 K.lLlIGNSSVGKT 1 K.LQIWDTAGQERY 
RAB3B NP-002858 
RAB3C NP-612462 
Structural Proteins and Adaptors 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
ACTA1 NP 001091 f6.ctln, alpha ~ K.EITALAPSTMK.I ~ =:~~v~~~~GQK.O ACTA2 NP-001604 RHQGVMVGMGQK.D 
ACTB NP 001092 ~ctln, beta or gamma 1 RGYSFTTTAERE 1 R.TTGIVMDSGOOVTHTVPIYEGYALP 
ACTG1 NP=001605 P ~:~~~~~G:aS6~~'~TVPIYEGYALP r~~~~EEHPVLL TEAPLNPK.A ~~~~ALpEEHPVLL TEAPLNPK.A 
HCLS1 NP _005326 HematopOietic lineage cell-speclflc 1 K.KISSEAWPPVGTPPSSESEPVRT 1 KKISSEAWPPVGTPPSSESEPVRT 
protein 1 
MYH9 NP_002464 Myosin heavy chain 1 K.OFSALESQLODTOELLOEENRQK L 1 K ANLQIOOINTDLNLERS 1 K.OFSALESOLODTQELLQEENROK.L 
K.LQVELDNVTGLLSOSOSKS K DFSALESQLQ010ELLOEENRQK.L R.VISGVLOLGNIVFK K 
R QLLQANPILEAFGNAK.T R.ELEOATETADAMNRE 
RRGOLPFWPR.R RGOLPFWPR.R 
K.HSQAVEELAEQLEQTKR.V 




TUBB2 NP _001060 ubulln, beta 3 1 R.SGPFGQIFRPDNFVFGOSGAGNN 1 R.SGPFGOIFRPDNFVFGOSGAGNN 1 R.AIL VDLEPGTMOSVR.S 
tovAKG rAK.G R.SGPFGOIFRPONFVFGQSGAGNN 
AKG 
VIM NP_003371 r-tlmentln 1 K.FADLSEAANR N 1 K.FAOLSEAANR.N 
P ~::t~~t~~~~OGK S 
K.NLQEAEEWYK.S 
R.TNEKVELQELNORFANYIOK.V 
ZYX NP 003452 lZyxln 1 KVNPFRPGOSEPPPAPGAORA 1 K VNPFRPGOSEPPPAPGAORA 
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Kinases and Phosphatases 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
PTPRC NP 002829 Protein tyrosine phosphatase, receptor 1 K.KRDPPSEPSPLEAEfaRL 1 K.KRDPPSEPSPLEAEFQR L 
NP-563578 itweC KROPPSEPSPLEAEFQR L NP-563579 
Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
AZU1 NP 001691 lAzurocldln 1 preproproteln 1 RQFPFLASIQNQGRH R.QFPFLASIQNQGRH 
BPI NP _001716 Bactericidal/permeability-Increasing 1 K.FFGTFLPEVAK.K 1 K.FFGTFlPEVAK.K 1 R.EFOLPSSQISMVPNVGLK.F KGHYSFYSMOIR.E K.GHYSFYSMDIR.E K.FFGTFlPEVAK K protein prec. KGLOYASQQGTAALQK.E K.GlDYASQQGTAALOK.E KFSISNANIKI 
R.IKIPDYSOSFK,I RIKIPDYSDSFK.I K.GHYSFYSMDIR.E 
KLQPYFOTLPVMTK I K.GLOYASOOGTAALOK.E 






11 R VOL YNWLQPHQNFLlFGADWYK.-
PPGB NP_000299 !cathepsin A 1 K.YGDSGEQIAGFVK.E 1 KHLHYWFVESQK.O KYGDSGEQIAC3FVK E 
CTSC NP _001805 Fathepsln C (dlpeptldyl-peptldase I) 1 K.NSWGTGWGENGYFRJ 1 K.NSWGTGWGENGYFR.I 
R.NVHGINFVSPVR.N RNVHG1NFVSPVRN 
CTSG NP _001902 Fathepsln G preproproteln R1FGSYDPR.R 1 R lFGSYDPR R 1 R1FGSYDPRR 
RNRNVNPVAlPRA RIFGSYDPRRO RIFGSYDPRR.O 
K.SSGVPPEVFTRV RNVNPVALPRA RNRNVNPVALPR.A 
RTIONDIMLLOLSRR K.SSGVPPEVFTRV RNVNPVALPRA 
RVSSFLPVIIIRT K.SSGVPPEVFTRVSSFLPWIR.T K.SSGVPPEVFTR.V 
R.TIONDlMLLOLSR.R RTIONDIMLLOLSR R 
RVSSFLf'lNlRT RVSSFLf'lNlRT 
DPP7 NP _037511 Dlpeptldyl peptidase 7 preproproteln ~ RAPDPOFOER.F ~ R.ASHPEDPASWEAR.K 1 RASHPEDPASVVEAR.K 
RLDHFNFERF R.LDHFNFERF K.DLFLOGAYDTVRW 
R.LDHFNFER F 
ELA2 NP 001963 Elastase 2 1 RWLGAHNLSRR 1 R.REPTROVFAVOR.I 
EPX ~P _000493 lEoslnophll peroxidase 1 RIGLDLAALNMORS 1 R.IGLDLAALNMORS 1 R.ASAPNSHVPLSSAFFASWRI 
RIVYEGGIDPILRG R.IVYEGGIOPILRG R.DFLPlVLGK.A 
K.LNRODAMLVDELRD R.NGFLLPLVR.A R FGHTMLQPFMFR.L 






10 RTNYLGLLAINQRF 10 RRNGFLLPLVRA 
11 RWNGDKlYNEARK 11 RRPLLGASNQALARW 
12 RTNYLGLLAINQRF 
13 R VANVFTtAFRF 
14 RWNGDKLYNEAR.K 
FTL NP _000137 Ferritin, light polypeptide 1 RLGGPEAGLGEYLFER.L 1 RLGGPEAGLGEYLFERL 
K.LNQALLDLHALGSAR.T 
GGH NP_003869 pammalllutamyl hydrolase precursor 1 K.NLQ(3ISHAPNAVK.T K.TAFYLAEFFVNEAR.K 1 K.NLDGISHAPNAVK.T 
K.TAFYLAEFFVNEAR.K K.TAFYLAEFFVNEARK 
MMP9 NP_004985 pelatlnase 1 R.KLOSVFEEPlSK.K 1 R.KLOSVFEEPLSK.K 1 RGSRPQGPFLlADKW 
K KLFFFS<3RO K OLSLPETGELDSATLK.A RKLDSVFEEPLSKK 
R.OLAEEYLYRY K.QLSLPETGELDSATLK.A 
K.OLSLPETGELDSATLK A R.OSTLVLFPGDLR T 
ROWv'VYTGASVLGPR.R K.SLGPALLLLOK.O 
K.SLGPALlLLOK.O 
GUSB NP 000172 Glucuronidase, beta 1 R.GFEEQWYR.R 1 K.SLLEQYHLGLOOK.R 
CAMP NP _004336 hCAP-18 1 RFALLGDFFRK 1 RFALLGDFFRK.S 1 R.FALLGDFFR K 
RFALLGDFFRK S 
HEXA NP _000511 Hexosamlnldase A preproproteln ~_::~L~~:~~~EPLAFEGTP ~ ::~t¢"~~~~~EPLAFEGTP 
kiK.A EOK.A.A 
HEXB NP_000512 Hexosamlnldase B preproproteln 1 R VLPEFDTPGHTLSWGK.G 1 K.KLESFYIOK.V ~ K.LAPGTIVfV\NKDSAYPEELSR.V 
R.VLPEFDTPGHTLSWGK.G 
HYAL3 NP 003540 Hvaluronldase 3 1 K.NOLGL YPYFGPRG 1 K.NQLGLYPYFGPRG 
LTF NP_002334 Lactoferrln 1 K.DLLFKOSAIGFSRV 1 K.FOLFGSPSGQK.O 1 R.OGAGDVAFIRE 
K.DSAIGFSR.V K.FQLFGSPSGQKDLLFK.O K.EDAIWNllRQ 
K.EDAIWNllR.Q K KGGSFOlNELQGLK.S K.FOLFGSPSGOK.D 
K.FOLFGSPSGOK.D RSVNGKEOAIWNllR.O K.GGSFOLNELQGlK.S 
K.FQLFGSPSGQKOlLFK.D K.KGGSFQlNElQGLK.S 
K.KGGSFQLNElOGlK.S K.LRPVAAEvYGTERQ 
RSVNGKEDArwNLlR.Q RRSOTSL TWNSVK.G 
RSVNGKEOAM'NLLR.Q 
CST? NP 003641 Leukocystatin; Cystatin 1 K.TNDPGVLQAARY 1 K.TNOPGVlQAARY 
LCN2 NP_005555 Llpocalln 2; NGAL 1 K.ElTSElKENFIR.F 1 K VPlOQNFQONQFOGKW 1 K.EL TSELKENFIR.F 
K.VPlQQNFOONQFOGKW K.YPlQONFQONOFOGK W 
ACP6 NP 057445 Lysophosphatidic acid phosphatase 1 K.VGMOQMFAlGER.l 1 K.YGMQOMFAlGER.l 
ACP2 NP 001601 Lysosomal acid phosphatase 2 1 K.TYPKOPVOEEEWPOGFGOlTK.E 1 K.TYPKOPYOEEEWPOGFGQl TK.E 
GAA NP _000143 Lysosomal alphalllucosldase 1 RVTSEGAGlOlQK.V 1 R.AGVUPlQGPGl TTTESR.O 
RAPSPLYSVEFSEEPFGVIVHR.O 
R.VTSEGAGLOLOK.V 










MPO NP_000241 Myeloperoxldase 1 ROHGLPGYNAWRR R.AVSNEIVRFPTOOL TPOOER S 1 R.AVSNEIVRFPTDQl TPOOERS RFPTOOl TPDOERS R.FPTDOL TPOOER.S RDHGLPGYNAWR R 
RIANVFTNAFR Y R.IANVFTNAFR.Y RDYlPLVLGPTAMR.K 
R.IGLDLPAlNMORS R.IGLDLPALNMOR.S R.FPTOQl TPOOER.S 
R.NQINAL TSFVOASMVYGSEEPLAR N R.NQINALTSFVOASMvYGSEEPLARN R.IANVFTNAFRY 
RQNQIAVDEIR.E R.WlEGGIOPILR.G R.IGLDlPAlNMOR.S 
R.WLEOGIDPILR.G R.WLPAEYEOOFSLPYGWTP<3VKR.N R.KLMEQYGTPNNIDrNMGGVSEPlK,R 







14 R.wLPAEYEOGFSLPYGWTPGVK R 
15 R.WLPAEYEOGFSLPYGWTPGVKR.N 
PRTN3 iNP _002768 Proteinase 3 1 R.LVNVVU3AHNVR.T 1 RLVNVVLGAHNVR.T R.TQEPTQQHFSVAOVFLNNYDAENK,L RTQEPTQQHFSVAOVFLNNYDAENK.L 
PRG2 NP _002719 Proteoglycan 2 1 R.FOWVOGSRW 1 RGNLVSIHNFNINYR.I RRFOWVDGSRW RRFOWVDGSRW 
RWNFA'tWAAHQMSR G 
TPP1 NP _000382 rlpeptldyl-peptldase I 1 RLFGGNFAHQASVARV 1 RL YQQHGAGLFDVTR.G 1 R.LFGGNFAHaASVARV R.LYQQHGAGLFDVTRG 
Membrane Traffic and Fusion Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1st Identification 2nd Identification 3rd Identification 
SYTL1 NP 116261 Svnaototaamin-like 1 1 K.lLTGDWFQEAR.S 1 K.lL TGDWFOEARS 
C20orf178 NP _789782 ~nf7 homologue associated with Allx 1 1 REAlENANTNTEVLK N 1 RLRDTEEMLSKK KGGPTPOEAIQR.L 
STX7 NP 003560 ~yntaxln 7 1 RTLNOLGTPODSPELRQ 1 RTLNOLGTPODSPELRQ 1 R.TLNOLGTPODSPELR.O 
VAMP8 NP_003752 VAMP 8 1 K.NIMTONVERI 1 K.NIMTONVER.t 1 KNIMTONVERI RNKTEDLEATSEHFK.T RNKTEDlEATSEHFK.T 
R.NLOSEVEGVK.N 
Redox Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
PDIA3 NP _005304 Grp58 1 R.TADGIVSHLKK 1 RFLQDYFDGNLKR.Y fJv~. KTFSHELSDFG LEST AGEIP 
AIRT 
K.MDATANDVPSPYEVRG 
CYBB NP_000388 gp91-phox ~ ~:~~yH::p~~~EFK.T 1 K.TLYGRPN'NDNEFK,T 1 RGVHFIFNKENF.-K.TLYGRPN'NDNEFK.T 
Other Proteins 
Entrez Entrez Protein Name Peptide Sequences Detected Gene Protein 1 st Identification 2nd Identification 3rd Identification 
C9orf19 NP _071738 9orf19, glioma pathogenesis-related 1 R.YFPAGNWNEGFFEENVLPPKK.- 1 K.ASASOOSSFVVARY 
protein RYFPAGNWNEGFFEENVLPPKK.-
DDX4 NP _061912 DEAD (Asp-Glu-Ala-Asp) box 1 R.ELVNOI'l'lEARK 1 RELVNQIYLEAR.K 1 R.ELVNOIYLEARK 
polypeptide 4 
HCLS1 NP_005326 Hematopoietic ceil-specific Lyn 1 KKISSEAWPPVGTPPSSESEPVRT 1 K.KISSEAWPPVGTPPSSESEPVRT 
ubstrate 1 
HIST1H1C NP_005310 Histone H1 family 1 K,ALAAAGYDVEKN 1 KALAAAGYDVEK.N 
K.ALAAAGYDVEKNNSR.I 
HIST1H2BG NP 003509 Histone H2B 1 KAMGIMNSFVNDIFERI K,AMGIMNSFVNDIFERI 
K.VLKOVHPDTGISSK.A 
HIST1H41 NP 003486 Histone H4 1 K.VFLENVIR.D 1 R.ISGUYEETRG 
ARL10B NP _620150 Hypothetical protein BCOl5408 1 RDLPGALDEKElIEK.M 1 R.DLPGALDEKELIEK.M 
K.LWDIGGOPRF K.LWDIGGOPR F 
TMEM30A NP _060717 Hypothetical protein FLJ10856 1 RKSOLHPTLPAGR.Y 1 KFRNPPGGDNLEER.F 1 KFRNPPGGONLEER.F RKSDlHPTLPAGR.Y 
FLJ22662 NP_079105 Hypothetical protein FLJ22662 1 K.LGLDYSYDLAPR.A 1 K.LGLDYSYOLAPR.A 
K,TIGWGILEIR.A 
SQSTM1 NP_003891 lSequestosome 1 1 R.AGEARPGPTAESASGPSEOPSVN 1 R.AGEARPGPTAESASGPSEDPSVN 
LK.N K.N 
TOLLIP NP_061882 !Toil-interacting protein 1 RGNKOAAINSLLOMGEEP.- 1 RGPVYIGELPOOFLRI 1 R.GPVYIGELPODFLR.I 
R.GPVYIGELPODFLR.I 
RPS27A NP 002945 Ublqultln precursor t ~:~~:E~~~:~~~JK.A ~ K TITLEVEPSDTIENVK.A 1 K.ESTLHLVLRL NP-061828 K,TITLEVEPSOTIENVKAK.1 -.MQIFVK.T UBB f K.TLTGKTITLEVEPSDTIENVK.A K.TITLEVEPSDTIENVK.A 
UBA52 NP-003324 
UBC NP-066289 
The table lists the peptides used to identify proteins III at least two of three 2D-HPLC 
ESI-MSIMS experiments. Proteins with corresponding gene and protein designation are 
listed according to the literature-based functional classification for each granule subset, as 
described in Table 3. 
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Supplementary Table 2 
Peptides used for identification of proteins from a single 2D-HPLC ESI-MS/MS 
Experiment 
GELATINASE GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
ITGB5 NP 002204 Integrin, B 5 1 R.LGFGSFVDK.D 1.13 
Channels and Transporters 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
MVP NP_059447 Major vault protein 1 R.LAQDPFPL YPGEVLEK.D 1.79 
NP 005106 
GTPases 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
GNB1 NP_002065 G 131,2 1 K.vHAIPLR.S 2.82 
GNB2 NP 005264 
Structural Proteins 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
CFL1 NP_005498 Cofilin 1 1 K.KEDLVFIFWAPESAPLK.S 10.24 
NP _068733 
NP 619579 
Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
FCN1 NP 001994 Ficolin 1 precursor 1 R.VDLVDFEGNHQFAK.Y 4.29 
AZU1 NP 001691 Azurocidin 1 preproprotein 1 R.QFPFLASIQNQGR.H 5.18 
OLFM4 NP 006409 GW112 1 R.LEFTAHVLSQK.F 2.16 
Other Proteins 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
ALB NP_000468 IAlbumin 1 K.KVPQVSTPTLVEVSR.N 2.46 
SEMG1 NP _002998 Semenogelin I 1 K.DIFSTQDELLVYNK.N 10.14 
NP_937782 K.GHYQNWEVR.E 3 R.KQGGSQSSYVLQTEELVANK.Q 
R.KSQQYDLNALHK.T 
5 R.LPSEFSQFPHGQK.G 
SEMG2 NP _002999 Semenogelin II 1 K.DIFTIQDELLVYNK.N 7.27 
K.DVSQSSISFQIEK.L 
3 R.TQGGSQSSYVLQTEELWNK.Q 
TOLLIP NP 061882 IT oil-interacting protein 1 R.GPVYIGELPQDFLR.I 5.11 
HCLS1 NP_005326 Hematopoietic cell-specific Lyn 1 K.KISSEAWPPVGTPPSSESEPVR.T 4.53 
isubstrate 1 
HSPA1A NP 005336 Hsp701A 1 K.HWPFQVINDGDKPK.V 4.21 
K.NQVALNPQNTVFDAK.R 
SPECIFIC GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
DSG1 NP _001933 Desmoglein preproprotein 1 R.ISGVGIDQPPYGIFVINQK.T 3.15 
K.YQGTILSIDDNLQR.T 
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FLOT1 NP 005794 Flotillin-1 1 K.LPQVAEEISGPLTSANK.I 3.98 
HLA-A NP _002107 H LA-A 1 1 R.FIAVGYVDDTQFVRF 3.84 
NP 002108 
ICAM3 NP 002153 ICAM-3 precursor 1 R.TFVLPVTPPRL 1.83 
ITGB5 NP 002204 InteQrin, 13 5 1 RLGFGSFVDK.D 1.13 
LAMP2 NP_002285 LAMP2 1 K.YLDFVFAVK.N 2.20 
NP 054701 
LAIR1 NP_002278 Leukocyte-associated Ig-like 1 R.GPVGVQTFRL 11.15 
NP_068352 receptor 1 R.lDSVSEGNAGPYR.C 
NP 068354 
VNN1 NP_004657 !Vanin 1 1 RFGQTPVQER.L 6.43 
K.MSENIPNEVYALGAFDGLHTVEGR 
VNN2 NP_004656 !Vanin 2 1 K.DNSIYVLANLGDK.K 2.78 
NP 511043 
Channels and Transporters 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
ATP5F1 NP _001679 ~TP synthase, H+ transporting, 1 RHYLFDVQR.N 3.13 
mitochondrial FO complex, 
subunit b 
ATP5H NP_006347 ~TP synthase, H+ transporting, 1 RLAALPENPPAIDWAYYK.A 10.56 
mitochondrial FO complex, 
~ubunit d 
TCIRG1 NP _006010 ~TPase, H+ transporting, 1 RTPLLQAPGGPHQDLRV 4.58 
116kD, vacuolar, T cell imune 
regulator 
ATP6VOD1 NP _004682 ATPase, H+ transporting, 1 RFFEHEVKL 1.99 
lysosomal, VO subunit D 
isoform 1 
SLC25A24 NP 037518 Calcium-binding transporter 1 R.QLLAGGIAGAVSRT 2.73 
SLC25A3 NP_005879 Mitochondrial phosphate carrier 1 RLPRPPPPEMPESLKK 3.87 
NP 002626 precursor isoform 1 a or 1 b 
PLSCR1 NP 066928 Phospholipid scram blase 1 1 R.EAFTDADNFGIQFPLDLDVKM 6.29 
HRNR XP 373868 Similar to hornerin 1 R.GPYESGSGHSSGLGHRE 2.26 
VDAC1 NP_003365 Voltage-dependent anion 1 KTDEFQLHTNVNDGTEFGGSIYQKV 8.13 
channel 1 
VDAC3 NP_005653 Voltage-dependent anion 1 K.AADFQLHTHVNDGTEFGGSIYQKV 12.72 
channel 3 ~ K.LTLDTIFVPNTGKK 
GTPases 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
CDC42 NP_001782 Cdc42 1 K.NVFDEAILAALEPPEPK.K 1.4 
RAB1A NP _004152 RAB1 1 K.EFADSLGIPFLETSAK.N 7.8 
RAB1B NP 112243 
RAB2 NP_002856 RAB2 ~ K.lQEGVFDINNEANGIK.1 14.1 
K.TASNVEEAFINTAKE 
GNB1 NP_002065 G P1,2 1 KLlIWDSYTTNKV 3.2 
GNB2 NP 005264 
Structural Proteins 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
PFN1 NP _005013 Profilin 1 1 K.STGGAPTFNVTVTK.T 12 K.TFVNITPAEVGVLVGK.D 21.4 
VIM NP _003371 !Vimentin 1 REEAENTLQSFR.Q 8.8 ~ R.FANYIDKV 
3 RISLPLPNFSSLNLRE 
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Kinases and Phosphatases 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
PTPN7 NP _002823NP Protein tyrosine phosphatase, 1 RRGSNVALMLDVRSLGAVEPICSVNT 7.5 
542155 non-receptor type 7 PRE 
Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
CHIT1 NP 003456 Chitotriosidase 1 R.FTILVODLANAFOOEAOTSGK.E 4.51 
CALR NP 004334 Calreticulin precursor 1 K.EOFLDGDGWTSRW 2.88 
ELA2 NP 001963 Elastase 2 1 RWLGAHNLSRR 3.75 
MMP25 NP _071913 Matrix metalioproteinase 25 1 RDGLQQL YGK.A 1.6 
NP 073209 leukolysin) 
ANPEP NP_001141 Membrane alanine 1 RFSTEYELQQLEQFK.K 1.45 
aminopeptidase 
PADI4 NP _036519 Peptidyl arginine deiminase, 1 R.ELGLAESDIIDIPQLFK.L 9.35 
type IV 12 R.GPQTGGISGLDSFGNLEVSPPVTVRG 3 K.LFQEQQNEGHGEALLFEGIK.K 








Membrane Traffic and Fusion Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
DNAJC5 NP_079495 DnaJ (Hsp40) homolog, 1 K.YHPDKNPDNPEAADK.F 7.58 
!subfamily C, member 5 
STX7 NP _003560 Syntaxin 7 1 K.EFGSLPTIPSEQRQ 16.09 
2 RLVAEFTISLTNFQK.V 
3 RTLNQLGTPQDSPELRQ 
VAMP2 NP _004772 ~AMP2 1 RADALQAGASQFETSAAK.L 17.00 
NP 055047 
Redox Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
PDIA3 NP _005304 Glucose regulated protein, 1 KVVVAENFDEIVNNENK.D 1.98 
58kDa 
Other Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
ALB NP 000468 !Albumin 1 KVPQVSTPTLVEVSR.N 2.3 
DSP NP_004406 Desmoplakin 1 RAELlVQPELK.Y 2.3 12 K.QQIQNDLNQWK.T 
3 K.SAIYQLEEEYENLLK.A ~ K.SVQNDSQAIAEVLNQLK.D 
5 R.TLELQGLlNDLQRE 
FGB NP _005132 Fibrinogen ~ chain 1 K.DNENWNEYSSELEK.H 3.05 
Ipreproprotein 





EHD1 NP 006786 lTestilin 1 REHQISPGDFPSLR.K 2.43 




HCLS1 NP _005326 Hematopoietic cell-specific Lyn 1 K.KISSEAWPPVGTPPSSESEPVR.T 4.53 
substrate 1 
HIST1H1C NP 005310 Histone H1 family 1 K.ALAAAGYDVEK.N 5.16 
HIST1H2BG NP_003509 Histone H2B 1 K.AMGIMNSFVNDIFER.I 30.95 12 R.KESYSVYVYK.v 
3 K.vLKQVHPDTGISSK.A 
AZUROPHIL GRANULES 
Receptors and Membrane Anchors 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
CANX NP 001737 Calnexin 1 R.KIPNPDFFEDLEPFR.M 2.53 
FLOT1 NP 005794 Flotilin 1 K.vSAQYLSEIEMAK.A 3.04 
FCER1G NP 004097 FCER1G gene product 1 K.SDGVYTGLSTR.N 12.79 
LAMP2 NP_002285 LAMP2 1 K.YLDFVFAVK.N 2.20 
NP 054701 
GTPases 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
RAB3D NP 004274 RAB3D 1 R.DAADQNFDYMFK.L 5.48 
Structural Proteins and Adaptors 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
ANXA1 NP 000691 Annexin I, (Iipocortin I) 1 K.GGPGSAVSPYPTFNPSSDVAALHK.A 6.94 
FLNA NP 001447 Filamin 1 1 K.AFGPGLQGGSAGSPAR.F 0.6 
LCP1 NP 002289 L-plastin 1 K.vNDDIIVNWVNETLR.E 2.39 
PFN1 NP _005013 Profilin 1 1 R.DSLLQDGEFSMDLR.T 21.43 
2 K.TFVNITPAEVGVLVGK.D 
TUBA1 NP _005991 Tubulin alpha 1 1 R.QLFHPEQLlTGKEDAANNYAR.G 8.71 
K.VGINYQPPTVVPGGDLAK.V 
Luminal and Host Defense Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
CALR NP _004334 Cal reticulin precursor 1 R.FYALSASFEPFSNK.G 7.67 
2 K.FYGDEEKDKGLQTSQDAR.F 




OLFM4 NP_006409 GW112 1 R.LEFTAHVLSQK.F 2.16 i2 K.L YVYNDGYLLNYDLSVLOKPO.-
CTSZ NP _001327 Cathepsin Z (X) 1 R.NVDGVNYASITR.N 7.26 
R.vGDYGSLSGR.E 
CRISP3 NP 006052 !sgp-28, CRISP-3 1 K.MEWNKEAAANAQK.W 5.31 
Membrane Traffic and Fusion Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
DNAJC5 NP_079495 DnaJ (Hsp40) homolog, 1 K.EINNAHAILTDATK.R 8.59 
isubfamily C, member 5 i2 K.YHPDKNPDNPEAADKFK.E 
VAMP2 NP_004772 IVAMP2 1 R.LQOTQNQVDEWDIMR.v 16.0 
NP 055047 
Redox Proteins 
Entrez Entrez Protein Name Peptides Detected % Coverage Gene Protein 
CYBA NP 000092 p22-phox 1 R.KKPSEEEAAAAAGGPPGGPQVNPIPVTDEW 5.13 
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Other Proteins 
Entrez Entrez Protein Name Peptides Detected 0/0 Coverage Gene Protein 
PPIA NP_066953 CyclophilinA 1 KVKEGMNIVEAMER.F 12.38 
NP_982254 
NP_982255 
HSPA5 NP_OO5338 Hsp705A 1 K.DNHLLGTFDLTGIPPAPR.G 9.48 [2 K.NQL TSNPENTVFDAK.R 
3 KSQIFSTASDNQPTVTIK.V 
R.lWNDPSVQQDIK.F 
S100AB NP 002955 MRP-B 1 K.GADVWFK.E 7.53 
S100A9 NP_OO2956 MRP-14 1 R.KDLQNFLK.K 31.58 ~ K.LGHPDTLNQGEFKE 
~ K.LGHPDTLNQGEFKELVR.K 
14 R.NIETIINTFHQYSVK.L 
The table lists peptides used for protein identification from a given granule subset by only 
one 2D-HPLC ESI-MSIMS experiment, but identified by either 2DE or at least twice by 
2D-HPLC ESI-MSIMS in another granule subset. Sequences of corresponding peptides 
and the percent coverage of proteins are shown. 
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Supplementary Table 3 
Proteins Rejected as Granule Components 
GELATINASE GRANULE REJECTED PROTEINS (349) 
Number of % coverage Protein Name peptides 
1 7.42 % 1-acyIQlycerol-3-phosphate O-acyltransferase 1 
1 2.88% 6-phosphofruclo-2-kinase/fruclose-2,6-biphosphalase 3 
1 1.07% !a disintegrin and metalloprotease domain 10 
1 3.55% IAAA-ATPase T063 
1 5.22% IAAIR8193 
2 5.18% lacidic (leucine-rich) nuclear phosphoprotein 32 family, member 6 
1 3.46 % !aconitase 2 
1 3.76% lactin related protein 2/3 complex subunit 16 
1 1.58% !acyl-CoA synthetase long-chain family member 1 
1 1.83% acyl-Coenzyme A dehydroQenase, very lonQ chain precursor 
1 3.64% acyl-Coenzyme A oxidase 
1 4.84% adenylyl cyclase-associated protein 
1 2.65% aldehyde dehydrogenase 3A 
1 3.85% aldolase A; fructose-bisphosphate aldolase 
1 3.06 % alkaline sphingomyelinase 
1 1.55% alpha 1 type XI collagen preproprotein 
2 6.15% amine oxidase (flavin-containing) 
1 .88% amyotrophic lateral sclerosis 2 (iuvenile) chromosome reQion, candidate 3 
2 10.69 % androgen-regulated short-chain dehydrogenase/reductase 1 
1 5.53% anQiopoietin-like 6; anQiopoietin-related protein 5 
1 4.56 % apoptosis inhibitor 5; fibroblast growth factor 2-interacting factor 2 
1 .61 % ash1 (absent, small, or homeotic)-like 
1 19.12% ~TP synthase FO subunit 8 
1 10.14% ~TP synthase, H+ transporting, mitochondrial FO complex, subunit e 
1 13% ~TP synthase, H+ transporting, mitochondrial FO complex, subunit g 
1 3.59% ~TP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
1 1% ~TPase, Class V, type 10A; ATPase type IV, phospholipid transporting (P-type) 
1 1.92% ~TPase, Class VI, type 11 
1 1.42 % ~TP-bindinQ cassette, sub-family A 
1 1.08% ~TP-binding cassette, sub-family 6 
1 .58% ~TP-bindinQ cassette, sub-family C 
1 3.79% ~TP-binding cassette, sub-family D 
1 1.94% 6-cell CLUlymphoma 9 
1 3.66% 6-cell receptor-associated protein 31 
1 2.21 % beta 3-Qlycosyltransferase-like 
1 2.18% beta adrenergic receptor kinase 1 
1 2.27% beta-Qalactoside alpha-2,6-sialyltransferase II 
1 4.09% bone marrow stromal cell antigen 1 precursor 
1 2.52% ~Ipain 1, large subunit 
1 5.81 % ~MP responsive element binding protein 1 
1 17.59% k;AMP responsive element modulator 
3 12.32% k;arcinoembryonic antigen-related cell adhesion molecule 8 
2 13.69% CD226 antiQen; adhesion Qlycoprotein 
1 4.41 % k;ell death-regulatory protein GRIM19; CGI-39 protein 
1 3.02% k;ell division cycle 2-like 
1 4.31 % cell division cycle associated 1 
1 4.21 % CG9886-like; glycerate kinase 
1 10.14% CGI-141 protein 
2 12.18 % chemokine-like factor superfamily 5 
1 13.89 % chromosome 10 open reading frame 70 
1 20.69 % chromosome 14 open reading frame 2 
1 2.7% chromosome 20 open reading frame 75 
1 1.76 % chromosome 5 open readinQ frame 7; putative zinc finger protein 
1 2.09 % chromosome 6 open reading frame 60 
1 5.8% chromosome 9 open reading frame 77; CGI-67 protein 
1 2.6% cisplatin resistance related protein CRR9p 
1 .55% coagulation factor VI I I isoform a precursor 
2 2.32% coagulation factor XIII A 1 subunit precursor 
2 12.44 % k;oated vesicle membrane protein 
1 1.44% complement component 3 precursor 
1 3.4 % k;omeodesmosin precursor 
1 2.68% COX15 homolog 
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1 3.85% CTD 
1 .67% CUB and Sushi multiple domains 1 
1 3.5% cytochrome b reductase 1 
1 23.29 % cytochrome b5 outer mitochondrial membrane precursor 
3 21.3% cytochrome c oxidase subunit IV isoform 1 precursor 
2 4.04% cytochrome P450, family 4 
1 2.2% cytoskeleton associated protein 2 
2 10.64% cytoskeleton related vitamin A responsive protein 
1 3.2% DEK oncogene (DNA binding) 
1 10.5% delta sleep inducing peptide, immunoreactor isoform 1 
2 1.19% desmocollin 1 
1 1.82% diaphanous 2 
1 3.09% dihydrolipoamide S-succinyltransferase 
1 1.04% dipeptidylpeptidase VI isoform 1 
1 1.95% DKFZP434D146 protein 
3 11.46 % DKFZP564J0863 protein 
1 6.15% DKFZP586A0522 protein 
1 3.02% Dok-like protein 
2 4.82% dolichyl-diphosphooligosaccharide-protein glycosyltransferase 
1 .5% dynein, cytoplasmic, heavy polypeptide 1 
1 .85% early endosome antigen 1, EEA 1 
2 6.25% ecotropic viral integration site 2B 
1 2.26 % elastin microfibril interfaeer 1 
1 3% electron transfer flavoprotein, alpha polypeptide 
2 4.55% endothelin converting enzyme 1 
3 8.01 % ~ukaryotic translation elongation factor 1 
1 1% atty acid synthase 
1 2.12% Ibroblast growth factor receptor 4 
1 4.49 % FK506-binding protein 8; FK506-binding protein 8 (38kD) 
1 4.03% ~avin containing monooxygenase 2 
1 2.65% FLJ20160protein 
1 8.1 % FLJ44290 protein 
1 7.14% rataxin 
1 2.95% G protein-coupled receptor kinase 6 (GRK6) 
4 38.97 % Igalectin 7; lectin galactoside-binding soluble 7 
2 11.11 % GL004 protein 
1 4.37 % 19lucose transporter protein 10; glucose transporter protein 11 
1 3.41 % glutamate dehydrogenase 1 
1 2.3% glutamate receptor, metabotropic 4 
1 3.73% glutathione-S-transferase omega 1 
1 3.25% glycoprotein, synaptic 2; synaptic glycoprotein SC2 
1 16.18% guanine nucleotide binding protein (G protein), gamma 5 
2 5.29% guanine nucleotide binding protein (G protein), q polypeptide 
1 1.17% guanylate cyclase 2F; RetGC-2 
1 7.28% heme oxygenase (decyclizing) 2 
1 4.1 % heterogeneous nuclear ribonucleoprotein F 
1 1.79 % heterogeneous nuclear ribonucleoprotein L 
1 6.22% high-mobility group box 2 
1 4.84% HLA-B associated transcript 5 
1 3.57% HMG-box transcription factor TCF-3 
1 3.67% hydroxysteroid (17-beta) dehydrogenase 4 
1 1.89% hypothetical protein BC001584 
1 2.7% hypothetical protein BC009732 
1 4.84% hypothetical protein BC015408 
1 4.3% hypothetical protein DJ971 N18.2 
1 1.94% hypothetical protein DKFZp43411610 
1 3.08% hypothetical protein DKFZp761D0211 
1 10.12% hypothetical protein DKFZp7620076 
2 11.14% hypothetical protein FLJ 1 0842 
1 1.53% hypothetical protein FLJ12649 
1 4.77% hypothetical protein FLJ14743; homolog of yeast FAR11 protein 1 
1 1.46 % hypothetical protein FLJ20200 
2 6.62% hypothetical protein FLJ20245 
2 5.62% hypothetical protein FLJ20481 
2 14.91 % hypothetical protein FLJ20625 
1 2.67% hypothetical protein FLJ20626 
1 5.04% hypothetical protein FLJ22390 
1 4.12% hypothetical protein FLJ22555 
1 6.67% hypothetical protein FLJ22649 similar to signal peptidase SPC22/23 
1 .67% hypothetical protein FLJ25045 
1 10.5% hypothetical protein FLJ25084 
182 
1 2.53% hypothetical protein FLJ25477 
2 4.69 % hypothetical protein FLJ32001 
1 2.72% hypothetical protein FLJ32009 
1 10.8% hypothetical protein FLJ32809 
1 4.92% hypothetical protein FLJ33718 
1 3.85% hypothetical protein FLJ35728 
1 4.93% hypothetical protein LOC144501 
1 1.68% hypothetical protein LOC259173 
1 1.87% hypothetical protein LOC283431 
1 1.46 % hypothetical protein LOC51 061 
1 5.46 % hypothetical protein MGC10084 
1 5.98% hypothetical protein MGC13251 
1 6.79% hypothetical protein MGC15396 
1 6.06 % hypothetical protein MGC26610 
1 4.55% hypothetical protein MGC35140 
1 3.45 % hypothetical protein MGC39827 
1 2.47 % hypothetical protein MGC4562 
1 9.45 % hypothetical protein MGC48998 
1 15.45 % hypothetical protein XP 376840 
1 8.05% hypothetical protein XP 378325 
1 20.91 % hypothetical protein XP 379678 
1 9.49 % hypothetical protein XP 379754 
1 6.51 % hypothetical protein ZD52F1 0 
1 6.86 % immunity associated protein 1 
1 .82% inositol 1.4,5-triphosphate receptor, type 3 
1 1.28% integrin alpha L precursor; antigen CD11A (p180) 
3 2.84% integrin alpha X precursor 
2 4.76% integrin VLA-4 beta subunit 
1 3.32% integrin-linked kinase 
1 5.82% intercellular adhesion molecule 2 precursor 
1 14.4% interferon induced transmembrane protein 1 (9-27) 
3 5.91 % 'unction plakoglobin; gamma-catenin 
1 4.51 % KH domain containing, RNA binding, signal transduction associated 1 
1 3.17% KlAA0095 gene product 
2 12.33% KlAA0152 gene product 
2 4.97% KlAA0830 protein 
1 2.75% KlAA0937 protein 
1 3.09% KlAA1185 protein 
3 10.4 % KlAA1271 protein 
1 2.97% KIAA 1340 protein 
1 1.4 % KlAA1614 protein 
1 1.57% KlAA1836 protein 
1 4.52% lactate dehydrogenase A 
1 4.21 % LAG1 longevity assurance homolog 2 
1 .72% laminin, alpha 4 precursor 
3 11.52% lectin, man nose-binding 2; endoplasmic reticulum glycoprotein 
1 3.92% lectin, man nose-binding, 1 precursor; intracellular mannose specific lectin 
2 6.77% leucine zipper-EF-hand containing transmembrane protein 1 
1 10.96 % lipoma HMGIC fusion partner-like 2 
1 .13% lipoprotein, Lp(a); Apolipoprotein Lp(a) 
1 3.57% major histocompatibility complex, class I 
1 2.15% mannosyl-oligosaccharide glucosidase 
1 5.31 % mel transforming oncogene 
1 3.51 % membrane cofactor protein 
4 6.53% meta-vinculin 
1 3.86% metaxin 1 
1 1.14% MICAL-like 2 isoform 2 
1 9.21 % microsomal glutathione S-transferase 3 
1 .82% microtubule-associated protein 2 
1 3.33% mitogen-activated protein kinase 1; ERK 2 
1 2.34% molybdenum cofactor synthesis-step 1 
1 1.71 % multimerin 1; glycoprotein la' 
2 3.05% myosin IG 
1 .74% myosin IXB 
1 4.51 % NADH dehydrogenase (ubiquinone) 1 
1 5.4 % NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
1 1.41 % NADPH oxidase 3; NADPH oxidase catalytic subunit-like 3 
1 2.44 % NEDD9 interacting protein with calponin homology and LIM domains 
1 17.95% neurogranin; protein kinase C substrate; calmodulin-binding protein 
1 4.56% neutrophil cvtosolic factor 
1 7.22% NK6 transcription factor related, locus 2 
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1 32.81 % nucleolar protein family A, member 3; homolog of yeast Nop1 Op 
1 1.67% optic atrophy 1 
1 1.4% oxoglutarate (alpha-ketQglutarate) dehydrQfLenase (Iipoamide) 
1 3.76 % Ip21-activated kinase 7; protein kinase PAK5 
2 2.7% Iphosphatidate cytidylyltransferase 2; CDP-diglyceride synthetase 2 
2 4.97% Iphosphogluconate dehydrogenase 
1 1.58 % Iphospholipase D1, phophatidylcholine-specific 
1 2.98 % PITPNM family member 3; PYK2 N-terminal domain-interacting receptor 1 
1 6.11 % Iplatelet-activating factor acetyl hydrolase, isoform Ib, beta subunit 30kDa 
1 1.76% Ipleckstrin homology domain containing, family C (with FERM domain) member 1 
1 6.86% Ipleckstrin; p47 
1 .33% Iplectin 1 
2 2.17% lexin C1; receptor for virally-encoded semaphorin 
1 1.01 % Ipolymerase (RNA) III (DNA directed) (155kD) 
1 4.5% PP1201 protein 
1 8.52% Iprogesterone membrane binding protein 
1 2.28 % Pro5APiP2 protein 
3 9.68 % Iprostaglandin-endoperoxide synthase 1 
3 .75% Iprotein kinase, DNA-activated, catalytic polypeptide 
1 4.73% Iproteinllhosphatase 1, regulatory (inhibitor) subunit 16A 
1 3.36 % Iprotein tyrosine phosphatase, non-receptor type 6 
1 3.49 % Iprotocadherin 21 precursor; MT -protocadherin 
1 5.19% purine nucleoside phosphorylase 
1 4.05% putative breast adenocarcinoma marker 
1 8.81 % putative NFkB activating protein HNLF 
1 7.28% RAB18 
1 5.42 % RAB30 
1 4.8% RAB33B 
1 5.47 % RAB35 
1 5.09% RAB37 
1 5.16 % RAB39B 
1 5.19 % RAB41 protein 
1 5.05% RAB4A 
1 4.44% RAB4B 
1 5.12% RAB5A 
1 5.12% RAB5B 
1 5.31 % RAB8B 
1 1.93% Ras and Rab interactor 3; RAB5 interacting protein 3 
1 1.79 % RA5 guanyl releasing protein 2 
1 8.9% ras homolog gene family, member G (rho G); RhoG 
1 8.85% ras-related C3 botulinum toxin substrate 1; Rac1 
1 3.3% reticulon 2 isoform A 
1 1.34% retinoblastoma binding protein 2; retinoblastoma-binding protein 2 
1 10.17% retinoblastoma-binding protein 6 
1 3.19% Rho GTPase activating protein 1; Rho GAP 
1 .46 % Rho guanine nucleotide exchange factor (GEF) 11 
1 8.59% ribonuclease 6 precursor 
1 5.45% ribosomal protein L 12; 605 ribosomal protein L 12 
2 12.23% ribosomal protein L 18; 605 ribosomal protein L 18 
1 5.11 % ribosomal protein L28; 605 ribosomal protein L28 
1 2.23% ribosomal protein L3; 605 ribosomal protein L3 
1 2.11 % ribosomal protein L4; 605 ribosomal protein L4 
2 5.9% ribosomal protein L6; 605 ribosomal protein L6 
1 7.66% ribosomal protein L 7; 605 ribosomal protein L 7 
1 3.47 % ribosomal protein PO; 605 acidic ribosomal protein PO 
1 9.93% ribosomal protein 513; 405 ribosomal protein 513 
1 7.28% ribosomal protein 514; 405 ribosomal protein 514 
1 10.77% ribosomal protein 515a; 405 ribosomal protein 515a 
1 5.26% ribosomal protein 518; 405 ribosomal protein 518 
1 5.35% ribosomal protein 53; 405 ribosomal protein 53 
1 6.46 % ribosomal protein 54, X-linked X isoform 
2 7.22% ribosomal protein 54, Y-linked 2 
1 4.64% ribosomal protein 59; 405 ribosomal protein 59 
1 7.59 % ring finger protein 8 isoform 2; C3HC4-type zinc finger protein 
1 1.33% RNA binding motif protein 15; one twenty two protein 
1 6.7% RNA binding motif, single stranded interacting protein 1 
1 .34% Iryanodine receptor 2 
1 15.24% 5100 calcium binding protein A11 (calgizzarin) 
1 3.77% secernin 3 
1 5.01 % serine (or cysteine) proteinase inhibitor 
1 4.23% serine palmitoyltransferase subunit 1 
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1 2.8 % ~erinelthreonine protein kinase TA01 homolog 
1 1.86% ~erologically defined colon cancer antigen 1 
1 5.9% signal recognition particle receptor, beta subunit 
1 5.24% signal sequence recejJtor, alpha 
1 10.98% signal sequence receptor, delta 
1 3.38 % signal transducer and activator of transcription 3 
1 6.1 % similar to 1810012H11 Rik 
1 16.13% similar to 60S ribosomal protein L29 (Cell surface heparin binding protein HIP) 
1 3.76% similar to anaphase promoting complex subunit 1 
1 1.81 % similar to CAGL 79 
1 3.68% similar to carbonic anhydrase XV 
1 .11% similar to Centromeric protein E (CENP-E protein) 
1 6.73% similar to CGI-62 protein 
1 6.78% similar to dJ 14N1.2 (novel S-1 OO/ICaBP type calcium binding domain protein) 
1 10.17% similar to Elongation factor 1-alpha 1 
1 .59 % imilar to embryonic blastocoelar extracellular matrix protein precursor 
1 3.81 % similar to KlAA0408 protein 
1 14.15% similar to KlAA0563 gene product 
1 3.85% similar to mouse fat 1 cadherin 
1 1.3% similar to RIKEN cDNA 4632411J06 
1 8.88% similar to tropomyosin 3 
1 1.75% SKI-like; ski-related oncogene snoN 
1 2.61 % SNF-1 related kinase 
1 4.08 % solute carrier family 16, member 10; T-type amino acid transporter 1 
1 2.77% solute carrier family 2 member 10; sugar transporter GLUT1 0 
1 2.79% solute carrier family 9 (sodium/hydrogen exchanger) 
1 1.69% source of immunodominant MHC-associated peQtides 
1 52.38 % S-phase response (cyclin-related) 
1 2.6 % sphingomyelin phosphodiesterase 3 
1 8.54% splicing factor, arginine/serine-rich 3 
1 2.19% sterol carrier protein 2 
1 4.21 % stomatin (EPB72)-like 2; stomatin-like protein 2 
1 5.24% stratifin 
2 5.4% stromal interaction molecule 1 precursor 
1 5.82% surfeit 6; surfeit locus protein 6 
1 3.64% synaptobrevin-like 1 
1 6.27% isyntaxin 11 
1 4.5% syntaxin 3A 
2 3.96% -complex 1; T -complex locus TCP-1 
1 3.35% ektin 1 
1 .97% estis expressed gene 10 
1 2.86% etracycline transporter-like protein 
1 3.26 % hromboxane A synthase 1 
1 .32% hyroid hormone receptor interactor 8 
1 3.24% tigger transposable element derived 2 
1 2.33% imeless-interacting protein; tipin 
1 .58% ranscription factor-like nuclear regulator 
1 .84% ranscriptional regulator ATRX 
1 .86 % ransient receptor potential cation channel, subfamily M, member 2 
3 10.59% ransketolase 
1 2.11 % ransmembrane 9 superfamily member 2 
1 2.99% ransmembrane protein (63kD), endoplasmic reticuium/Goigi 
2 12.33% ransmembrane trafficking protein 
1 5.59 % rans-prenyltransferase 
1 5.14% riggering receptor expressed on myeloid cells-like 1 
2 8.13% rru translation elongation factor, mitochondrial 
1 6.87% umor necrosis factor alpha 
1 3.1 % umor-associated calcium signal transducer 2 precursor 
1 26.98 % ubiQuinol-cvtochrome c reductase complex 7.2kDa protein 
1 3.97% ubiquinol-cvtochrome c reductase core protein II 
1 2.17% ubiquitin-activating enzyme E1-like; ubiQuitin-activating enzyme-2 
1 1.55% uveal autoantigen with coiled-coil domains and ankyrin repeats 
1 3.68% ~asodilator-stimulated phosphoprotein 
1 6.51 % r"esicle trafficking protein sec22b 
1 .64% von Willebrand factor precursor 
1 .49 % werner syndrome protein; Werner Syndrome helicase 
1 8.05% inc finger protein 435 
1 3.16% !zinc finger, CW-type with coiled-coil domain 2 
1 4.21 % !zinc metalloproteinase STE24 homolog; CAAX prenyl protease 
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Number of % coverage Protein Name peptides 
1 3.53% 1-acylglycerol-3-phosphate O-acyltransferase 1 
1 3.11 % 3-hvdroxvisobutvryl-Coenzvme A hvdrolase isoform 1 
1 2.88% 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
1 2.01 % a disintearin and metalloprotease domain 10 
1 1.82% a disintearin and metalloproteinase domain 17 
2 5.56% aldehyde dehydrogenase 3Bl; aldehyde dehydrogenase 7 
1 2.58% alkylglvcerone phosphate synthase precursor 
1 1.28% alpha 1 type II collagen 
1 .88% amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 
1 2.97% annexin A 11 ; annexin XI 
2 5.05% annexin VI (p68) 
1 .49 % ~ntigen identified by monoclonal antibody Ki-67 
1 3.74% ~PG12 autophagy 12-like 
1 2.51 % ~rsenate resistance protein ARS2 
1 .4% asp (abnormal spindle)-like, microcephaly associated 
1 13.83% ~TP synthase, H+ transporting, mitochondrial FO complex, subunit f 
1 12.62% ~TP synthase, H+ transporting, mitochondrial FO complex, subunit g 
1 2.01 % ~TPase, Class VI, type 11 B 
1 1.76% ~TPase, Na+/K+ transporting 
1 .85% ~TP-binding cassette, sub-family A 
1 .78% ~ TP-binding cassette, sub-family C 
1 13.6% basic leucine zipper transcription factor, ATF-like 
1 4.09% bone marrow stromal cell antigen 1 precursor 
1 .29 % bullous pemphigoid antigen 1 isoform 1 
1 4.2% C21orf80 protein isoform C 
1 .54% k:adherin EGF LAG seven-pass G-type receptor 3 
1 1.4 % alpain 1, large subunit 
1 .98 % k;aspase recruitment domain protein 12; ICE::Q!'otease activatingfactor 
1 1.75% CD44 antigen; homing function 
1 1.4 % CDC42-bindingprotein kinase alQha 
1 .79% chromosome 20 open reading frame 104 
1 8.97% chromosome 6 open readil'lfl frame 82; divalent cation toleranljJrotein CUTA 
1 8.88% chromosome 8 open reading frame 13 
1 .77% coagulation factor VIII isoform a ~ecursor 
1 1.67% colony stimulating factor 2 receptor, beta, low-affinity 
1 4.78% concentrative Na+-nucleoside cotran§Qorter 
1 3.4 % corneodesmosin precursor 
2 9.79% Icytochrome b reductase 1 
1 4.41 % cytochrome c oxidase II 
1 6.51 % !cytochrome c oxidase subunit IV isoform l~ecursor 
2 27.71 % !cytochrome c oxidase subunit Vila polypeptide 2 (liver) precursor 
1 3.69 % k:vtochrome c-1 
1 .96% !cytoplasmic linker 2 isoform 1; Williams-Beuren syndrome chromosome region 4 
1 .34% ~edicator of cytokinesis 6 
4 2.8% desmocollin 1 
1 3.85% DNA methyltransferase 1-associated protein 1 
1 1.83% DNA2 DNA replication helicase 2-like 
1 9.72% down regulated in renal cell carcinoma 
1 .32% dvnein, cytoplasmic, heavy po~eptide 
1 4.58% EF hand domain containing 2 
1 6.28% endometrial bleeding associated factor preproprotein 
1 1.4 % evolutionarily conserved G-patch domain containing 
1 .26 % Fc fragment of IgG binding protein 
1 .67% FERM, RhoGEF, and pleckstrin domaingrotein 
1 4.81 % FLJ44290 protein 
1 2.3% FLJ44299 protein 
1 1.03% ormin 2 
1 1.02% FYVE-finaer-containina Rab5 effectorgrotein rabeno~n-5 
1 3.8% G6B protein; immunoglobulin receptor 
1 6.07% laasdermin 
1 4% k.llycogenin 
1 8.95% igrowth and transformation-dependent protein 
1 2.89% Iguanine nucleotide binding protein (G protein) alpha 12 
1 2.92% Iguanine nucleotide bindingQl'oteinJGj)I'oteirtl, a~ha 13 
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1 5.43% H2A histone family 
1 5.15% H3 histone family 
1 1.91 % heat shock 90kOa protein 
1 3.79% heterogeneous nuclear ribonucleoprotein H 
2 7.18% high-mobility Qroup box 2 
1 6.15% hypothetical protein 669 
1 1.89% hypothetical protein BC001584 
1 1.72% hypothetical protein OKFq,566M1046 
1 3.08% hypothetical protein OKFZp761 00211 
1 2% hypothetical protein ET 
1 3.03% hypothetical protein FLJ 1 0211 
1 4.78% hypothetical protein FLJ10213 
1 3.79% hypothetical protein FLJ 1 0350 
1 9.75% hypothetical protein FLJ 12598 
1 4.6% hypothetical protein FLJ13612 
1 6.52 % hypothetical protein FLJ13902 
1 2.14% hypothetical protein FLJ20272 
1 2.67% hypothetical protein FLJ20626 
1 .99 % hypothetical protein FLJ23577 
1 3.2% hypothetical protein LOC92912 
1 4.55% hypothetical protein LOC92922 
1 6.06 % hypothetical protein MGC26610 
1 3.45 % hypothetical protein MGC39827 
1 6.71 % hypothetical protein MGC50809 
1 6.52% hypothetical protein XP 172995 
1 11.01 % hypothetical protein XP 378656 
1 4.13% hypothetical protein XP 379226 
1 .64% insulin receptor substrate 1 
1 2.05% involucrin 
1 3.54% isocitrate dehydrogenase 2 (NAOP+), mitochondrial precursor 
6 11.68% 'unction plakoglobin; gamma-catenin 
1 .4% KlAA0100 Qene product 
1 1.59 % KlAA0645 gene product 
1 1.45 % KlAA0747 protein 
1 3.11 % KlAA0767 protein 
1 1.5% KlAA0999 protein 
2 .93% KIAA 1093 protein 
1 1.75% KIAA 1627 protein 
1 3.95% KIAA 1948 protein 
1 6.59% killer cell immunoglobulin-like receptor 
1 1.56% leukocyte antigen C097 
1 1.25% leukocyte receptor cluster (LRC) member 8 
1 1.8 % likely ortholog of mouse 5-azacytidine induced gene 1 
1 .13% apolipoprotein Lp(a) 
1 1.11% L YST-interacting protein LlP8 
1 5.31 % mel transforming oncogene; mel transforming oncogene 
1 .53% microtubule-associated protein 1 B 
1 5.62% mitochondrial malate dehydrogenase precursor 
1 1.07% MMS19-like (MET18 homoloQ, S. cerevisiae) 
1 .55% nebulin 
1 1.47 % neurofilament, heavy polypeptide 200kOa 
1 2.28% neuropilin 1 
1 3.59 % neutrophil cytosolic factor 1 
1 1.2% nicotinamide nucleotide transhydrogenase 
1 2.82% nuclear receptor subfamily 1, group H, member 2 
1 2.67% opioid growth factor receptor-like 1 
1 3.23% origin recognition complex, subunit 3 
1 6.71 % osteoglycin preproprotein; osteoinductive factor; mimecan 
1 8.42 % oxidised low density lipoprotein (lectin-like) receptor 1 
1 2.38% Iparaneoplastic cancer-testis-brain antigen 
1 2.7% Iperforin 1 (pore forming protein) 
1 1.17% Iperoxisome biogenesis factor 1 
1 5.1 % PFTAIRE protein kinase 1 
1 1.59% iphosphoinositide-3-kinase, catalytic susbunit 
2 4.4 % Iphosphoinositide-3-kinase, regulatory subunit 
1 4.34% Iplatelet-activating factor acelylhydrolase 2 
1 6.86% Ipleckstrin; p47 
1 1.97 % Ipodocan 
1 3.01 % Ipoly(rC)-binding protein 2 
1 3.73% Ipotassium inwardly-reclifyinQ channel J 15 
1 4.5% PP1201 protein 
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1 .24% Iprotein kinase, DNA-activated, catalytic polypeptide 
1 2.69% Iprotein phosphatase 1, regulatory subunit 9B; neurabin II 
1 10.31 % Iputative nuclear protein ORF1-FL49 
1 5.42 % RAB30 
1 4.8% RAB33B 
1 5.09% RAB37 
1 5.16% RAB39B 
1 5.19 % RAB41 protein 
1 5.05% RAB4A 
1 5.31 % RAB8B 
2 1.89% radixin 
1 1.53% regulator of G-protein signalling 3 
1 5.69% repressor of estrogen receptor activity; B-cell associatedQrotein 
1 1.04% Rho guanine nucleotide exchange factor (GEF) 12 
1 9.38% ribonuclease, RNase A family, 3 (eosinophil cationicprotein~ 
1 5.32% ribosomal protein L 18; 60S ribosomal protein L 18 
1 3.28% ribosomal protein L4; 60S ribosomalprotein L4 
1 7.66 % ribosomal protein L 7; 60S ribosomal protein L 7 
1 3.47 % ribosomal protein PO; 60S acidic ribosomalprotein PO 
1 11.3% ribosomal protein P2; 60S acidic ribosomal protein P2 
1 7.28 % ribosomal protein S14; 40S ribosomal protein S14 
1 4.18% ribosomal protein S4, X-linked X isoform 
1 4.18% ribosomal protein S4, Y -linked Y isoform 
1 11.86% ribosomal protein S7; 40S ribosomalprotein S7 
1 6.25% ribosomal protein S8; 40S ribosomal protein S8 
1 1.43% ribosome bindinQ protein 1 
1 4.95% ring finger protein 8; C3HC4-type zinc finger protein 
1 1.33% RNA binding motif protein 15; one twenty twoprotein 
1 1.16% RNA binding motif protein 6 
1 1.85% sarcosine dehydroQenase 
1 4.31 % serine (or cysteine) proteinase inhibitor 
1 6.96 % serine/threonine protein kinase SSTK 
1 2.8% serine/threonine protein kinase TA01 homolog 
1 5.69 % SH3 domain conlaininQ rinQ fill9.er 2 
1 1.78 % similar to 4930579E17Rik protein 
1 3.27% imilar to F-box only protein 2 
1 5.91 % Isimilar to mCBP 
1 11.47 % similar to Phosphorylase B kinase alpha regulatory chain 
1 5.31 % similar to retina and anterior neural fold homeobox 
1 4.39 % Isimilar to Ribonuclease-like protein 9 precursor 
1 3% similar to RIKEN cDNA 0610009J22 
1 2.05% similar to RIKEN cDNA E230015L20 gene 
1 8.33% similar to SpermatoQenesis associatedprotein 2 
1 1.68% skeletal myosin light chain kinase 
1 2.8% solute carrier family 16, member 3; monocarbQ)(ylate tran~orter 3 
1 4.46 % solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier) 
1 1.87% solute carrier family 4, anion exchall9.er, member 1 band 4.1 
1 2.35% solute carrier organic anion transporter family, member 4C1 
1 .76% splicing coactivator subunit SRm300; RNA binding protein 
1 2.8% splicing factor 3a, subunit 2, 66kDa; Spliceosome protein SAP-62 
1 1.88% step II splicing factor SLU7 
1 2.04% stromal interaction molecule 1 precursor 
1 7.79% superoxide dismutase 1, soluble; CulZn superoxide dismutase 
1 1.5% surface glycoprotein, Ig superfamily member 
1 6.27% syntaxin 2 
1 4.22% syntaxin binding protein 3; syntaxin 4 binding protein 
1 5.99% rrG-interacting factor; homeobox protein TGIF 
1 12.38% hioredoxin 
1 5.75% hyroid autoantigen 70kDa (Ku antigen] 
1 .06% itin isoform; connectin 
1 7.23% ranscription factor MLR1 
1 2.32% ranscription factor NRF; ITBA4 gene 
1 1.97% ranslation initiation factor I F2 
1 6.87% umor necrosis factor alpha 
1 1.25% umor rejection antigen (gp96) 
1 4.24% uncharacterized hematopoietic stemiQr0.9.enitor cellsprotein MDS031 
1 .5% utrophin; dystrophin-related protein 
1 1.25% r"esicle docking protein p115; transcytosis-associatedprotein 
1 1.52% ~esicular inhibitory amino acid transporter 
1 2.16% vitrin 
1 1.68% ~ingless-type MMTV integration site family, member 9B precursor 
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1 1.05% izinc finger CCCH type domain containin& 3 
1 3.32% inc finger protein 185 (LIM domain) 
1 2.37% inc finger protein 226 
1 1.85% izinc finger protein 536 
1 2.61 % inc finger protein 596 
AZUROPHILIC GRANULE REJECTED PROTEINS 12311 
Number of % coverage Protein Name peptides 
1 5.62% acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 
1 5.5% adaptor-related protein complex 3, mu 1 subunit; mu-adaptin 3A 
1 2.62% adenylate cyclase 5; adenylate cyclase, type V 
1 2.99% aldehyde dehydrogenase 3B 
1 3.85% aldolase A; fructose-bisphosphate aldolase 
1 1.3% alpha 1 type III collagen; Collagen III, alpha-1 polypeptide 
1 1.98% alpha 2 type I collagen; Collagen I, alpha-2 polypeptide 
1 1.87% alpha 2 type V collagen preproprotein; Collagen V, alpha-2 polypeptide 
1 10.4 % alternative reading frame p14; multiple tumor suppressor 1 
1 .86% androgen-induced prostate proliferative shutoff associated protein 
2 4.15% arachidonate 5-lipoxygenase 
1 3.35% iarylsulfatase precursor 
1 2.13% ataxin 7 
1 .67% ATP-binding cassette, sub-family A 
1 .98% IATP-binding cassette, sub-family. B jMDRIT A'=L 
1 4.59% BCL2-like 14; apoptosis regulator BCL-G 
1 2.01 % block of proliferation 1 
1 4.09% bone marrow stromal cell antigen 1 precursor 
1 5.11 % BTB (PaZ) domain containirlg 14A 
1 6.4 % C21 orf19-like protein; CGI-27 protein 
1 2.46 % calmegin 
1 1.53% CAP-binding protein complex interacting protein 1 
1 .61 % ~ASP8 associated protein 2; FLICE associated huge; human FLASH 
1 3.72% cat eye syndrome critical regionjll"otein 1 
1 3.6 % CD36 antigen (collagen type I receptor, thrombospondin receptor) 
1 .94% CDC42-binding protein kinase beta 
1 5.84% chromosome 9 open reading frame 87 
1 1.89% c-Maf-inducing protein 
1 1.67% colony stimulating factor 2 receptor, beta, low-affinity 
1 1.71 % icomplement component 8, alPha~o~ide.J)l"ecursor 
1 1.35% !cyclic AMP-regulated phosphoprotein, 21 kD isoform 
1 8.74% icytochrome b reductase 1 
1 1 % Idiscs large homolog 5; placenta and prostate DLG 
1 1.06% Idiscs large homolog 7; Dros~hila discs large-1 tumor sllQQl"essor-like 
1 .66% Dmx-like 1 
1 7.58% DOK5 protein isoform b; downstream of tyrosine kinase 5 
1 .29 % dynein, axone mal, heavy polypeptide 
1 2.43 % elongation protein 4 homolog; PAX6 neighbor gene 
1 2.94% F-box only protein 10 
1 1.66% F-box only protein 11 
1 3.9% Ibrinogen C domain containing 1 
1 2.07% FKSG42 
1 2.39% ucosidase, alpha-L- 1, tissue 
1 1.85% use-binding protein-interacting repressor 
1 6.83% G protein-coupled receptor MRGX1 
2 5.36% galactosidase, alpha 
1 2.22% galactosidase, beta 
1 1.71 % gene near HD on 4p16.3 with homoloill'.to ~othetical S. pombegene 
1 3.04% general transcription factor IIIC, polypeptide 4, 90kDa 
1 2.36 % glucosamine (N-acetyl)-6-sulfatase precursor 
1 6.42 % glutathione S-transferase M1; HB subunit 4 
1 1.41 % Golgi autoantigen, golgin subfamily a, 2; golgin-95 
1 4.19% growth differentiation factor 5 preproprotein 
1 2.89% guanine nucleotide binding proteinJ.G jlI"oteinl aIQha 12 
1 2.92% Iguanine nucleotide binding protein (G protein), alpha 13 
1 1.54% Iguanylate cvclase 2D, membrane 
2 13.24% H3 histone family 
1 1.79 % heat shock protein 12A 
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1 .39 % hemicentin-2 
1 6.86% hepatocyte nuclear factor 4, gamma 
1 1.37% heterogeneous nuclear ribonucleoprotein M 
1 4.4 % homeo box 03; homeobox protein Hox-03 
3 17.2% hypothetical protein BC015408 
1 2.71 % hypothetical protein OKFZp434B227 
1 1.58% hypothetical protein OKFZp686A17109 
1 3.41 % hypothetical protein FLJ 1 0252 
1 4.09% hypothetical protein FLJ 1 0891 
1 1.8% hypothetical protein FLJ 12994 
1 10.5% hypothetical protein FLJ 13448 
1 6.47% hypothetical protein FLJ 13646 
1 6.8% hypothetical protein FLJ 14281 
1 6.13% hypothetical protein FLJ20249 
1 8.07% hypothetical protein FLJ20625 
1 3.35% hypothetical protein FLJ21128 
1 1.41 % hypothetical protein FLJ21308 
1 3.32% hypothetical protein FLJ22301 
1 5.63% hypothetical protein FLJ36031 
1 1.85% hypothetical protein FLJ40342 
1 1.78% hypothetical protein FLJ40722 
2 5.11 % hypothetical protein LOC51244 
1 2.1 % hypothetical protein MGC13125 
1 13.56% hypothetical protein MGC15619 
1 3.47 % hypothetical protein MGC16044 
1 5.49 % hypothetical protein MGC24132 
1 2.7% hypothetical protein MGC34763 
1 4.88% hypothetical protein XP 096852 
1 9.88% hypothetical protein XP 294867 
1 12.07% hypothetical protein XP 375081 
1 4.23% hypothetical protein XP 377074 
1 15.22% hypothetical protein XP 378234 
1 6.08% hypothetical protein XP 378322 
1 6.8% hypothetical protein XP 378509 
1 17.35% hypothetical protein XP 378680 
1 4.89% hypothetical protein XP 378730 
1 11.54% hypothetical protein XP 379024 
1 9.32% hypothetical protein XP 379139 
1 11.32% hypothetical protein XP 379482 
1 18.18% hypothetical protein XP 379573 
1 11.32% hypothetical protein XP 380098 
1 1.09 % inositol polyphosphate-5-pho~halase, 145kOa 
1 5.73% isopentenyl-diphosphate della isomerase 2 
1 3.66 % KlAA0220 protein 
1 1.18% KlAA0553 protein 
1 1.44 % KlAA0676 protein 
1 1.89 % KIAA0720 protein 
1 3.67% KlAA0889 protein 
1 .69 % KIAA 1117 protein 
1 1.22% KlAA1210 protein 
1 2.82% KlAA1465 protein 
1 1.03% KlAA1509 
1 2.72% 1(3)mbt-like isoform I; lethal (3) malignant brain tumor 1(3) 
1 2.66% leucine rich repeat containinQ 16 
1 1.08% leucine-rich PPR motif-containing protein 
1 .81 % low density lipoprotein receptor-related jJl"otein 4 
1 1.57% LU1 protein 
1 2.66% macrophage scayenger rece~tor 1 
1 8.13% MA04; Mad4 homoloQ 
1 3.49 % MAP/microtubule affinity-regulating kinase 4 
1 .96% melanoma antiQen, family C, 1 
1 2.1 % metalioprotease related protein 1 
1 2.78% minichromosome maintenance protein 4 
1 1.29% myosin XVIIIB; myosin 18B 
1 1.91 % NACHT, leucine rich repeat and PYO containing 4 
1 4.89 % natrium-phosphate cotransporter lIa C-terminal-associated protein 2 
1 1.54% nephroretinin 
1 4.55% niban protein 
1 1.27% nicastrin 
1 7.22% NK6 transcription factor related, locus 2 
1 1.95% N009 protein 
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1 1.46% NPF/calponin-like protein 
1 1.59 % nuclear factor related to kappa B binding protein 
1 3.82% nucleolin 
1 13.9 % nucleoside-diphosphate kinase 4 
1 4% nucleosome assembly protein 1-like 4 
1 1.94% NY -REN-24 antigen 
1 .45% odd Ozlten-m homoloQ 4 
1 8.42% oxidised low density lipoprotein (lectin-like) receptor 1 
1 .84% pericentriolar material 1 
1 5.46 % peroxisome biogenesis factor 13 
1 .39% phosphatidylinositol 4-kinase, catalytic, alpha polypeptide isoform 2 
1 5.53% phosphoQlycerate mutase 2 
1 1.3% phospholipase D1, phophatidylcholine-specific 
1 3.88% phosphorylase kinase 
1 .3% PI-3-kinase-related kinase 5MG-1 
1 .78 % plexin D1 
1 1.74% positive cofactor 2, glutamine/Q-rich-associated protein 
1 5.5% potassium inwardly-rectitvinQ channel J14 
1 1.76% PRIP-interacting protein PIPMT 
1 1.22% PR02000 protein 
1 .36% progestin-induced protein; ubiquitin-protein ligase 
1 .73% programmed cell death 11 
1 9.09% pro-melanin-concentrating hormone 
1 6.69% [proteasome activator subunit 2; proteasome activator hPA28 subunit beta 
1 3.09% Iprotein kinase, AMP-activated, alpha 1 catalytic subunit; AMPK alpha 1 
1 4.46 % [pyruvate dehydrogenase (Iipoamide) beta 
1 1.6% RAB GTPase activating protein 1 
2 6.02% RAB37 
2 12.08 % RAB8B 
1 5.99% rab-related GTP-binding protein 
1 3.12% Ras-interactinQ protein 
1 5.29% Rab-15 
1 3.47 % REC8-like 1 
1 .7% retinitis pigmentosa RP1 protein 
1 3.78% RGM domain family, member A 
1 2.26% Rho GTPase activating protein 18 
1 .56% Rho GTPase activating protein 21 
1 5.32% ribosomal protein L 18; 605 ribosomal protein L 18 
1 5.65% ribosomal protein L7; 605 ribosomal protein L7 
1 14.04% ribosomal protein P1; 605 acidic ribosomal protein P1 
1 9.93% ribosomal protein 513; 405 ribosomal protein 513 
1 5.26 % ribosomal protein 518; 405 ribosomal protein 518 
1 3.96 % 5-adenosylhomocysteine hydrolase-like 1 
1 3.32% serine carboxypeptidase 1 precursor protein 
1 2.45% [serinelthreonine protein phosphatase with EF-hand motifs 1 
1 1.2% 5H3 and multiple ankyrin repeat domains 2 isoform 1 
2 1.04% 5H3-domain binding protein 4 
1 15.24% similar to Alpha-endosulfine 
1 .17% similar to Centromeric protein E (CENP-E protein) 
1 14.88 % similar to crystallin, zeta; NADPH:quinone reductase 
1 2.9 % similar to dJ25J6.2 (novel zinc finger protein) 
1 36.52 % similar to DKFZP4340047 jlI"otein 
1 9.41 % similar to High mobility group protein 1 (HMG-1) (Amphoterin) 
1 2.19% similar to hypothetical protein DKFZp434A 171 
1 24.3% similar to hypothetical protein FLJ30921 
1 3.25% similar to hypothetical protein MGC57211 
1 1.07% similar to KlAA2026 protein 
1 2.95% similar to MGC76216 protein 
1 5.16% similar to MGC9515 protein 
1 2.27 % similar to orphan sodium- and chloride-dependent neurotransmitter transporter 
1 3.05% similar to osteotesticular protein tyrosine phosphatase 
1 5.3% Isimilar to putative transmembrane protein 
2 10.88% [similar to Rab12 protein 
1 6.53% similar to retina and anterior neural fold homeobox 
1 6.4 % [similar to RIKEN cDNA 061 0012A05 
1 2.79 % similar to RIKEN cDNA 9430067K14 Qene 
1 1.56 % similar to RIKEN cDNA E430004N04 gene 
1 5.12 % similar to 5erinelthreonine protein kinase PRKX 
1 4.63% similar to zinc finger protein 495 
1 3.9% sinQle IQ IL-1 R-related molecule 
1 4.23% sirtuin 6; sir2-related protein type 6; sirtuin type 6 
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2 1.85% skeletal myosin light chain kinase 
1 6.87% small GTPase protein E-Ras; 
1 13.54% small inducible cytokine A 1 precursor; inflammatory cytokine 1-309 
1 1.48% smooth muscle cell associated protein-1 
1 .97% spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 
1 1.94% sperm associated antigen 1; infertility-related sjlJlrm protein 
1 2.9 % sphingomyelin phosphodiesterase 3, neutral membrane 
1 5.32% SPRY domain-containillfL sacs box protein SSB-2 
1 1.29% suppressor of Ty 5 homolog 
1 4.16% surfeit 6; surfeit locus protein 6 
1 5.45% synaptobrevin-like 1 
1 3.61 % syntaxin 10 
1 7.63% syntaxin 8 
1 5.59% ltachykinin receptor 3; NK-3 receptor; neurokinin B receptor 
1 2.64% itarget of mybl 
1 2.88% hree prime repair exonuclease 1 
1 2.33% imeless-interactinQ protein; tipin 
1 .06 % itin isoform; connectin 
1 4.21 % ranscription elonQation factor B polvpeptide 3C (elonQin A3) 
1 1.18% ranscriptional co-repressor Sin3A 
1 2.24% ransmembrane protein 16C; chromosome 11 open readinQ frame 25 
1 3.66 % ripartite motif protein 15 isoform alpha 
6 9.09 % umor reiection antigen(gQ96) 
1 3.43 % ubiquitin-conjugating enzyme E2-like; signaling molecule ATTP 
1 .43 % vacuolar protein sorting 13Cprotein 
1 5.15% Williams Beuren syndrome critical region 20A 
1 3.26% Wilms tumor 1 
1 3.77% inc finger protein 205; zinc finger protein 210 
1 .38% izinc fillfLer protein 469 
1 3.06 % inc finger protein AP4 
The table shows the number of peptides and the percent coverage for proteins identified 
only once by 2D-HPLC ESI-MS/MS. 
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